WO2024036227A2 - Edible composition comprising recombinant human secretory protein - Google Patents
Edible composition comprising recombinant human secretory protein Download PDFInfo
- Publication number
- WO2024036227A2 WO2024036227A2 PCT/US2023/071955 US2023071955W WO2024036227A2 WO 2024036227 A2 WO2024036227 A2 WO 2024036227A2 US 2023071955 W US2023071955 W US 2023071955W WO 2024036227 A2 WO2024036227 A2 WO 2024036227A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- human
- edible
- milk
- oil
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 249
- 108091058545 Secretory proteins Proteins 0.000 title claims abstract description 116
- 102000040739 Secretory proteins Human genes 0.000 title claims abstract description 116
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 175
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 108
- 210000004027 cell Anatomy 0.000 claims description 111
- 235000018102 proteins Nutrition 0.000 claims description 106
- 102000010445 Lactoferrin Human genes 0.000 claims description 40
- 108010063045 Lactoferrin Proteins 0.000 claims description 40
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 39
- 229940078795 lactoferrin Drugs 0.000 claims description 39
- 235000021242 lactoferrin Nutrition 0.000 claims description 39
- 239000006041 probiotic Substances 0.000 claims description 37
- 235000018291 probiotics Nutrition 0.000 claims description 37
- 239000000843 powder Substances 0.000 claims description 35
- 230000000529 probiotic effect Effects 0.000 claims description 33
- 108010046377 Whey Proteins Proteins 0.000 claims description 32
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 32
- 239000011707 mineral Substances 0.000 claims description 32
- 210000005253 yeast cell Anatomy 0.000 claims description 32
- 102000011632 Caseins Human genes 0.000 claims description 30
- 108010076119 Caseins Proteins 0.000 claims description 30
- 229940088594 vitamin Drugs 0.000 claims description 30
- 229930003231 vitamin Natural products 0.000 claims description 30
- 235000013343 vitamin Nutrition 0.000 claims description 30
- 239000011782 vitamin Substances 0.000 claims description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- 102000007544 Whey Proteins Human genes 0.000 claims description 28
- 239000012141 concentrate Substances 0.000 claims description 27
- 235000013336 milk Nutrition 0.000 claims description 27
- 239000008267 milk Substances 0.000 claims description 27
- 210000004080 milk Anatomy 0.000 claims description 27
- 235000021119 whey protein Nutrition 0.000 claims description 27
- 235000021244 human milk protein Nutrition 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 239000003921 oil Substances 0.000 claims description 22
- 235000019198 oils Nutrition 0.000 claims description 22
- 241000124008 Mammalia Species 0.000 claims description 21
- 241000235648 Pichia Species 0.000 claims description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 20
- 230000003248 secreting effect Effects 0.000 claims description 20
- 241000894006 Bacteria Species 0.000 claims description 19
- 241000223252 Rhodotorula Species 0.000 claims description 18
- 235000019486 Sunflower oil Nutrition 0.000 claims description 18
- 150000002632 lipids Chemical class 0.000 claims description 18
- 239000002600 sunflower oil Substances 0.000 claims description 18
- 241000233866 Fungi Species 0.000 claims description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 16
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 16
- 102000004407 Lactalbumin Human genes 0.000 claims description 15
- 108090000942 Lactalbumin Proteins 0.000 claims description 15
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 14
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 14
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 13
- 235000019485 Safflower oil Nutrition 0.000 claims description 12
- 235000005713 safflower oil Nutrition 0.000 claims description 12
- 239000003813 safflower oil Substances 0.000 claims description 12
- 229940062827 2'-fucosyllactose Drugs 0.000 claims description 11
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims description 11
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims description 11
- 102000014171 Milk Proteins Human genes 0.000 claims description 11
- 108010011756 Milk Proteins Proteins 0.000 claims description 11
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims description 11
- 229960000367 inositol Drugs 0.000 claims description 11
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 10
- 102000004555 Butyrophilins Human genes 0.000 claims description 10
- 108010017533 Butyrophilins Proteins 0.000 claims description 10
- 241000235555 Cunninghamella Species 0.000 claims description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 10
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 10
- 241000235649 Kluyveromyces Species 0.000 claims description 10
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 10
- 101710191666 Lactadherin Proteins 0.000 claims description 10
- 102100039648 Lactadherin Human genes 0.000 claims description 10
- 229930003268 Vitamin C Natural products 0.000 claims description 10
- 229910052742 iron Inorganic materials 0.000 claims description 10
- 235000021239 milk protein Nutrition 0.000 claims description 10
- 235000019154 vitamin C Nutrition 0.000 claims description 10
- 239000011718 vitamin C Substances 0.000 claims description 10
- 108010076365 Adiponectin Proteins 0.000 claims description 9
- 102000011690 Adiponectin Human genes 0.000 claims description 9
- 241000228212 Aspergillus Species 0.000 claims description 9
- 241001306132 Aurantiochytrium Species 0.000 claims description 9
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 9
- 241000221760 Claviceps Species 0.000 claims description 9
- 241001527609 Cryptococcus Species 0.000 claims description 9
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 9
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 9
- 108010023244 Lactoperoxidase Proteins 0.000 claims description 9
- 102000045576 Lactoperoxidases Human genes 0.000 claims description 9
- 102000016267 Leptin Human genes 0.000 claims description 9
- 108010092277 Leptin Proteins 0.000 claims description 9
- 241000221479 Leucosporidium Species 0.000 claims description 9
- 241001149698 Lipomyces Species 0.000 claims description 9
- 102100033468 Lysozyme C Human genes 0.000 claims description 9
- 241000235575 Mortierella Species 0.000 claims description 9
- 108010014251 Muramidase Proteins 0.000 claims description 9
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 9
- 241001112159 Ogataea Species 0.000 claims description 9
- 241000196250 Prototheca Species 0.000 claims description 9
- 241000235527 Rhizopus Species 0.000 claims description 9
- 241000235070 Saccharomyces Species 0.000 claims description 9
- 241000235346 Schizosaccharomyces Species 0.000 claims description 9
- 241001506047 Tremella Species 0.000 claims description 9
- 241000223230 Trichosporon Species 0.000 claims description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 9
- 102000005773 Xanthine dehydrogenase Human genes 0.000 claims description 9
- 108010091383 Xanthine dehydrogenase Proteins 0.000 claims description 9
- 108010093894 Xanthine oxidase Proteins 0.000 claims description 9
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 9
- 229940057428 lactoperoxidase Drugs 0.000 claims description 9
- 229940039781 leptin Drugs 0.000 claims description 9
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 9
- 235000010335 lysozyme Nutrition 0.000 claims description 9
- 229960000274 lysozyme Drugs 0.000 claims description 9
- 239000004325 lysozyme Substances 0.000 claims description 9
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 9
- 235000021246 κ-casein Nutrition 0.000 claims description 9
- 241001523626 Arxula Species 0.000 claims description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 8
- 241000159512 Geotrichum Species 0.000 claims description 8
- 241001302784 Kodamaea Species 0.000 claims description 8
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 8
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 8
- 241000370151 Wickerhamomyces Species 0.000 claims description 8
- 241000235013 Yarrowia Species 0.000 claims description 8
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 8
- 235000020958 biotin Nutrition 0.000 claims description 8
- 239000011616 biotin Substances 0.000 claims description 8
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 8
- 229960002079 calcium pantothenate Drugs 0.000 claims description 8
- 239000003240 coconut oil Substances 0.000 claims description 8
- 235000019864 coconut oil Nutrition 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- 235000019152 folic acid Nutrition 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- 229960003966 nicotinamide Drugs 0.000 claims description 8
- 235000005152 nicotinamide Nutrition 0.000 claims description 8
- 239000011570 nicotinamide Substances 0.000 claims description 8
- 239000002151 riboflavin Substances 0.000 claims description 8
- 229960002477 riboflavin Drugs 0.000 claims description 8
- 235000019192 riboflavin Nutrition 0.000 claims description 8
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 8
- 101150063569 slgA gene Proteins 0.000 claims description 8
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 8
- 241000907999 Mortierella alpina Species 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 229940011671 vitamin b6 Drugs 0.000 claims description 7
- 235000008939 whole milk Nutrition 0.000 claims description 7
- 235000021247 β-casein Nutrition 0.000 claims description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 6
- 229930003316 Vitamin D Natural products 0.000 claims description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 235000001465 calcium Nutrition 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 229960001231 choline Drugs 0.000 claims description 6
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 6
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims description 6
- 229940062780 lacto-n-neotetraose Drugs 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 claims description 6
- 235000013406 prebiotics Nutrition 0.000 claims description 6
- 235000019155 vitamin A Nutrition 0.000 claims description 6
- 239000011719 vitamin A Substances 0.000 claims description 6
- 235000019166 vitamin D Nutrition 0.000 claims description 6
- 239000011710 vitamin D Substances 0.000 claims description 6
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 6
- 229940045997 vitamin a Drugs 0.000 claims description 6
- 229940046008 vitamin d Drugs 0.000 claims description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 5
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- 229930003448 Vitamin K Natural products 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 5
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 5
- 235000019161 pantothenic acid Nutrition 0.000 claims description 5
- 239000011713 pantothenic acid Substances 0.000 claims description 5
- 229940055726 pantothenic acid Drugs 0.000 claims description 5
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 235000008160 pyridoxine Nutrition 0.000 claims description 5
- 239000011677 pyridoxine Substances 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 5
- 235000012424 soybean oil Nutrition 0.000 claims description 5
- 229960003495 thiamine Drugs 0.000 claims description 5
- 235000019157 thiamine Nutrition 0.000 claims description 5
- 239000011721 thiamine Substances 0.000 claims description 5
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 5
- 229930003799 tocopherol Natural products 0.000 claims description 5
- 235000010384 tocopherol Nutrition 0.000 claims description 5
- 229960001295 tocopherol Drugs 0.000 claims description 5
- 239000011732 tocopherol Substances 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 235000019168 vitamin K Nutrition 0.000 claims description 5
- 239000011712 vitamin K Substances 0.000 claims description 5
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 5
- 229940046010 vitamin k Drugs 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 claims description 4
- AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 claims description 4
- WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 claims description 4
- LKOHREGGXUJGKC-UHFFFAOYSA-N Lactodifucotetraose Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)OC2CO)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O LKOHREGGXUJGKC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019482 Palm oil Nutrition 0.000 claims description 4
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 claims description 4
- LKOHREGGXUJGKC-GXSKDVPZSA-N alpha-L-Fucp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)]-beta-D-Glcp Chemical compound C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]2O[C@@H]2[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@@H]1O LKOHREGGXUJGKC-GXSKDVPZSA-N 0.000 claims description 4
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 claims description 4
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 claims description 4
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 claims description 4
- 239000002540 palm oil Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 3
- 229940045999 vitamin b 12 Drugs 0.000 claims description 3
- 102000003839 Human Proteins Human genes 0.000 claims description 2
- 108090000144 Human Proteins Proteins 0.000 claims description 2
- 102000007562 Serum Albumin Human genes 0.000 claims description 2
- 108010071390 Serum Albumin Proteins 0.000 claims description 2
- 235000013861 fat-free Nutrition 0.000 claims description 2
- 239000003531 protein hydrolysate Substances 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000013350 formula milk Nutrition 0.000 abstract description 163
- 238000000034 method Methods 0.000 abstract description 59
- 235000016709 nutrition Nutrition 0.000 abstract description 31
- 230000035764 nutrition Effects 0.000 abstract description 13
- 230000008901 benefit Effects 0.000 abstract description 10
- 150000007523 nucleic acids Chemical class 0.000 description 55
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 53
- 102000050459 human LTF Human genes 0.000 description 52
- 108090000765 processed proteins & peptides Proteins 0.000 description 41
- 235000020256 human milk Nutrition 0.000 description 39
- 102000004196 processed proteins & peptides Human genes 0.000 description 38
- 102000039446 nucleic acids Human genes 0.000 description 35
- 108020004707 nucleic acids Proteins 0.000 description 35
- 238000009472 formulation Methods 0.000 description 34
- 229920001184 polypeptide Polymers 0.000 description 34
- 210000004251 human milk Anatomy 0.000 description 33
- 239000013598 vector Substances 0.000 description 33
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 31
- 239000008101 lactose Substances 0.000 description 31
- 235000010755 mineral Nutrition 0.000 description 31
- 239000007788 liquid Substances 0.000 description 29
- 238000002156 mixing Methods 0.000 description 29
- 239000004615 ingredient Substances 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 27
- 150000004676 glycans Chemical class 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 235000008504 concentrate Nutrition 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- 244000005700 microbiome Species 0.000 description 21
- 229920001542 oligosaccharide Polymers 0.000 description 20
- 150000002482 oligosaccharides Chemical class 0.000 description 20
- 239000007787 solid Substances 0.000 description 19
- 241000235058 Komagataella pastoris Species 0.000 description 16
- 239000000796 flavoring agent Substances 0.000 description 16
- 235000013305 food Nutrition 0.000 description 16
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 238000013019 agitation Methods 0.000 description 15
- 239000005018 casein Substances 0.000 description 15
- 235000019634 flavors Nutrition 0.000 description 15
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 15
- 101000946384 Homo sapiens Alpha-lactalbumin Proteins 0.000 description 14
- 235000021240 caseins Nutrition 0.000 description 14
- 241001099157 Komagataella Species 0.000 description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 13
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 13
- 235000019197 fats Nutrition 0.000 description 13
- -1 for example Chemical class 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 241000894007 species Species 0.000 description 13
- 235000019742 Vitamins premix Nutrition 0.000 description 12
- 235000013361 beverage Nutrition 0.000 description 12
- 239000000828 canola oil Substances 0.000 description 12
- 235000019519 canola oil Nutrition 0.000 description 12
- 235000013618 yogurt Nutrition 0.000 description 12
- 241000283690 Bos taurus Species 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 11
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 11
- 235000015097 nutrients Nutrition 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 10
- 235000013365 dairy product Nutrition 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 10
- 108700019146 Transgenes Proteins 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 238000001694 spray drying Methods 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 239000011573 trace mineral Substances 0.000 description 9
- 235000013619 trace mineral Nutrition 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 8
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 8
- 102000003886 Glycoproteins Human genes 0.000 description 8
- 108090000288 Glycoproteins Proteins 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 8
- 108091006905 Human Serum Albumin Proteins 0.000 description 8
- 241001099156 Komagataella phaffii Species 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 229940004120 bifidobacterium infantis Drugs 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 239000000787 lecithin Substances 0.000 description 8
- 229940067606 lecithin Drugs 0.000 description 8
- 235000010445 lecithin Nutrition 0.000 description 8
- 241000186000 Bifidobacterium Species 0.000 description 7
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 7
- 229930182830 galactose Natural products 0.000 description 7
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000001223 reverse osmosis Methods 0.000 description 7
- 235000020357 syrup Nutrition 0.000 description 7
- 239000006188 syrup Substances 0.000 description 7
- 229920002774 Maltodextrin Polymers 0.000 description 6
- 239000005913 Maltodextrin Substances 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229940114079 arachidonic acid Drugs 0.000 description 6
- 235000021342 arachidonic acid Nutrition 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 6
- IERHLVCPSMICTF-ZAKLUEHWSA-N cytidine-5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-ZAKLUEHWSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940035034 maltodextrin Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 description 6
- 239000008158 vegetable oil Substances 0.000 description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 5
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 5
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 5
- 108010084695 Pea Proteins Proteins 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 5
- 108090000284 Pepsin A Proteins 0.000 description 5
- 239000005862 Whey Substances 0.000 description 5
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 5
- 229950006790 adenosine phosphate Drugs 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 229960005069 calcium Drugs 0.000 description 5
- 229940090949 docosahexaenoic acid Drugs 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 5
- 229940091250 magnesium supplement Drugs 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 108010071421 milk fat globule Proteins 0.000 description 5
- 235000019702 pea protein Nutrition 0.000 description 5
- 229940111202 pepsin Drugs 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 229960003080 taurine Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000428705 Komagataella pseudopastoris Species 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- 244000299461 Theobroma cacao Species 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 4
- 229960004874 choline bitartrate Drugs 0.000 description 4
- 229960002104 cyanocobalamin Drugs 0.000 description 4
- 235000000639 cyanocobalamin Nutrition 0.000 description 4
- 239000011666 cyanocobalamin Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 235000011147 magnesium chloride Nutrition 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229960003975 potassium Drugs 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 239000001508 potassium citrate Substances 0.000 description 4
- 229960002635 potassium citrate Drugs 0.000 description 4
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 4
- 235000011082 potassium citrates Nutrition 0.000 description 4
- 235000007715 potassium iodide Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 4
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 4
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 4
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229940091258 selenium supplement Drugs 0.000 description 4
- 229940083542 sodium Drugs 0.000 description 4
- 229940071440 soy protein isolate Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 108091030071 RNAI Proteins 0.000 description 3
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004376 Sucralose Substances 0.000 description 3
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002009 allergenic effect Effects 0.000 description 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 3
- 239000001354 calcium citrate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 229910000365 copper sulfate Inorganic materials 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000011790 ferrous sulphate Substances 0.000 description 3
- 235000003891 ferrous sulphate Nutrition 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 235000015243 ice cream Nutrition 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 3
- 235000014666 liquid concentrate Nutrition 0.000 description 3
- 235000012680 lutein Nutrition 0.000 description 3
- 229960005375 lutein Drugs 0.000 description 3
- 239000001656 lutein Substances 0.000 description 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- 229940099596 manganese sulfate Drugs 0.000 description 3
- 239000011702 manganese sulphate Substances 0.000 description 3
- 235000007079 manganese sulphate Nutrition 0.000 description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000009931 pascalization Methods 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 235000021568 protein beverage Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229940108325 retinyl palmitate Drugs 0.000 description 3
- 235000019172 retinyl palmitate Nutrition 0.000 description 3
- 239000011769 retinyl palmitate Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000011781 sodium selenite Substances 0.000 description 3
- 235000015921 sodium selenite Nutrition 0.000 description 3
- 229960001471 sodium selenite Drugs 0.000 description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 3
- 235000019408 sucralose Nutrition 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 3
- 239000011747 thiamine hydrochloride Substances 0.000 description 3
- 229960000344 thiamine hydrochloride Drugs 0.000 description 3
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 235000013337 tricalcium citrate Nutrition 0.000 description 3
- DJJCXFVJDGTHFX-ZAKLUEHWSA-N uridine-5'-monophosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-ZAKLUEHWSA-N 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- 229960001763 zinc sulfate Drugs 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 2
- 102100035687 Bile salt-activated lipase Human genes 0.000 description 2
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 2
- 235000006008 Brassica napus var napus Nutrition 0.000 description 2
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 2
- 244000188595 Brassica sinapistrum Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 241000178290 Geotrichum fermentans Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000183045 Tetrapisispora phaffii Species 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 240000006677 Vicia faba Species 0.000 description 2
- 235000010749 Vicia faba Nutrition 0.000 description 2
- 235000002098 Vicia faba var. major Nutrition 0.000 description 2
- 241001276012 Wickerhamomyces ciferrii Species 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 108010087173 bile salt-stimulated lipase Proteins 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000021185 dessert Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- PVBRXXAAPNGWGE-LGVAUZIVSA-L disodium 5'-guanylate Chemical compound [Na+].[Na+].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O PVBRXXAAPNGWGE-LGVAUZIVSA-L 0.000 description 2
- KURVIXMFFSNONZ-WFIJOQBCSA-L disodium;[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(=O)NC(=O)C=C1 KURVIXMFFSNONZ-WFIJOQBCSA-L 0.000 description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 235000020218 follow-on milk formula Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 239000004137 magnesium phosphate Substances 0.000 description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 2
- 229960002261 magnesium phosphate Drugs 0.000 description 2
- 235000010994 magnesium phosphates Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000021243 milk fat Nutrition 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 238000010397 one-hybrid screening Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
- DROVUXYZTXCEBX-WCCKRBBISA-N (2s)-2-amino-5-(carbamoylamino)pentanoic acid;2-hydroxybutanedioic acid Chemical compound OC(=O)C(O)CC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=O DROVUXYZTXCEBX-WCCKRBBISA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 241000003595 Aurantiochytrium limacinum Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000680806 Blastobotrys adeninivorans Species 0.000 description 1
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101100494773 Caenorhabditis elegans ctl-2 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000221751 Claviceps purpurea Species 0.000 description 1
- 241001290628 Cunninghamella echinulata Species 0.000 description 1
- 241000580885 Cutaneotrichosporon curvatus Species 0.000 description 1
- 241000223233 Cutaneotrichosporon cutaneum Species 0.000 description 1
- 241000235646 Cyberlindnera jadinii Species 0.000 description 1
- 101150067325 DAS1 gene Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 101100112369 Fasciola hepatica Cat-1 gene Proteins 0.000 description 1
- 241001491951 Filobasidium wieringae Species 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000801742 Homo sapiens Triosephosphate isomerase Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241001480034 Kodamaea ohmeri Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 101150026520 Lalba gene Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000408747 Lepomis gibbosus Species 0.000 description 1
- 241001514698 Leucosporidium creatinivorum Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 241001489207 Lipomyces lipofer Species 0.000 description 1
- 241001149691 Lipomyces starkeyi Species 0.000 description 1
- 241000529878 Lipomyces tetrasporus Species 0.000 description 1
- 101150022813 Ltf gene Proteins 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 241000235048 Meyerozyma guilliermondii Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 241001443590 Naganishia albida Species 0.000 description 1
- 101100005271 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-1 gene Proteins 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 241001099341 Ogataea polymorpha Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 241000196248 Prototheca zopfii Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- 241000007101 Rhodotorula babjevae Species 0.000 description 1
- 241000223253 Rhodotorula glutinis Species 0.000 description 1
- 241000223254 Rhodotorula mucilaginosa Species 0.000 description 1
- 241000007102 Rhodotorula paludigena Species 0.000 description 1
- 241000221523 Rhodotorula toruloides Species 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- 101100010928 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) tuf gene Proteins 0.000 description 1
- 101100008874 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) DAS2 gene Proteins 0.000 description 1
- 101100516268 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NDT80 gene Proteins 0.000 description 1
- 101100190054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PEX8 gene Proteins 0.000 description 1
- 244000253911 Saccharomyces fragilis Species 0.000 description 1
- 235000018368 Saccharomyces fragilis Nutrition 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- 241000233671 Schizochytrium Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000123447 Solicoccozyma terreus Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 101150001810 TEAD1 gene Proteins 0.000 description 1
- 101150074253 TEF1 gene Proteins 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 102100033598 Triosephosphate isomerase Human genes 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000306282 Umbelopsis isabellina Species 0.000 description 1
- 241001053370 Vanrija albida Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- ZTOKCBJDEGPICW-GWPISINRSA-N alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc Chemical group O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)O2)O)[C@@H](CO)O1 ZTOKCBJDEGPICW-GWPISINRSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 229940072440 bovine lactoferrin Drugs 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 108010067454 caseinomacropeptide Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 108010020919 eel intestinal pentapeptide Proteins 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 101150026046 iga gene Proteins 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 235000021129 infant diet Nutrition 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229940031154 kluyveromyces marxianus Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000002703 mannose derivatives Chemical group 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229940127284 new molecular entity Drugs 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000020787 nutritional impact Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- NEGYEDYHPHMHGK-UHFFFAOYSA-N para-methoxyamphetamine Chemical compound COC1=CC=C(CC(C)N)C=C1 NEGYEDYHPHMHGK-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000014483 powder concentrate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 235000020236 pumpkin seed Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/18—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from yeasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1315—Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/44—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/38—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/04—Animal proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/14—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/22—Working-up of proteins for foodstuffs by texturising
- A23J3/26—Working-up of proteins for foodstuffs by texturising using extrusion or expansion
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/56—Flavouring or bittering agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/68—Acidifying substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y117/00—Oxidoreductases acting on CH or CH2 groups (1.17)
- C12Y117/01—Oxidoreductases acting on CH or CH2 groups (1.17) with NAD+ or NADP+ as acceptor (1.17.1)
- C12Y117/01004—Xanthine dehydrogenase (1.17.1.4)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/46—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing dairy products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4717—Plasma globulins, lactoglobulin
Definitions
- Embodiments relate to human secretory proteins, compositions comprising such proteins, and use thereof in specific edible compositions, such as, food, beverage and supplement compositions, including an infant formula.
- Secretory proteins have important roles in a body, including nutrition, protection, lubrication and so on.
- Dedicated cell machinery is needed to modify an incipient secreted protein, for example, glycosylation, and to traffic that nascent secretory protein to a membrane or out of a cell.
- secretory proteins may be similar across taxa, the range, amount and structure of a secretory protein is a species-specific characteristic or feature.
- type of secretory protein amount of a secretory protein and structure of a secretory protein, for example, nature of glycosylation and structure of carbohydrates, vary, and can vary considerably from species to species.
- the secretory protein or glycosylation profile, pattern or fingerprint of bovine milk varies from that of human milk.
- [5] secretions, serous fluid and the like containing secretory proteins also contain a range of lipids and carbohydrates, which can be unique to an organ, a stage of life and so on.
- human milk contains fat globules encased in a milk fat globule membrane (MFGM), a complex assemblage of lipids and proteins. Composition of MFGM can vary as an infant ages.
- Oligosaccharides human milk oligosaccharides, HMO
- HMO also vary in content and amount amongst species.
- HMO HMO’s of breast milk are not necessarily an energy source for an infant, instead, may serve to provide a conducive environment and food source of microbes in the gut of an infant.
- infant formula commonly is based on bovine milk proteins, which differ from human breast milk proteins, for example, in total amino acid composition.
- bovine protein level in infant formula generally is raised. That provides a much higher total intake of protein by formula-fed infants, which can precipitate metabolic stress on infants.
- whey protein approximately 70% of protein found in human milk is whey protein.
- Primary whey proteins are ⁇ -lactalbumin, lactoferrin (LF) and secretory IgA.
- LF lactoferrin
- Those proteins are bioactive and possess unique properties, such as, antimicrobial activities, anti-inflammatory activity and anti -oxi dative properties. Those proteins also may aid in absorption of key vitamins and minerals.
- human secretory molecules in a range of edible or potable compositions, such as, drinks, infant formulae, bars, dairy products, beverages and so on.
- compositions comprising such proteins and methods of use for providing nutrition to a subject.
- Such compositions achieve immunomodulatory and other benefits of native human secretory proteins, previously only available using non-human sources.
- aspects of the disclosure include combinations of individual ingredients to maximize immunomodulatory impact of a formulation.
- compositions of the disclosure include, in addition to one or more human secretory proteins, one or more human secretory oligosaccharides (for example, 2'-fucosyllactose), a probiotic bacterium (for example, Bifidobacterium, such as, Bifidobacterium infantis), a lipid source, such as, MFGM, and so on.
- human secretory proteins for example, one or more human secretory oligosaccharides (for example, 2'-fucosyllactose)
- a probiotic bacterium for example, Bifidobacterium, such as, Bifidobacterium infantis
- a lipid source such as, MFGM, and so on.
- an edible composition comprising lactose, one or more lipids, protein, a human secretory oligosaccharide, such as, a human milk oligosaccharide (HMO), one or more minerals, one or more vitamins, a probiotic organism and a human secretory protein.
- HMO human milk oligosaccharide
- an HMO is 2'-fucosyllactose, lacto-N-neotetraose, 3-fucosyllactose, 6'-sialyllactose, difucosyllactose or lacto-N-tetraose.
- an HMO is 2'-fucosyllactose.
- an HMO is lacto-N-neotetraose.
- an edible composition comprises one or more of high oleic sunflower oil, mid-oleic sunflower oil, canola oil, safflower oil, coconut oil, low erucic rapeseed oil, sunflower oil, ascorbyl palmitate, mixed tocopherol concentrate, Mortierella alpina oil, alga oil, soybean oil or palm oil.
- an edible composition comprises high oleic sunflower oil, coconut oil, low erucic rapeseed oil, canola oil, sunflower oil, ascorbyl palmitate, mixed tocopherol concentrate, Mortierella alpina oil and alga oil.
- one or more minerals comprise one or more of calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium or selenium.
- an edible composition comprises calcium phosphate, calcium citrate, magnesium chloride, potassium citrate, potassium chloride, sodium chloride, copper sulfate, ferrous sulfate, manganese sulfate, zinc sulfate, sodium selenite or potassium iodide.
- one or more vitamins comprise one or more of vitamin A, vitamin D, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, niacinamide, calcium pantothenate, folic acid, pantothenic acid, vitamin Bl 2, vitamin C, biotin, choline, inositol, and salts thereof.
- an edible composition comprises vitamin A palmitate, vitamin D3, D-a tocopherol, vitamin KI, thiamine hydrochloride, riboflavin, niacinamide, calcium pantothenate, pyridoxine hydrochloride, biotin, folic acid, cyanocobalamin, choline bitartrate, inositol and ascorbic acid.
- an edible composition comprises one or more nucleotides.
- one or more nucleotides comprise one or more of cytidine 5 ’-monophosphate, uridine 5 ’-monophosphate, adenosine 5 ’ -monophosphate or guanosine 5 ’-monophosphate.
- an edible composition comprises cytidine 5 ’-monophosphate, disodium uridine 5 ’-monophosphate, adenosine 5 ’-monophosphate and disodium guanosine 5 ’-monophosphate.
- an edible composition comprises a whey protein-lipid concentrate, for example, an edible composition comprises from about 3.0% to about 5.0% by weight whey protein-lipid concentrate.
- an edible composition comprises milk fat globule membrane (MFGM) [19]
- an edible composition comprises casein, such as, a micellar casein.
- an edible composition comprises from about 5% to about 8% by weight micellar casein.
- an edible composition comprises from about 50% to about 55% by weight of lactose powder. In embodiments, an edible composition comprises a whole milk powder. In embodiments, an edible composition comprises from about 13% to about 18% by weight whole milk powder.
- a probiotic organism is a Bifidobacterium.
- a Bifidobacterium is Bifidobacterium infantis.
- an edible composition comprises from about 43% to about 70% by weight of lactose, from about 0.5% to about 6% by weight of milk fat, from about 9% to about 13% by weight of protein, from about 1.5% to about 3.0% by weight of minerals, from about 0.5% to about 2.0% by weight of vitamins, from about 0.5% to about 2.0% by weight of 2'-fucosyllactose, from about 5x10 8 cfu/lOOg to about IxlO 11 cfu/100g of probiotic microbe and from about 0.02% to about 0.3% by weight of a human secretory protein.
- an edible composition comprises from about 0.01% to about 0.06% by weight of nucleotides.
- an edible composition comprises from about 0.06% to about 0.4% by weight of arachidonic acid (ARA).
- ARA arachidonic acid
- an edible composition comprises from about 0.03% to about 0.3% by weight of docosahexaenoic acid (DHA).
- DHA docosahexaenoic acid
- an edible composition comprises from about 0.00002% to about 0.00009% by weight of lutein.
- an edible composition comprises from about 0.025% to about 0.07% by weight of taurine.
- an edible composition comprises from about 0.002% to about 0.015% by weight of L-carnitine.
- an edible composition comprising lactose, one or more lipids, protein, a human milk oligosaccharide (HMO), one or more minerals, one or more vitamins, a probiotic microbe and recombinant human lactoferrin (rhLF), which can comprise one or more human-like glycans, N-glycan found in human protein.
- HMO human milk oligosaccharide
- rhLF recombinant human lactoferrin
- an edible composition comprising a recombinant human secretory protein from a non-mammal cell, a recombinant human secretory protein comprising one or more human-like glycans, N-glycans found on human glycoproteins.
- a human secretory protein is a recombinant protein.
- a human secretory protein is from a mammal cell.
- a human secretory protein is from a non-mammal cell.
- a human secretory protein is from a bacterium.
- a human secretory protein is from a fungus cell.
- a human secretory protein is from a yeast cell.
- a yeast cell is of a genus, Arxula, Aspergillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tr erne Ila, Trichosporon, Wicker hamomyces or Yarrowia.
- a human secretory protein is secretory IgA (slgA), human serum albumin, xanthine dehydrogenase, lactoferrin, lactoperoxidase, butyrophilin, lactadherin, adiponectin, ⁇ -casein, ⁇ -casein, leptin, lysozyme or ⁇ -lactalbumin.
- a human secretory protein is human lactoferrin.
- a human secretory protein is a human whey protein.
- a human secretory protein comprises a human-like glycan, that is, an N-glycan found in human glycoprotein.
- a human secretory protein comprises a hybrid N-glycan.
- a human secretory protein comprises a complex N-glycan.
- a human secretory protein comprises a bi-antennary, a tri-antennary or a tetra-antennary N-glycan.
- the human secretory protein comprises a glycan comprising sialic acid, galactose, N-acetylgalactosamine or fucose.
- a human secretory protein comprises a high-mannose N-glycan. In embodiments, a human secretory protein comprises a glycan having less than ten mannose residues. In embodiments, a human secretory protein comprises a glycan having less than four mannose residues. In embodiments, a human secretory protein comprises a glycan having four or more mannose residues.
- a method for providing nutrition to a subject comprising feeding said subject an edible composition of interest as described herein.
- a method for producing an edible composition comprising generating a mixture disclosed herein, for example, a mixture comprising a protein and a human secretory protein (for example, a recombinant human milk protein, such as, a recombinant human lactoferrin, which can have human-like glycans), and optionally including one or more of, a lactose, one or more lipids, protein, a human secretory oligosaccharide, such as, a human milk oligosaccharide (HMO), one or more minerals, one or more vitamins and a probiotic microbe.
- a human secretory protein for example, a recombinant human milk protein, such as, a recombinant human lactoferrin, which can have human-like glycans
- a lactose for example, a recombinant human milk protein, such as, a recombinant human lactoferrin, which can have human-like g
- an edible composition comprises a food, such as, a bar, a dairy product, such as, a yogurt or an ice cream, a nutritional powder, an infant formula powder, a candy, such as, a gummy, and so on.
- An edible composition of interest also comprises a potable composition, such as, a beverage, a smoothie, a shake, a ready to use infant formula, a liquid nutraceutical, a drinkable nutritional composition and so on.
- the invention relates to an infant formula comprising lactose, one or more lipids, protein, a human milk oligosaccharide (HMO), one or more minerals, one or more vitamins, a probiotic microbe and a human secretory protein.
- lactose lactose
- one or more lipids protein
- a human milk oligosaccharide HMO
- one or more minerals one or more minerals
- one or more vitamins a probiotic microbe and a human secretory protein.
- the infant formula of the first embodiment comprises secretory IgA (slgA), human serum albumin, xanthine dehydrogenase, lactoferrin (LF), such as, human LF (hLF), lactoperoxidase, butyrophilin, lactadherin, adiponectin, ⁇ -casein, ⁇ -casein, leptin, lysozyme or ⁇ -lactalbumin.
- slgA secretory IgA
- human serum albumin such as, xanthine dehydrogenase
- lactoferrin such as, human LF (hLF), lactoperoxidase, butyrophilin, lactadherin, adiponectin, ⁇ -casein, ⁇ -casein, leptin, lysozyme or ⁇ -lactalbumin.
- LF lactoferrin
- the human secretory protein of the second embodiment is human lactoferrin.
- the human secretory protein is a human whey protein.
- the human secretory protein of any of the formula of embodiments 1-4 comprises a hybrid N-glycan.
- the human secretory protein of any of the formula of embodiments 1-4 comprises a complex N-glycan.
- the human secretory protein of the 6 th embodiment comprising a bi-antennary, tri-antennary or tetra-antennary N-glycan.
- the human secretory protein of any of the formula of embodiments 1-4 comprises a high-mannose N-glycan.
- the human secretory protein of any of the formula of embodiments 1-4 comprises sialic acid, galactose, N-acetylgalactosamine, or fucose.
- the human secretory protein of any of the formula of embodiments 1-4 comprises a glycan having less than ten mannose residues.
- the human secretory protein of any of the formula of embodiments 1-4 comprises a glycan having less than four mannose residues.
- the human secretory protein of any of the formula of embodiments 1-4 comprises a glycan having four or more mannose residues.
- the formula of embodiment 13 comprises 2'-fucosyllactose.
- the formula of embodiment 13 comprises
- the formula of any of the previous embodiments comprises one or more of high oleic sunflower oil, mid-oleic sunflower oil, safflower oil, coconut oil, canola oil, low erucic rapeseed oil, sunflower oil, ascorbyl palmitate, mixed tocopherol concentrate, Mortierella alpina oil, alga oil, soybean oil and palm oil.
- the formula of the 16th embodiment comprises high oleic sunflower oil, coconut oil, canola oil, low erucic rapeseed oil, sunflower oil, ascorbyl palmitate, mixed tocopherol concentrate, Mortierella alpina oil and alga oil.
- the formula of any of the previous embodiments comprises one or more of calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium and selenium.
- the formula of the 18th embodiment comprises calcium phosphate, calcium citrate, magnesium chloride, potassium citrate, potassium chloride, sodium chloride, copper sulfate, ferrous sulfate, manganese sulfate, zinc sulfate, sodium selenite and potassium iodide.
- the formula of any of the previous embodiments comprises one or more of vitamin A, vitamin D, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, niacinamide, calcium pantothenate, folic acid, pantothenic acid, vitamin B 12, vitamin C, biotin, choline, inositol, and salts thereof.
- the formula of the 20 th embodiment comprises vitamin A palmitate, vitamin D3, D-a-tocopherol, vitamin KI, thiamine hydrochloride, riboflavin, niacinamide, calcium pantothenate, pyridoxine hydrochloride, biotin, folic acid, cyanocobalamin, choline bitartrate, inositol and ascorbic acid.
- nucleotides comprise cytidine 5 ’ -monophosphate, uridine 5 ’-monophosphate, adenosine 5 ’-monophosphate and guanosine 5 ’-monophosphate.
- the formula of the 23 rd embodiment comprises cytidine 5 ’-monophosphate, disodium uridine 5 ’-monophosphate, adenosine 5 ’-monophosphate and di sodium guanosine 5 ’-monophosphate.
- the formula of the 25th embodiment comprising from about 3.0% to about 5.0% whey protein-lipid concentrate.
- the formula of the 28th embodiment comprising from about 5% to about 8% micellar casein.
- the formula of the 25 th to 29 th embodiments comprises from about 50% to about 55% by weight of lactose powder.
- the formula of the 1 st to 24 th embodiments comprises whole milk powder.
- the human secretory protein of any of the formula of the previous embodiments which is a recombinant protein.
- the human secretory protein of the formula of the 35 th embodiment which is from a mammal cell.
- the human secretory protein of the formula of the 35 th embodiment which is from a non-mammal cell.
- the human secretory protein of the formula of the 35 th embodiment which is from a bacterium.
- the human secretory protein of the formula of the 35 th embodiment which is from a fungus cell.
- the human secretory protein of the formula of the 35 th embodiment which is from a yeast cell.
- the human secretory protein of the formula of the 40 th embodiment which is from a yeast cell of an Arxula, Aspergillus, Aurantiochy trium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon, Wicker hamomyces or Yarrow ia.
- the formula of any the prior embodiments comprises from about 43% to about 70% by weight of lactose, from about 0.5% to about 6% by weight of milk fat, from about 9% to about 13% by weight of protein, from about 1.5% to about 3.0% by weight of minerals, from about 0.5% to about 2.0% by weight of vitamins, from about 0.5% to about 2.0% by weight of 2'-fucosyllactose, from about 5xl0 8 cfu/lOOg to about IxlO 11 cfu/lOOg of the probiotic organism and from about 0.02% to about 0.3% by weight of the human milk protein.
- the formula of any of the previous embodiments comprising from about 0.06% to about 0.4% by weight of arachidonic acid
- the formula of any of the previous embodiments comprising from about 0.03% to about 0.3% by weight of docosahexaenoic acid.
- the forty-ninth embodiment relates to an infant formula comprising lactose, one or more lipids, protein, a human milk oligosaccharide (HMO), one or more minerals, one or more vitamins, a probiotic microbe, and a recombinant human lactoferrin protein comprising one or more human-like glycans.
- HMO human milk oligosaccharide
- the fifty-second embodiment relates to a method for providing nutrition to an infant comprising feeding to an infant the infant formula of any of the prior embodiments.
- the fifth-third embodiment relates to an infant formula comprising a recombinant human secretory protein from a non-mammal cell, comprising one or more human-like glycans.
- the human secretory protein is secretory IgA (slgA), human serum albumin, xanthine dehydrogenase, lactoferrin, lactoperoxidase, butyrophilin, lactadherin, adiponectin, ⁇ -casein, ⁇ - casein, leptin, lysozyme, or ⁇ -lactalbumin.
- the human secretory protein is human lactoferrin (hLF).
- the human secretory protein is a human whey protein.
- the human secretory protein of embodiments 53-56 comprising a glycan comprising sialic acid, galactose, N-acetylgalactosamine, or fucose.
- the human secretory protein of embodiments 53-56 comprises a complex N-glycan.
- the human secretory protein of embodiment 58 comprises a bi-antennary, tri-antennary or tetra-antennary N-glycan.
- the human secretory protein of embodiments 53-56 comprising a hybrid N-glycan.
- the human secretory protein of the 53rd embodiment is from a bacterium.
- the human secretory protein of the 53rd embodiment is from a fungus cell.
- the human secretory protein of the 53rd embodiment is from a yeast cell
- the yeast cell of the 63rd embodiment is of a genus Arxiila, Aspergillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon, Wickerhamomyces or Yarrowia.
- the sixty-fifth embodiment relates to a method for providing nutrition to an infant comprising feeding to an infant the infant formula of any of embodiments 53-64.
- the sixty-sixth embodiment relates to a method for producing an infant formula comprising generating a mixture comprising lactose, one or more lipids, bovine protein, a human milk oligosaccharide (HMO), one or more minerals, one or more vitamins, a probiotic microbe, and a human secretory protein.
- a mixture comprising lactose, one or more lipids, bovine protein, a human milk oligosaccharide (HMO), one or more minerals, one or more vitamins, a probiotic microbe, and a human secretory protein.
- HMO human milk oligosaccharide
- the human secretory protein is from a mammal cell.
- the human secretory protein is from a non-mammal cell.
- the cell in a sixty-ninth embodiment, in the method of the 68th embodiment, is a yeast cell.
- the yeast cell is of a genus of Arxula, Aspergillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon, Wickerhamomyces or Yarrowia.
- the human secretory protein is secretory IgA (slgA), human serum albumin, xanthine dehydrogenase, lactoferrin, lactoperoxidase, butyrophilin, lactadherin, adiponectin, ⁇ -casein, ⁇ -casein, leptin, lysozyme or u-lactalbumin.
- secretory IgA slgA
- human serum albumin xanthine dehydrogenase
- lactoferrin lactoperoxidase
- butyrophilin lactadherin
- lactadherin lactadherin
- adiponectin ⁇ -casein
- leptin lysozyme or u-lactalbumin.
- the human secretory protein is human lactoferrin.
- the human secretory protein is human whey protein.
- the human secretory protein comprises a glycan comprising sialic acid, fucose, galactose or N-acetylgalactosamine.
- the human secretory protein comprises a complex N-glycan.
- the human secretory protein comprises a bi-antennary, tri-antennary or tetra-antennary N-glycan.
- the human secretory protein comprises a hybrid N-glycan.
- the human secretory protein comprises a high-mannose N-glycan.
- aspects of the present disclosure address the lack or scarcity of human secretory proteins in the commercial market by including a source of recombinant human secretory proteins (for example, lactoferrin) for use as a food ingredient or foodstuff in edible compositions, such as, an infant formula. That will bring the antimicrobial, anti-inflammatory and anti -oxi dative properties of those proteins to consumers who previously, realistically, could only access those proteins in non-human milk, despite interspecies differences in milk of different mammals, or from human milk.
- Edible compositions comprise, in addition to one or more human secretory protein, custom combinations of other individual ingredients of similar biologic activity to maximize immunomodulatory and nutritional impact of a formulation of interest.
- an edible composition comprising one or more human secretory proteins together with one or more human oligosaccharides, such as, human milk oligosaccharides (HMO) with probiotic microbes (for example, a Bifidobacterium, such as, Bifidobacterium infantis).
- HMO human milk oligosaccharides
- probiotic microbes for example, a Bifidobacterium, such as, Bifidobacterium infantis.
- an, “infant formula,” is any composition comprising components which serve as a simulation of human milk or as a complete or partial substitute for human milk.
- an, “infant formula,” is a composition as defined in 21 U.S.C. ⁇ 321.
- An infant formula of the present disclosure may be a solid composition (for example, a powder).
- An infant formula of the disclosure may be a liquid composition.
- a liquid composition can be a concentrate or ready to use.
- A, “nutritional composition,” or an, “edible composition,” according to the instant invention is, for example, an, “infant formula,” and relates to a foodstuff intended for nutritional use by infants from birth and during the first 6-12 months of life and satisfying nutritional requirements of infants and babies.
- An infant formula can be intended for use as the only source of nutrients from birth to about 6 months of age.
- a formula used in the first six months of life can be termed a, “starter formula.”
- preterm infant formula means an infant formula intended for a preterm infant.
- milk fortifier refers to liquid or solid edible and nutritional compositions suitable for mixing with breast milk (which is human milk for a human milk fortifier) or infant formula.
- a milk fortifier can be used to increase calories, protein content, mineral amount and vitamins in breast milk fed to preterm infants or infants with a low birth weight.
- Breast milk is not only milk but also relates to colostrum of a mother, or a donor milk or a colostrum of a donor.
- an edible composition according to the invention may be intended as a, “follow-on formula,” a complement or as a part of a progressively diversified diet wherein formula feeding starts, for example, when an infant is about 4 months of age and feeding of formula is part of an infant diet up to the first year birthday of a baby.
- An infant may start to include a formula according to the invention between 4-6 months, which is when most infants start with solids, or at least when breastfed infants nutrient intake is complemented with solids from 6 months up to 12 months.
- a follow-on formula is a formula intended to be used from about 6 months onwards during a weaning period, as a complement to solids which are introduced at about 6 months.
- An infant formula can be mixed with a cereal to form an, “infant cereal composition,” a foodstuff intended for particular nutritional use by infants or children, such as, young children, during first years of life.
- An edible composition can be a powder concentrate or a liquid concentrate intended to be mixed with water before use, or a liquid ready-to-use product.
- ready-to-use product refers to liquid formulae suitable for direct oral administration out of a packaging to an infant, wherein a formula is a ready to-feed liquid, a reconstituted powder or a diluted liquid concentrate.
- an, “infant,” is a child under the age of 12 months.
- Isolated is used to describe a biologic moiety that is removed from a normal environment thereof. Isolating is a form of, “purifying,” as extraneous material is removed from a target of interest.
- a gene can be excised from a chromosome away from upstream and downstream elements normally associated with an open reading frame.
- a protein can be removed from the soup of the intracellular milieu or can be dissociated from an intracellular structure or from a membrane, for example. An external intervention removes an entity from normal surroundings thereof to isolate that entity.
- ‘Recombinant,” in biotechnology or molecular biology means pieces of biologic molecules not normally found together are joined to form a new, artificial, synthetic composite molecule. Hence, pieces of nucleic acids of different origin are joined to make a new, unnatural unitary nucleic acid that otherwise, would not be found in nature. Similarly, as to proteins, polypeptides or domains thereof can be joined to form a new molecular entity with composite or new functions, that otherwise would not be found in nature. A recombinant is artificial.
- a synonymous term in the art is, “engineered,” or grammatic forms thereof.
- N-glycan is an N-linked oligosaccharide, that is, a sugar attached by an asparagine-N-acetylglucosamine linkage to nitrogen of an asparagine residue of a polypeptide.
- N-glycan is a glycan (also termed a polysaccharide) having both substituted (GlcNAc linkage) and unsubstituted mannose residues.
- N-glycan is a glycan having at least one GlcNAc attached to a 1,3-mannose arm and at least one GlcNAc attached to a 1,6-mannose arm of a trimannose core.
- a complex N-glycan has at least one branch that terminates in an oligosaccharide such as, for example, NeuNAc-, NeuAca2-6GalNAcal-, NeuAca2-3Galbl-3GalNAcal- orNeuAca2- 3/6Galbl-4GlcNAcbl-.
- Complex N-glycans also can have intrachain substitutions comprising, “bisecting,” GlcNAc and core fucose (“Fuc”).
- high-mannose is a glycan having at least 4 mannose residues.
- a high-mannose glycan has 4, 5, 6, 7, 8, 9 or more mannose (Man) residues.
- MFGM Milk fat globule membrane
- Sphingomyelin, phosphatidyl choline, phosphatidyl serine and phosphatidyl ethanolamine are dominating phospholipids of MFGM.
- Butyrophilin, MUC1, PAS6/7 (lactadherin), CD14, TLR1 and TLR4 are examples of MFGM proteins, those with antimicrobial effect (Spitsberg, J Dairy Sci, 2005, 88:2289-2294; Reinhardt & Lippolis, J Dairy Res, 2006,.
- Lacprodan MFGM-10 (Aria Foods, Viby J, Denmark) or similar raw materials from other suppliers are enriched in MF GM and may be used as enriched phospholipid whey protein concentrate solids or a lipid source in an edible composition of interest.
- Recombinant refers to a cell, nucleic acid, protein or vector, which has been modified due to introduction of an exogenous nucleic acid or alteration of a native nucleic acid by human manipulation or intervention. Resulting cells, nucleic acids, proteins or vectors are considered recombinant, as are progeny, offspring, duplications or replications thereof, which also are considered recombinant. Thus, for example, recombinant cells can express genes not found within a native (non-recombinant) form of the cell or express native genes differently than those same genes are expressed by a non-recombinant cell.
- Recombinant cells can, without limitation, include recombinant nucleic acids that encode for a gene product or for suppression elements, such as mutations, knockouts, antisense, interfering RNA (RNAi) or dsRNA and so on that reduce level of an active gene product in a cell.
- RNAi interfering RNA
- A, "recombinant nucleic acid,” is derived from nucleic acid originally formed in vitro, in general, by exogenous, human-originated or human-mediated manipulation of nucleic acid, for example, using polymerases, ligases, exonucleases and endonucleases, or otherwise to form an artificial form not normally found in nature.
- a recombinant nucleic acid refers to nucleotide sequences that comprise an endogenous nucleotide sequence and an exogenous nucleotide sequence; thus, an endogenous gene that has undergone recombination with an exogenous promoter is a recombinant nucleic acid.
- A, "recombinant protein,” is a protein made using recombinant techniques, for example, through expression of a recombinant nucleic acid.
- A, B, and/or C includes: A alone, B alone, C alone, a combination of A and B, a combination of A and C, a combination of B and C, or a combination of A, B, and C.
- “and/or,” operates as an inclusive or.
- compositions and methods for use thereof can, “comprise,” “consist essentially of,” or, “consist of,” any of ingredients or steps disclosed throughout the specification.
- Compositions and methods, “consisting essentially of,” ingredients or steps disclosed defines scope of a claim to specified materials or steps which materially impact the basic and novel characteristic of the claimed embodiment.
- Consumable foodstuff include compositions that are edible or are used to produce foodstuffs, that is, food-grade ingredients that are edible.
- Food grade relates to material used to make a foodstuff or is permitted to come into direct contact with a foodstuff intended for human consumption.
- Food grade generally means a material that is FDA compliant and meets FDA guidelines and rules for foodstuffs.
- GRAS safe
- Foodstuffs can be manufactured and handled under local and federal guidelines and regulations, such as, compliance with ISO 9001 or 22000 (International Organization of Standardization, Geneva, CH) and GMP guidelines provided by the FDA, such as, 21 CFR, various parts, such as, 117, to provide foodstuffs safe for human consumption.
- “edible,” relates to a composition that can be consumed by a subject.
- An edible composition can be a solid or a liquid.
- a solid has definite volume and definite shape, such as, a powder, a bar, a gummy, a pasta and so on.
- a liquid, a potable has volume but no shape, such as, a beverage, a syrup, a lotion, a tonic and so on.
- Edible food products can be consumer packaged good (CPG), loose or bulk items and so on, consumable items and packages thereof found in, for example, groceries, stores, supermarkets, convenience stores, service stations, markets, vending machines and so on that vend, sell or distribute edible compositions.
- CPG consumer packaged good
- a flavorant is any ingredient in an edible composition that imparts a flavor, taste on or to that composition.
- a flavorant can include compounds and compositions in the food and pharmaceutic arts for imparting a taste or flavor, such as, an essence, a compound, for example, butyric acid, and so on, with no apparent or necessary nutritional value, but as used herein, flavorant also includes any ingredient, compound or composition used in an edible composition of interest to impart a flavor or taste on or to an edible composition, such as, a juice, milk, milk solids, ascorbic acid, corn syrup, lactose, sugar, nuts, which may be ground, fruit, which may be dried, macerated and so on, roots, vegetables and so on.
- ichia pastoris is a yeast commonly used for commercial production of recombinant protein. Recently, the genus, Pichia, was renamed, “Komagataella,” and the species as, “Komagataella pastoris ”
- probiotic describes microbial cells or components of microbial cells with a beneficial effect on health or well-being of a host.
- a probiotic bacterium can be of the genera, Lactobacillus, Bifidobacterium and Bacillus, known to possess probiotic activity.
- a probiotic composition can comprise a fungus or a yeast.
- Probiotic microbes may be present in a compositions of any aspect or embodiment of the instant invention, for example, in an amount: >5 million, >10 million, >15 million, >20 million, >25 million, >30 million, >35 million, >45 million, >50 million, >75 million, >100 million, >250 million, >500 million, >750 million, >1 billion or >2 billion bacteria per serving.
- a probiotic may be present in amounts of: 5 million to 2500 million, 10 million to 2500 million, 30 million to 2500 million, 50 million to 2500 million, 50 million to 1000 million, 75 million to 2500 million, 75 million to 1000 million, 100 million to 2500 million, 100 million to 1000 million, 250 million to 2500 million, 250 million to 1000 million, 500 million to 2500 million, 500 million to 1000 million, 750 million to 2500 million or 750 million to 1000 million, 1 billion to 2.5 billion, 1.5 to 2.5 billion or more microbes per serving.
- compositions of the instant invention may be formulated to provide a daily dose of a probiotic microbe of, for example, from 10 3 to 10 14 , 10 4 to 10 12 , 10 5 to 10 12 , 10 6 to 10 12 , 10 7 to 10 11 , from about 10 7 to about 10 10 or more colony forming units (cfu), microbes or other unit of measurement.
- a probiotic microbe of, for example, from 10 3 to 10 14 , 10 4 to 10 12 , 10 5 to 10 12 , 10 6 to 10 12 , 10 7 to 10 11 , from about 10 7 to about 10 10 or more colony forming units (cfu), microbes or other unit of measurement.
- a probiotic microbe may be cultured according to any suitable method and prepared for addition to an edible composition by known techniques, such as, for example, freeze-drying or spray-drying.
- Probiotic microbe preparations can be purchased, for example, from Morinaga Milk, Institut Rosell, Christian Hansen and so on.
- A, “prebiotic,” molecule or moiety is a compound that fosters, encourages, supports, enhances and so on growth of beneficial microbes in vivo, such as, in the gut, providing a conducive microbiota.
- a prebiotic moiety is indigestible in stomach, is fermented by microbes and stimulates growth of microbes.
- Compounds considered prebiotic include fiber, ⁇ -glucan, inulin, oligosaccharides, pectin, HMO’s, fructans, xylans and so on.
- ingredients for making an edible composition of interest are known, are available commercially as food grade or pharmaceutical grade ingredients, or can be made or obtained as taught in the art.
- some ingredients taught herein can be purchased from Hilmar Cheese, Hilmar, CA (lactose, whey protein isolate, whey protein hydrosylate, whey protein concentrate and milk protein isolate), Foremost Farms, Middleton, WI (lactose), Adams Group, Arbuckle, CA (vegetable oil blend and lecithin), AAK USA Inc., Edison, NJ (Sn2 palmitate and vegetable oil blend), Fonterra, Chicago, IL (whole milk powder and milk protein isolate), Leprino Nutrition, Denver, CO (whey protein concentrate), Aria Foods, Basking Ridge, NJ (MFGM and ⁇ -lactalbumin enriched whey protein), DSM Foods USA, Germantown, WI (mineral mix, 2’-fucosyllactose, lutein, DHA oil and ARA-DHA blend), Balchem, Montvale,
- Protein refers to a molecule comprising at least five amino acid residues.
- Wild-type refers to an endogenous version of a molecule that occurs naturally in an organism in the wild. A wild type form generally is the more prevalent from in a panmictic population. A common form may be, for example, a gene, a protein, a trait and so on.
- a wild-type version of a protein or polypeptide is employed, however, in embodiments of the disclosure, a modified protein or polypeptide can be employed.
- the terms described above may be used interchangeably.
- A, “modified protein,” or, “modified polypeptide,” “mutant,” “altered,” or a, “variant,” refers to a protein or polypeptide where the chemical structure thereof, particularly the amino acid sequence thereof, is altered relative to the wild-type protein or polypeptide; or a variant carries one or more other elements attached to a wild type polypeptide.
- a modified/variant protein or polypeptide has at least one modified activity or function (recognizing that proteins or polypeptides may have multiple activities or functions).
- a modified/variant protein or polypeptide may be altered with respect to one activity or function yet retain a wild-type activity or function in other respects
- a protein specifically is mentioned herein, that reference is to a native (wild-type) or a recombinant (modified) protein, such as, an incipient secreted protein in which any signal sequence attached thereto is removed.
- a protein may be isolated directly from an organism of which it is native, produced by a recombinant DNA/exogenous expression method, produced by solid-phase peptide synthesis (SPPS) or other in vitro method.
- SPPS solid-phase peptide synthesis
- size of a protein or polypeptide may comprise, but is not limited to, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 2
- polypeptides may be mutated by truncation, rendering a polypeptide shorter than a corresponding wild-type or modified form.
- a polypeptide might be altered by fusing or conjugating a heterologous protein or polypeptide sequence with a particular function (for example, for targeting or localization, for purification etc.) thereto or therewith.
- domain refers to a distinct functional or structural unit or portion of a protein or polypeptide, and generally refers to a sequence of amino acids with one of a structure or function recognizable by one skilled in the art associated with a protein with that one or multiple structures or functions.
- Polynucleotide refers to a nucleic acid molecule that either is recombinant or has been isolated from total genomic nucleic acid. Included within the term, “polynucleotide,” are oligonucleotides (nucleic acids 100 residues or less in length), recombinant vectors, including, for example, plasmids, cosmids, phage, viruses and the like. Polynucleotides include regulatory sequences, isolated substantially away from associated or related naturally occurring genes or protein encoding sequences, such as, control sequences.
- Polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be RNA, DNA (genomic, cDNA, synthetic and so on), analogs thereof or a combination thereof. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide.
- a polynucleotide may be modified as known in the art for a desired purpose, such as, codon optimization, stability and so on.
- Gene “polynucleotide,” or, “nucleic acid,” is used to refer to a nucleic acid that encodes a protein, polypeptide or peptide (including any sequences, such as control sequences, required for proper transcription, post-translational modification or localization).
- the term encompasses genomic sequences, expression cassettes, cDNA sequences and smaller engineered nucleic acid segments that express, or may be adapted to express, proteins, polypeptides, domains, peptides, fusion proteins and mutants.
- a nucleic acid encoding all or part of a polypeptide may contain a contiguous nucleic acid sequence encoding all or a portion of such a polypeptide.
- polypeptide may be encoded by nucleic acids containing variations, having slightly different nucleic acid sequences but, nonetheless, encode the same or substantially similar protein, and so, herein, which can be identified as modified polynucleotides.
- polynucleotide variants having substantial identity to sequences disclosed herein; those comprising at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher sequence identity, including all values and ranges there between, compared to a polynucleotide sequence provided herein using methods described herein (for example, BLAST analysis using standard parameters).
- an isolated polynucleotide will comprise a nucleotide sequence encoding a polypeptide that has at least 90%, and in some cases, 95% or more identity to an amino acid sequence described herein, over the entire length of the sequence; or a nucleotide sequence complementary to said isolated polynucleotide.
- Nucleic acid segments regardless of length of the coding sequence, an open reading frame, may be combined with other nucleic acid sequences, such as, promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments other control and expression regions and the like, such that overall length may vary considerably. Nucleic acids can be any length.
- a nucleic acid of interest can be, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 175, 200, 250, 300, 350, 400, 450, 500, 750, 1000, 1500, 3000, 5000 or more nucleotides in length, and/or can comprise one or more additional sequences, for example, regulatory sequences, and/or be a part of a larger nucleic acid, for example, a vector. It therefore is contemplated that a nucleic acid fragment of almost any length may be employed, with total length preferably being limited by ease of preparation and manipulation, and use in an intended recombinant nucleic acid protocol.
- a nucleic acid sequence may encode a polypeptide sequence with additional heterologous coding sequences, for example, to allow for purification of a polypeptide, transport, secretion, post-translational modification, or for therapeutic benefit, such as, targeting or efficacy.
- a tag or other heterologous polypeptide may be added to a modified polypeptide-encoding sequence, wherein, “heterologous,” refers to a polypeptide that is not the same as the modified polypeptide.
- Polypeptides, proteins or polynucleotides encoding such polypeptides or proteins of the disclosure may include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (or any derivable range therein) or more variant amino acids, or nucleic acid substitutions; or be at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any derivable
- Nucleotide as well as a protein, polypeptide and peptide sequences for various genes have been previously disclosed, and may be found in recognized computerized databases. Two commonly used databases are Genbank and Genpept of the National Center for Biotechnology Information (ncbi.nlm.nih.gov) and The Universal Protein Resource (UniProt at uniprot.org). Coding regions for genes may be amplified and/or expressed using techniques disclosed herein or as would be known to those of ordinary skill in the art.
- compositions of the disclosure there is between about 0.001 mg and about 10 mg of total polypeptide, peptide and/or protein per ml.
- Concentration of protein in a composition can be about, at least about or at most about 0.001, 0.010, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0 mg/ml or more (or any range derivable therein).
- human milk proteins as well as compositions comprising such proteins and methods of use thereof.
- a, “human milk protein,” describes any protein present in human breast milk.
- a human milk protein includes a protein derived from (for example, isolated from) human breast milk, as well as any protein produced by other means (for example, recombinant expression, chemical synthesis etc.) having an amino acid sequence of a protein present in human breast milk, the wild type form.
- human milk proteins are recognized in the art and are contemplated herein, including, but not limited to, secretory IgA (slgA), human serum albumin, xanthine dehydrogenase, lactoferrin (LF), lactoperoxidase, butyrophilin, lactadherin, adiponectin, ⁇ -casein, ⁇ -casein, leptin, lysozyme and ⁇ -lactalbumin.
- a human milk protein of the disclosure is a human whey protein.
- a human milk protein of the disclosure is a recombinant human milk protein (for example, produced by a non-mammal cell, such as, a yeast cell).
- Human-like glycans are glycans having structures present in human glycoprotein.
- Such glycans include, for example, hybrid N-glycans, complex N-glycans, bi-antennary, tri-antennary and tetra-antennary N-glycans, high-mannose glycans and glycans comprising sialic acid, galactose, N-acetylgalactosamine or fucose.
- Human-like glycans include those having a Man3GlcNAc2 core structure.
- human milk proteins of the disclosure include those having one or more human-like glycans, for example, hybrid N-glycans, complex N-glycans, high-mannose glycans, bi-antennary N-glycans, tri-antennary N-glycans, tetra-antennary N-glycans and combinations thereof.
- human-like glycans for example, hybrid N-glycans, complex N-glycans, high-mannose glycans, bi-antennary N-glycans, tri-antennary N-glycans, tetra-antennary N-glycans and combinations thereof.
- recombinant (r) human (rh) milk proteins comprising one or more human-like glycans.
- recombinant protein includes, for example, those produced by engineered mammal, fungus, yeast, bacterium or other cells, including engineered cells described herein.
- recombinant proteins can have a glycan pattern different from a glycan pattern of a corresponding natural or naturally occurring wild type human milk protein.
- a recombinant human lactoferrin comprising one or more human-like glycans, where the lactoferrin has a glycan pattern that can be different from a glycan pattern of any naturally occurring human lactoferrin (for example, human lactoferrin in human breast milk).
- a composition comprising a plurality of recombinant human lactoferrin proteins, where glycan pattern across all of the recombinant human lactoferrin proteins can be different than a glycan pattern across all naturally occurring human lactoferrin in a human secretion (for example, breast milk).
- Recombinant glycoproteins often have glycosylation profiles, patterns or fingerprint different from that found on, in or of the corresponding wild-type or naturally occurring glycoprotein. Nevertheless, the varying carbohydrates may not negatively impact glycoprotein function, such as, observed with the instant rhLF of interest, for example, binding iron. Also, carbohydrate on recombinant glycoprotein may not be as allergenic or immunogenic; or immunogenic or allergenic as wild type might be or is (Almond et al., Toxicology 301:50-57, 2012).
- lactoferrin is a whey protein found in exocrine fluids, such as, breast milk and is encoded by the LTF gene.
- LF binds iron (the holo form), and the apo form is free of iron.
- lactoferrin is understood to have antimicrobial and anti-inflammatory properties.
- hLF human lactoferrin
- P02788 Human lactoferrin
- SEQ ID NO: 1 Full sequence of human lactoferrin, including signal peptide, is provided as SEQ ID NO: 1.
- Sequence of mature human lactoferrin following cleavage of the signal peptide is provided as SEQ ID NO:2.
- a human lactoferrin of the present disclosure is a recombinant human lactoferrin (rhlactoferrin).
- a recombinant human lactoferrin of the disclosure is obtained from a mammal, fungus, yeast, bacterium or other cell.
- a recombinant human lactoferrin of the disclosure is not obtained from a mammal cell.
- a recombinant human lactoferrin of the disclosure is obtained from a yeast cell.
- the yeast cell may be, for example, from an Arxula, Aspergillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon, Wicker hamomyces or Yarrowia.
- the yeast cell is a Komagataella cell (for example, Komagataella phaffii, Pichia pastoris, Komagataella pastoris, Komagataella pseudopastoris). Additional yeast species suitable for recombinant protein production are recognized in the art and contemplated herein.
- a recombinant human lactoferrin of the disclosure is obtained from a bacterium.
- a human lactoferrin of the disclosure is isolated from a natural source.
- a human lactoferrin having at least one hybrid or complex N-glycan.
- a human lactoferrin comprises a glycan comprising one or more of sialic acid, galactose, N-acetylgalactosamine or fucose.
- a human lactoferrin comprises a bi-antennary, tri-antennary or tetra-antennary N-glycan.
- human lactoferrin having one or more hybrid, complex, bi-antennary, tri-antennary or tetra-antennary N-glycan may be useful in, for example, infant formula or other edible or nutritional compositions, or supplements.
- recombinant human secretory proteins of interest have at least three advantages over naturally occurring secretory protein. Because the instant method relates to a sole non-human source of secretory protein, the transformed microbe, once FDA approval of the manufacturing process of interest is obtained, that will make available unlimited amounts of recombinant secretory protein, such as, rhLF, which is less immunogenic and less allergenic than wild-type.
- the instant invention enables commercial development of edible compositions comprising human secretory proteins, allowing all to profit from benefits of human secretory proteins.
- aspects of the present disclosure are directed to ⁇ -lactalbumin (alpha-lac, a-lac and so on), as well as compositions comprising ⁇ -lactalbumin, including an infant formula composition.
- a-Lactalbumin is a whey protein found in breast milk and is encoded by the LALBA gene.
- aspects of the disclosure are directed to human ⁇ -lactalbumin (UniProtKB/Swiss-Prot accession number P00709), including isoforms thereof.
- Full sequence of human ⁇ -lactalbumin, including signal peptide is provided as SEQ ID NO:3. Sequence of mature human ⁇ -lactalbumin following cleavage of the signal peptide is provided as SEQ ID NO:4.
- a human ⁇ -lactalbumin of the present disclosure is a recombinant human ⁇ -lactalbumin.
- a recombinant human ⁇ -lactalbumin of the disclosure is obtained from a mammal, fungus, yeast, bacterium or other cell.
- a recombinant human ⁇ -lactalbumin of the disclosure is not obtained from a mammal cell.
- a recombinant human ⁇ -lactalbumin of the disclosure is obtained from a yeast cell.
- a yeast cell may be, for example, of a genus, Arxula, Aspergillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon, Wicker hamomyces or Yarrowia.
- a yeast cell is a Komagataella cell (for example, Komagataella phaffii, Pichia pastor is, Komagataella pastoris, Komagataella pseudopastoris). Additional yeasts suitable for recombinant protein production are recognized in the art and contemplated herein.
- a recombinant human ⁇ -lactalbumin of the disclosure is obtained from a bacterium.
- a human ⁇ -lactalbumin of the disclosure is isolated from a natural source.
- Particular aspects of the present disclosure are directed to human ⁇ -lactalbumin having at least one hybrid or complex N-glycan.
- a human ⁇ -lactalbumin comprises a glycan comprising one or more of sialic acid, galactose, N-acetylgalactosamine or fucose.
- a human lactoferrin comprises a bi-antennary, tri-antennary or tetra-antennary N-glycan.
- human ⁇ -lactalbumin having one or more hybrid, complex, bi-antennary, tri-antennary, or tetra-antennary N-glycan may be useful in, for example, an infant formula or other nutritional or edible compositions, or supplements.
- Additional human milk proteins contemplated in compositions (for example, edible compositions) and methods of the disclosure include, but are not limited to, as taught hereinabove for rhLF and rhaLac, and are applicable to secretory IgA (slgA), human serum albumin, xanthine dehydrogenase, lactoperoxidase, butyrophilin, lactadherin, adiponectin, 0- casein, ⁇ -casein, leptin, osteopontin, bile salt stimulated lipase (BSSL) and lysozyme. Any one or more of those human milk proteins, the coding sequences of which are available in the art, may be included in edible compositions (for example, edible or potable compositions) of the present disclosure. Any one or more of those human milk proteins may be excluded in embodiments.
- secretory IgA secretory IgA
- human serum albumin xanthine dehydrogenase
- aspects of the present disclosure are directed to edible compositions for consumption by a human, for example, an infant formula, as well as methods of use for providing nutrition to a subject, such as, an infant.
- the following description and that hereinabove relate also to making an edible composition of interest including nutritional compositions, such as, candy, bars, yogurt, ice cream, beverages and so on.
- a composition comprising lactose and a recombinant secretory protein of interest can comprise a dairy product, such as, ice cream, a milk-based nutritional beverage and so on. Any discussion herein relating to an infant formula applies also to any edible composition.
- An infant formula disclosed herein may be in any form capable of consumption, or capable of dissolving, combining or diluting for consumption.
- an infant formula can be in a ready-to-consume form.
- an infant formula is in a solid concentrated form (for example, as a powder).
- an infant formula is in liquid concentrate form.
- An infant formula of the present disclosure may comprise one or more components useful in providing nutrition to an infant.
- Such components may include, but are not limited to, lactose (for example, lactose from a lactose powder), lipids (for example, lipids from one or more oils, such as, sunflower oil, safflower oil, coconut oil, canola oil, low rapeseed erucic oil etc ), protein (for example, ⁇ -lactalbumin, whey protein concentrate etc.), casein, a human milk oligosaccharide (HMO) (for example, 2'-fucosyllactose, lacto-N-neotetraose, 3-fucosyllactose, 6'-sialyllactose, difucosyllactose, lacto-N-tetraose), minerals (for example, calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium, selenium, and salts thereof), vitamins (for example, vitamin A, vitamin D
- an infant formula comprising a human milk protein addresses various needs by providing a formula having particular benefits previously associated with breast milk alone, including anti-inflammatory and anti-bacterial benefits. Accordingly, aspects of the present disclosure are directed to infant formula compositions comprising a human secretory protein, in cases, a human milk protein, comprising one or more human-like glycans, and methods of use thereof in providing nutrition to an infant.
- an infant formula comprises lactose.
- an infant formula comprises at least, at most, about, or exactly 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70% or more lactose by weight of a dry composition, including any range or value derivable therein.
- an infant formula comprises at least 45% lactose by dry weight.
- an infant formula comprises at least 70% lactose by dry weight.
- An infant formula may comprise lactose from any source, including, for example, edible lactose powder.
- an infant formula comprises less than 5, 4, 3, 2, 1, 0.5, 0.1, 0.01 % lactose by dry weight, or less.
- an infant formula does not comprise lactose.
- an infant formula comprises one or more lipids.
- An infant formula may comprise one or more lipids from any source, including, for example, one or more of high oleic sunflower oil, mid-oleic sunflower oil, safflower oil, coconut oil, canola oil, low erucic rapeseed oil, sunflower oil, Mortierella alpina oil, alga oil (for example, from a Schizochytrium) soybean oil and palm oil. Any one or more, or all, of the preceding components may be included in an infant formula of the present disclosure. Any one or more of those components may be excluded from embodiments.
- an infant formula comprises at least, at most, about, or exactly 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8,
- an infant formula comprises protein.
- An infant formula may comprise a protein from any one or more sources including, for example, whey protein lipid concentrate, whole milk powder, whey protein concentrate, non-fat dry milk, milk protein concentrate or isolate, whey protein hydrolysate, isolated protein (for example, isolated ⁇ -lactalbumin) or any other source of protein. Any one or more, or all, of the preceding components may be included in an infant formula of the present disclosure. Any one or more of those components may be excluded from embodiments.
- an infant formula comprises at least, at most, about, or exactly 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2,
- an infant formula comprises one or more human milk oligosaccharides (HMO).
- HMO may be, for example, 2'-fucosyllactose or lacto-N-neotetraose.
- HMO human milk oligosaccharides
- an infant formula comprises at least, at most, about, or exactly 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3% of an HMO by dry weight, including any range or value derivable therein.
- an infant formula comprises one or more minerals.
- Various minerals are recognized in the art and are contemplated herein.
- an infant formula comprises one or more of calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium, selenium, including any salt thereof.
- an infant formula may comprise one or more (or all) of calcium phosphate, calcium citrate, magnesium chloride, potassium citrate, potassium chloride, sodium chloride, copper sulfate, ferrous sulfate, manganese sulfate, zinc sulfate, sodium selenite, calcium chloride, magnesium phosphate, sodium citrate, potassium phosphate and potassium iodide.
- an infant formula comprises at least, at most, about, or exactly 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3% of any one or more minerals by dry weight, including any range or value derivable therein.
- an infant formula comprises at least 0.1% of any one or more minerals by dry weight.
- an infant formula comprises at most, 3% of any one or more minerals by dry weight.
- an infant formula comprises one or more vitamins.
- vitamins are recognized in the art and contemplated herein.
- an infant formula comprises one or more of vitamin A, vitamin D, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, niacinamide, calcium pantothenate, pyridoxine hydrochloride, biotin, folic acid, pantothenic acid, cyanocobalamin, vitamin C, choline, inositol, L-carnitine, inositol, and taurine, including any salt thereof.
- an infant formula comprises one or more (or all) of vitamin A palmitate, vitamin D3, D- ⁇ tocopherol, vitamin KI, thiamine hydrochloride, riboflavin, niacinamide, calcium pantothenate, pyridoxine hydrochloride, biotin, folic acid, cyanocobalamin, choline bitartrate, inositol and ascorbic acid. Any one or more, or all, of the preceding components may be included in an infant formula of the present disclosure. Any one or more of those components may be excluded from embodiments.
- an infant formula comprises at least, at most, about, or exactly 0.000001, 0.00001, 0.0001, 0.001, 0.01, 0.1, or 1 % of any one or more vitamins by weight, including any range or value derivable therein. In embodiments, an infant formula comprises at least 0.000001 % of any one or more vitamins by weight, and at times, for liquid reagents, by volume. In embodiments, an infant formula comprises at most 1% of any one or more vitamins by weight.
- an infant formula disclosed herein comprises one or more probiotic microbes.
- a, “probiotic,” microbe as described above comprises a microbe, such as, a bacterium or other microorganism known or suspected to have a beneficial effect on health or well-being of an individual.
- a probiotic microbe such as, a bacterium or other microorganism known or suspected to have a beneficial effect on health or well-being of an individual.
- probiotics microbes are recognized in the art and are contemplated herein.
- Probiotic microbes which may be used in the disclosed compositions and methods include, for example, probiotic Lactobacillus and probiotic Bifidobacterium organisms.
- a probiotic microbe is Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus fermentum, Lactobacillus paracasei, Lactobacillus johnsonii, Lactobacillus helveticus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium adolescentis or Bifidobacterium infantis.
- An infant formula of the disclosure may comprise at least, at most, or exactly 1, 2, 3, 4 or 5 different probiotic species of microbe.
- an infant formula does not comprise a probiotic organism.
- an infant formula comprises Bifidobacterium infantis, for example, Bifidobacterium infantis M-63. Additional beneficial probiotic microbes are disclosed in, for example, U.S. Pat. No, 9,226,521, incorporated herein by reference in entirety.
- An infant formula of the disclosure may comprise at least, at most, about, or exactly 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , 10 15 or more colony forming units (cfu), particles or other metric of probiotic microbe (for example, Bifidobacterium infantis) per 100 grams, including any range or value derivable therein.
- probiotic microbe for example, Bifidobacterium infantis
- an infant formula comprises one or more nucleotides.
- nucleotides including nucleotides useful as supplements for infant formula or other food compositions, are recognized in the art and are contemplated herein
- an infant formula comprises one or more (or all) of cytidine 5 ’-monophosphate, uridine
- an infant formula comprises one or more additional components, including, but not limited to, arachidonic acid, docosahexaenoic acid, a prebiotic, casein, such as, micellar casein, and MFGM.
- additional components including, but not limited to, arachidonic acid, docosahexaenoic acid, a prebiotic, casein, such as, micellar casein, and MFGM.
- an infant formula comprising, in addition to one or more additional components described herein, a human secretory protein.
- An infant formula may comprise any human secretory protein, including human milk proteins disclosed herein, for example recombinant human milk proteins, human milk proteins comprising hybrid, complex or other human-like glycans, human whey proteins, as well as any one or more particular human milk protein, such as, lactoferrin (for example, recombinant lactoferrin).
- an infant formula comprises a naturally derived human secretory protein.
- an infant formula comprises a recombinant human secretory protein.
- an infant formula comprises a recombinant human secretory protein having a glycan pattern that is different from a glycan pattern of a corresponding natural human secretory protein.
- An infant formula of the present disclosure may comprise at least, at most, about, or exactly 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49, 0.5,
- slgA human serum albumin, xanthine dehydrogenase, lactoferrin, lactoperoxidase, butyrophilin, lactadherin, adiponectin, ⁇ -casein, ⁇ -casein, leptin, lysozyme, or ⁇ -lactalbumin
- dry weight including any range or value derivable thereof.
- an infant formula comprises about or exactly 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49, 0.5% or more human lactoferrin (for example, recombinant human lactoferrin) by dry weight, or any range or value derivable therein.
- human lactoferrin for example, recombinant human lactoferrin
- an infant formula comprises about or exactly 0.01, 0.02, 0.03, 0.04,
- aspects of the present disclosure include recombinant protein products (for example, human secretory proteins) generated by engineered microorganisms.
- recombinant human secretory proteins for example, recombinant lactoferrin
- an engineered microorganism for example, an engineered eukaryote cell, fungus cell, yeast cell, bacterium or other cell.
- Vectors for transforming microorganisms in accordance with the present disclosure can be prepared by known techniques familiar to those skilled in the art in view of the disclosure herein.
- a vector typically contains one or more genes, in which each gene codes for expression of a desired product (a gene product) and is operably linked to one or more control sequences that regulate gene expression or target a gene product to a particular location in a recombinant cell.
- Exogenous nucleic acid sequences including, for example, nucleic acid sequences encoding fusion proteins, nucleic acid sequences encoding wild-type or mutant protein and so on, may be introduced into different host cells.
- Nucleic acid sequences configured to facilitate a genetic mutation in a gene also may be introduced into various host cells, as described further herein. Suitable host cells are microbial hosts that can be found broadly within fungus families.
- suitable host strains include but are not limited to fungus or yeast species, such as, of genera, Arxula, Aspegillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Hansenula, Kluyveromyces, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon and Yarrowia.
- fungus or yeast species such as, of genera, Arxula, Aspegillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Hansenula, Kluyveromyces, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichi
- a host cell of the present disclosure is a Komagataella cell.
- a host cell of the present disclosure is Komagataella phaffii.
- a host cell of the present disclosure is Komagataella pastoris or Pichia pastoris.
- a host cell of the present disclosure is Komagataella pseudopastoris .
- Additional host cells include a non-fungus eukaryote cell and a bacterium.
- Microbial expression systems and expression vectors are known to those skilled in the art. Any such expression vector could be used to introduce instant genes and nucleic acid sequences into an organism.
- Nucleic acid sequences may be introduced into appropriate microorganisms via transformation techniques. For example, a nucleic acid sequence can be cloned in a suitable plasmid, and a parent cell can be transformed with a resulting plasmid.
- a plasmid is not particularly limited so long as said plasmid renders a desired nucleic acid sequence inheritable to progeny of that microorganism.
- Vectors or cassettes useful for transformation of suitable host cells are recognized in the art.
- a vector or cassette contains a gene, sequences directing transcription and translation of a relevant gene including a promoter, a selectable marker and sequences allowing autonomous replication or chromosome integration.
- Suitable vectors comprise a region 5' of a gene harboring a promoter and other transcriptional initiation controls (5’ untranslated region, 5’ UTR) and a region 3' of a DNA fragment that controls transcriptional termination (3’ UTR).
- Promoters, cDNA’s and 3' UTR’s, as well as other elements of vectors can be generated through cloning techniques using fragments isolated from native sources (Green & Sambrook, “Molecular Cloning: A Laboratory Manual,” (4th ed., 2012); and U.S. Pat. No. 4,683,202; both references incorporated herein by reference in entirety). Alternatively, elements can be generated synthetically using known methods (Gene 164:49-53, 1995).
- Vectors for transforming microorganisms in accordance with the present disclosure can be prepared by known techniques familiar to those skilled in the art in view of the disclosure herein.
- a vector typically contains one or more genes, in which each gene codes for expression of a desired product (the gene product) and is operably linked to one or more control sequences that regulate gene expression or target a gene product to a particular location in a recombinant cell.
- Control sequences are nucleic acid sequences that regulate expression of a coding sequence or direct a gene product to a particular location in or outside a cell.
- Control sequences that regulate expression include, for example, promoters that regulate transcription of a coding sequence and terminators that terminate transcription of a coding sequence.
- Another control sequence is a 3' untranslated sequence located downstream of a coding sequence that encodes a polyadenylation signal. Control sequences that direct gene products to particular locations, for example, those that encode signal peptides, which direct a protein attached thereto to a particular location inside a cell.
- an exemplary vector design for expression of a gene in a microbe contains a coding sequence for a desired gene product (for example, a selectable marker, an enzyme, a fusion protein etc.) in operable linkage with a promoter active in host yeast cells.
- a desired gene product for example, a selectable marker, an enzyme, a fusion protein etc.
- a coding sequence can be transformed into cells such that an open reading frame becomes operably linked to an endogenous promoter at vector integration.
- promoters contemplated herein include, but are not limited to, known and publicly available AOX1, GAP, TEF1, TPI1, DAS1, DAS2, CAT1 and FMD promoters.
- A- promoter used to express a gene can be a promoter naturally linked to that gene or a different promoter of a different gene.
- a promoter generally can be characterized as constitutive or inducible. Constitutive promoters generally are active or function to drive expression at all times (or at certain times in cell life cycle) at the same level. Inducible promoters are active (or rendered inactive) or are significantly up-regulated or down-regulated only in response to a stimulus. Both types of promoters find application herein. Useful inducible promoters include those that mediate transcription of an operably linked gene in response to a stimulus, such as, an exogenously provided small molecule, such as, methanol, temperature (heat or cold), lack of nitrogen in culture media etc. Suitable promoters can activate transcription of an essentially silent gene or upregulate transcription of an operably linked gene that is transcribed at a low level.
- a termination region may be native to a transcriptional initiation region (a promoter), may be native to a DNA sequence of interest or may be obtainable from another source (see, for example, Chen & Orozco, Nucleic Acids Research 16:8411, 1988).
- a full nucleotide sequence of a promoter is not necessary to drive transcription, and sequences shorter than full length nucleotide sequence of a promoter can drive transcription of an operably-linked gene.
- a minimal portion of a promoter termed a core promoter, include a transcription start site, a binding site for a RNA polymerase and a binding site for a transcription factor.
- a promoter may be linked to a target by introducing a promoter and a target into a nucleic acid molecule, for example, a vector.
- a vector may be introduced into a cell, thereby expressing promoter and target.
- a promoter is linked to a target by introducing a promoter into DNA of a cell, for example, via homologous recombination, thereby integrating a promoter into a genome of a cell.
- a gene typically includes a promoter, a coding sequence and termination control sequence.
- a gene When assembled by recombinant DNA technology, a gene may be termed an expression cassette and may be flanked by restriction sites for convenient insertion into a vector that is used to introduce that recombinant gene into a host cell.
- An expression cassette can be flanked by DNA sequences from a genome or other nucleic acid target to facilitate stable integration of an expression cassette into a genome by homologous recombination.
- a vector and expression cassette may remain unintegrated (for example, an episome), in which case, a vector typically includes an origin of replication, which is capable of providing for replication of a vector DNA.
- a common gene present on a vector is a gene encoding a protein, expression of which allows a recombinant cell containing a protein to be differentiated from cells that do not express that protein.
- a gene, and corresponding gene product is called a selectable marker or selection marker. Any of a wide variety of selectable markers can be employed in a transgene (foreign gene, recombinant gene or gene of interest) construct useful for transforming organisms covered in the disclosed embodiments.
- transgene messenger RNA mRNA
- a coding sequence of the present disclosure can be codon optimized for a particular host cell by replacing one or more rare codons with one or more codons more frequently found in a host cell.
- a rare codon in a host cell is a codon found in less than 5%, less than 10% or less than 20% of coding sequences in a host cell. Rare codons can be identified using methods known to those of skill in the art.
- aspects of the disclosure comprise transformation of a microorganism with a nucleic acid sequence comprising a gene that encodes a protein.
- a gene may be native to a cell or from a different species.
- a gene may be derived from a different species yet modified (for example, codon optimized) for optimal expression in a microorganism.
- a gene is inheritable in progeny of a transformed cell.
- a gene is inheritable by residing on a plasmid.
- a gene is inheritable by integrating into a genome of a transformed cell.
- aspects of the disclosure may comprise transformation of a microorganism with a nucleic acid sequence configured to generate a mutation in a gene of a microorganism.
- aspects of the disclosure may comprise transformation of a microorganism with a nucleic acid sequence comprising sequences upstream and downstream of a gene (for example, an 0CH1 gene encoding a 1,6-mannosyl transferase of yeast), thereby facilitating reduced expression or deletion of a gene via homologous recombination.
- a gene for example, an 0CH1 gene encoding a 1,6-mannosyl transferase of yeast
- a microorganism having a deletion or knockout mutation of a gene does not produce a functional copy of a protein.
- a recombinant yeast cell of the disclosure may comprise a deletion of an endogenous 0CH1 gene, such that a recombinant yeast cell does not express an endogenous, functional 0CH1 protein.
- a microorganism having reduced expression of a gene or protein can produce a functional copy of a protein, but at a reduced level as compared to wild-type (that is, a non-recombinant or non-genetically modified) microorganism of the same species.
- Methods for reducing expression of a protein are recognized in the art and include, for example, replacement of an endogenous promoter and/or modification of one or more regulatory elements.
- Cells can be transformed by any suitable technique including, for example, use of biolistic devices, electroporation, glass bead transformation, silicon carbide whisker transformation and so on. Any convenient technique for introducing a transgene into a microorganism can be employed in embodiments disclosed herein.
- an exemplary vector design for expression of a gene in a microorganism contains a gene encoding an enzyme in operable linkage with a promoter active in a microorganism.
- a gene can be transformed into cells to be operably linked to a native promoter at vector integration.
- a vector also can contain a second gene that encodes a protein.
- one or both gene(s) is/are followed by a 3' untranslated sequence containing a polyadenylation signal.
- Expression cassettes encoding those two genes can be physically linked in a vector or reside on separate vectors. Co-transformation of microbes also can be used, in which distinct vector molecules are simultaneously used to transform cells (Protist 155:381-93, 2004). Transformed cells optionally can be selected based on ability to grow in presence of an antibiotic or other selectable marker under conditions in which cells lacking a resistance cassette would not grow or flourish.
- aspects of the disclosure comprise genetically engineered cells (also, “engineered cells,” and, “recombinant cells,”) and methods for making and using such cells.
- recombinant cells comprise one or more exogenous nucleic acid sequences.
- methods for generating such recombinant cells comprising introducing one or more exogenous nucleic acid sequences into a host cell.
- methods for collecting one or more products for example, a mammal glycoprotein
- a recombinant cell is a prokaryote cell, such as, a bacterium.
- a recombinant cell is a eukaryote cell, such as, a mammal cell, a yeast cell, a filamentous fungus cell, a protist cell, an alga cell, a bird cell, a plant cell, an insect cell and so on.
- a recombinant cell is not a mammal cell.
- a host cell is a yeast cell. Those with skill in the art will recognize that many forms of fdamentous fungus produce yeast-like growth, and definition of yeast herein encompasses such cells.
- a recombinant cell of the disclosure may be selected from the group consisting of alga, bacterium, mold, fungus, plant and yeast.
- a recombinant cell of the disclosure is a bacterium (for example, E. coli), a fungus cell or a yeast cell, such as, Saccharomyces cerevisiae.
- a recombinant cell of the disclosure is a recombinant yeast cell.
- a recombinant yeast cell may be any suitable yeast cell recognized in the art.
- the yeast cell is an Arxula, Aspergillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon, Wicker hamomyces or Yarrowia cell.
- a yeast cell is Arxula adeninivorans, Aspergillus niger, Aspergillus orzyae, Aspergillus terreus, Aur anti ochy trium limacinum, Candida utilis, Claviceps purpurea, Cryptococcus albidus, Cryptococcus curvatus, Cryptococcus ramirezgomezianus, Cryptococcus terreus, Cryptococcus wieringae, Cunninghamella echinulata, Cunninghamella japonica, Geotrichum fermentans, Hansenula polymorpha, Kluyveromyces lact is, Komagalaella phaffii, Komagalaella pas tor is, Komagalaella pseudopastoris, Kluyveromyces marxianus, Kodamaea ohmeri, Leucosporidiella creatinivora, Lipomyces lipofer, Lipomyces starkeyi, Lipomyces te
- a yeast cell is a Komagataella cell.
- a yeast cell is Kluyveromyces phaffii, Pichia pastoris, Komagataella pastoris or Komagataella pseudopastoris.
- a yeast cell is Kluyveromyces phaffii cell.
- Edible compositions according to the present invention may be prepared by any known or otherwise suitable manner.
- an infant formula may be obtained by blending a protein with a human secretory protein, and optionally, a carbohydrate source and a lipid source, in appropriate proportions.
- Emulsifiers may be included. Vitamins and minerals may be added, but also may be added later during manufacture to avoid thermal degradation.
- Water such as, water subjected to purification, such as, reverse osmosis or deionized water, then may be added and mixed to form a liquid mixture. Temperature of mixing can be room temperature, but also may be higher to facilitate suspension and mixing, though below temperatures that might damage an ingredient.
- a liquid mixture is dried in a suitable drying apparatus, such as, a spray drier or freeze drier, and can be converted into or to a powder.
- Powdered infant formula may be produced using various processes, such as, dry blending dehydrated ingredients to constitute a uniform mixture or hydrating and wet-mixing a mixture of ingredients, such as, fat, protein and carbohydrate ingredients and then evaporating or spray drying the resultant mixture.
- a combination of processes may be used where a base powder is first produced by wet-mixing and spray drying all or some of the macro-ingredients and then dry blending the remaining ingredients, including carbohydrate, minerals and vitamins and other micronutrients, to create a final composition.
- Liquid formulae are available in a ready -to-feed format or as a concentrated liquid, which requires dilution, such as, 1 : 1, with water.
- a homogenized mixture is filled into suitable containers, preferably aseptically.
- a liquid composition may be retorted in a suitable container, using suitable apparatus for filling and retorting using commercially available machinery.
- a liquid food may be a beverage, such as, a nutraceutical drink, an energy drink, a milkshake, a performance or nutrition product, such as, a protein shake, and so on.
- Steps that eliminate or restrict microbial growth are practiced during production.
- a liquid mixture then may be thermally treated or sterilized by another method to reduce risk of spoilage.
- a mixture then may be homogenized.
- a manufacture of the invention can involve high-temperature-processing at about 110° C. or above.
- High-temperature-processing may be carried out at about 110° C. to about 150° C.
- high-temperature-processing may be carried out at about 110° C. to about 145° C , about 110° C. to about 140° C., about 110° C. to about 135° C., about 110° C. to about 130° C., about 110° C. to about 125° C., about 110° C. to about 120° C., about 110° C. to about 115° C., about 115° C. to about 150° C., about 115° C. to about 145° C., about 115° C. to about 140° C., about 115° C. to about 135° C., about 115° C.
- High-temperature-processing may be carried out for about 5 seconds to about
- 60 minutes for about 5 seconds to about 45 minutes, about 5 seconds to about 30 minutes, about 5 seconds to about 15 minutes, about 5 seconds to about 5 minutes, about 5 seconds to about 120 seconds, about 5 seconds to about 60 seconds, about 5 seconds to about 30 seconds, about 30 seconds to about 60 minutes, about 30 seconds to 45 minutes, about 30 seconds to about 30 minutes, about 30 seconds to about 15 minutes, about 30 seconds to about 5 minutes, about 30 seconds to about 120 seconds, about 30 seconds to about 60 seconds, about 60 seconds to about minutes, about 60 seconds to about 45 minutes, about 60 seconds to about 30 minutes, about 60 seconds to about 15 minutes, about 60 seconds to about 5 minutes, about 60 seconds to about 120 seconds, about 120 seconds to about 60 minutes, about 120 seconds to about 45 minutes, about 120 seconds to about 30 minutes, about 120 seconds to about 15 minutes, about 120 seconds to about 5 minutes, about 5 minutes to about 60 minutes, about 5 minutes to about 60 minutes, about 5 minutes to about 45 minutes, about 5 minutes to about 30 minutes, about 5 minutes to about 15 minutes, about 15 minutes to about 60 minutes, about 15 minutes to about
- High-temperature-processing may be carried out by direct or indirect heating.
- high-temperature-processing may be carried out by steam injection, heat exchange or using a retort.
- An edible composition can be treated with high pressure prior to packaging and sale, with high pressure enhancing safety and prolonging shelf life.
- High pressure processing is known and requires pressures of about 6000 bar or more. Pressure of 50 MPa to about 1000 MPa can be used at room temperature or lower, see, for example, US Pat Nos 5,213,029, 5,316,745; 5,683,735; and 6,033,717; and US Pub No 20080050507.
- An edible composition of interest is sterile filled into a suitable packaging, such as, a lined can, a pouch, a package wrapping, a powder container, a bottle and so on, which is sealed, optionally treated for quality control and shelf stability, and distributed for sale.
- a suitable packaging such as, a lined can, a pouch, a package wrapping, a powder container, a bottle and so on, which is sealed, optionally treated for quality control and shelf stability, and distributed for sale.
- percentages of dry ingredients are on a weight basis.
- percentages can be on a weight basis as water generally is the predominant medium with a density of 1 g/cc, or on a weight per volume basis.
- Percentages of liquid ingredients in a dry formulation can be on a weight basis. Ratios of ingredients in a dry formulation can be used to determine percentages of reagents in an analogous liquid formulation based on the targeted solids level in the analogous liquid formulation.
- a batch of a milk-based infant formula was prepared according to the formulation in the table below. Lactose was hydrated at 45-55% solids in 150-160° F water, then proteins were added. The vegetable oil blend, ARA-DHA blend and fat soluble vitamin premix were mixed into lactose. Mineral and trace minerals, as well as other minerals, vitamins and nutrients were added. The mix was held at 140-145° F with high agitation during mixing, then the mixture was homogenized at 2000-3500 PSI and cooled at 40° F. Nucleotide premix was added to the cold mix and agitated before pasteurization at 170-180° F for 60 seconds followed by spray-drying to a resulting moisture content of 1.5-3.5 %. Probiotic microorganisms and human lactoferrin were added to the base formulation via dry -blending.
- the powder was mixed with water at a rate of 1 tablespoon to 2 ounces of water to yield a drinkable infant formula.
- a batch of soy-based infant formula is prepared as provided in Example 1 and using the formulation provided in the table below.
- a batch of milk-based infant formula containing partially hydrolyzed whey is prepared as provided in Example 1 using the formulation noted in the table below.
- a batch of milk-based infant formula ready-to-feed is prepared as follows, using the formulation provided in Table 5.
- a quantity of reverse osmosis (RO) water representing 50% of the total quantity is heated to 150-160° F.
- Proteins and carrageenan are hydrated using high shear agitation. While maintaining high agitation, the vegetable oil blend, ARA-DHA blend and fat soluble vitamin premix are added followed by the lactose. Mineral and trace minerals as well as other minerals, vitamins and nutrients are added. The mix is held at 140-145° F at high agitation during mixing, then pasteurized at 185-190° F for 30 seconds, homogenized at 2000-3500 PSI and cooled at 40° F.
- Nucleotide premix and human lactoferrin are added to the cold mix along with the residual RO water to bring the total solids to 12.8-13.2% w/w.
- the mix is UHT -treated and filled aseptically in 8 oz plastic bottles.
- a batch of ready to use liquid nutritional beverage is prepared according to the formulation in Table 6.
- a quantity of reverse osmosis (RO) water representing 50% of the total quantity is heated to 150-160° F.
- Proteins milk protein concentrate and soy protein isolate
- cellulose gel & gum and carrageenan are hydrated using high shear agitation. While maintaining high agitation, the oils (high oleic safflower oil and canola oil), lecithin and fat soluble vitamin premix are added, followed by the maltodextrin, sugar and fructooligosaccharides.
- Individual minerals, the trace mineral premix, the water soluble vitamin premix and other nutrients are added.
- the mix is held at 140-145° F at high agitation during mixing, then the mixture is pasteurized at 185-190° F for 30 seconds, homogenized at 2000-3500 PSI and then is cooled at 40° F.
- Vitamin C in 5% solution with a portion of potassium hydroxide and human lactoferrin in 10% solution along with flavors are added to the cold mix along with the residual RO water to bring the total solids to 22.8-24.2% w/w
- the mix is UHT -treated and filled aseptically in 8 oz plastic bottles.
- a batch of ready to use liquid nutritional low glycemic index beverage is prepared as provided in Example 6 using the formulation of Table 7.
- Table 7
- a batch of nutritional beverage powder is prepared using the formulation of Table 8. Proteins (milk protein concentrate and soy protein isolate) are hydrated at 45-55% solids in 145-150° F water, then the oils (high oleic safflower oil and canola oil), lecithin and fat soluble vitamin premix are added followed by the maltodextrin, sugar and fructooligosaccharides. Mineral and trace minerals as well vitamins and nutrients are added. The mix is held at 140-145° F at high agitation during mixing, then homogenized at 2000-3500 PSI and cooled at 40° F. Vitamin C in 5% solution with a portion of potassium hydroxide and human lactoferrin in 10% solution along with N&A flavors are added to the cold mix. The mix is pasteurized at 170-180° F for 60 seconds followed by spray-drying to a resulting moisture content of 2.5 - 4.0 %.
- the human lactoferrin is added to the base formulation via dry-blending.
- Stable juice-based protein beverages are prepared by mixing a fruit juice with 0.1-10.0% of protein (for example, casein, lactalbumin, serum albumin, glycomacropeptide, soy protein, rice protein, pea protein, whey protein, canola protein, wheat protein, hemp protein, zein, flax protein, egg white protein, ovalbumin, gelatin protein and combinations thereof) using the formulation of Table 9. pH of the admixture is adjusted to between 2 and 3.4.
- protein for example, casein, lactalbumin, serum albumin, glycomacropeptide, soy protein, rice protein, pea protein, whey protein, canola protein, wheat protein, hemp protein, zein, flax protein, egg white protein, ovalbumin, gelatin protein and combinations thereof.
- an anti-foaming agent a nutrient, calcium, an herbal supplement, a flavoring agent, a sweetener, a coloring agent, a preservative and an energy-generating additive selected from caffeine, magnesium and citrulline malate
- an anti-foaming agent a nutrient, calcium, an herbal supplement, a flavoring agent, a sweetener, a coloring agent, a preservative and an energy-generating additive selected from caffeine, magnesium and citrulline malate
- EIPP high pressure processing
- a carbonated milk beverage with enhanced shelf stability is prepared based on the formulation provided in Table 10.
- skim milk powder solution is heated at least 85-138° C for 5 seconds.
- the milk liquid dairy product is ultra-heat treated at least at 150° C and at a pressure of 700 kPa.
- other ingredients are added and homogenized at 2,000-5,000 psi for 5 min.
- the liquid dairy product is cooled to a temperature of less than 10° C.
- the cooled liquid dairy product is subject to pressurized carbon dioxide so that at least 3-8 vols. of carbon dioxide are dissolved in the liquid dairy product.
- the carbonated liquid dairy product is packaged in shelf-stable closed containers that do not require refrigeration.
- a protein-fortified frozen dessert formulation is prepared using the formulation described in Table 11. The ingredients are blended at 5,000-7,000 rpm to prepare a sweet mix.
- the sweet mix is preheated at 30-60° C.
- the preheated sweet mix is pasteurized by heating at 69° C for 30 minutes (batch) or at 80° C for 25 seconds (continuous).
- the sweet mix is homogenized at 2000-3000 psi (one-stage homogenization) or at 2000-2500 psi, followed by 500 psi (two-stage homogenization).
- Homogenized sweet mix is cooled to 3-5° C for 4-6 hours to produce an aged sweet mix and the aged mix is frozen to prepare a protein-fortified frozen dessert.
- a protein-fortified spreadable yogurt product is prepared according to the formulation provided in Table 12 by combining a casein-containing ingredient with milk to make yogurt milk.
- Yogurt culture is added to the yogurt milk and allowed to ferment.
- the resulting yogurt mixture is separated into a yogurt retentate and a yogurt permeate.
- Yogurt retentate is used as a spreadable protein-fortified yogurt.
- the spreadable yogurt can be flavored and then packaged.
- a gummy snack with high protein is produced using the formulation in the following table.
- a mixture is formed by mixing water, glucose syrup, first sugar alcohol and second sugar alcohol.
- the mixture is cooked at 230-285° F for 10-60 minutes to form a sugar mixture, which then is cooled to 60-80° F.
- An acid solution (malic acid) is added to form a sugar-acid mixture of pH 2-4.
- the sugar-acid mixture is mixed with a gelatin for 4-12 minutes to form a sugar-gelatin mixture.
- the sugar-gelatin mixture is mixed with protein to form a gel mixture.
- the gel mixture then is processed by machinery for forming shapes.
- a high protein snack food is produced using the formulation provided in Table 14.
- any of a variety of protein particles (for example, chicken powder, pea protein powder etc.) are extruded to form protein pieces.
- the pieces or crisp and the remaining ingredients are combined and the mixture is used to form a bar, which is treated at 160° F until an internal temperature of 140° F is reached.
- a batch of nutritional plant-based beverage powder is prepared according to the formulation in Table 15.
- Proteins pea protein concentrate and fava bean protein isolate
- the oils high oleic safflower oil and canola oil
- lecithin and fat soluble vitamin premix are added followed by the maltodextrin, sugar and fructooligosaccharides.
- Mineral and trace minerals as well as vitamins and nutrients are added.
- the mix is held at 140-145° F at high agitation during mixing, then homogenized at 2000-3500 PSI and cooled to 40° F.
- Vitamin C in 5% solution with a portion of potassium hydroxide and human lactoferrin in 10% solution along with N&A flavors are added to the cold mix.
- the mix is pasteurized at 170-180° F for 60 seconds followed by spray-drying to a resulting moisture content of 2.5-4.0 %.
- An immunity shot beverage with human lactoferrin was prepared using the formulation of Table 16.
- Human lactoferrin was mixed with water and stirred for 10 minutes.
- a high protein content fruit juice is selected, for example, guava, orange, blackberry, banana, peach, kiwi and so on.
- a protein source such as, whey protein, can be included.
- An elderberry juice-based matrix was blended with the human lactoferrin solution for a few minutes and transferred to a plastic bottle ( ⁇ 60 mL). Blended samples were cooled to ⁇ 4 °C and high pressure process (HPP) treated at ⁇ 87,000 psi.
- HPP high pressure process
- a batch of liquid nutritional (ready -to-feed) composition is prepared using the formulation in Table 17.
- Reverse osmosis (RO) water is heated to 150-160° F.
- Pea protein isolate, cellulose gel & gum, and tapioca starch are hydrated using high shear agitation. While maintaining high agitation, the oils (high oleic safflower oil and canola oil), lecithin, and fat soluble vitamin premix are added followed by the maltodextrin and sucralose. Individual minerals, the trace mineral premix, the water soluble vitamin premix and other nutrients are added.
- the mix is held at 140-145° F at high agitation during mixing, then pasteurized at 185-190° F for 30 seconds, homogenized at 2000-3500 PSI and cooled at 40° F.
- Vitamin C in 5% solution with a portion of potassium hydroxide and human lactoferrin in 10% solution along with N&A flavors are added to the cold mix along with the residual RO water to bring the total solids to 20-30% w/w.
- the mix is UHT-treated and filled aseptically in 8 oz plastic bottle.
- composition is suitable for FODMAP (fermentable oligosaccharides, di saccharides, monosaccharides and polyols) diets.
- FODMAP fertilizer-derived oligosaccharides, di saccharides, monosaccharides and polyols
- a batch of milk-based infant formula was prepared according to the formulation in Table 18. Lactose was hydrated at 45-55% solids in 140-145° F water, then proteins were added followed by the vegetable oil blend, ARA-DHA blend and fat soluble vitamin premix. Mineral and trace minerals as well as vitamins and nutrients were added to the mixture. The mix was held at 117-127° F at high agitation during mixing, then homogenized at 2000-3500 PSI and pasteurized at 170-180° F for 60 seconds. The mixture was cooled to 122-131° F before spray-drying to a resulting moisture content of 1.5-3.5 %. Probiotics and human lactoferrin were added to the base formulation via dry -blending.
- the resulting infant formula powder was packaged.
- the powder was added to water to form a drinkable infant formula.
- a nutrition bar fortified with human milk oligosaccharides (HMO’s) and human lactoferrin is prepared using the formulation in Table 19.
- Powder ingredients including HMO’s powder, human lactoferrin and vitamin premix are mixed.
- Liquid components of binder syrup maltitol syrup, chocolate liquor
- Dry components of the binder such as, cocoa powder are mixed together and heated to 180° F.
- Binder materials are added to blended powder ingredients and stirred using a spatula. Approximately 160 g of mixed sample is placed into a bar press mold and chilled in the freezer for 5-10 minutes.
- a batch of milk-based infant formula with OPO is prepared according to the formulation in Table 20. Lactose is hydrated at 45-55% solids in 150-160° F water, then proteins are added followed by the vegetable oil blend consisting of Sn2 palmitate fat (OPO), coconut oil, high oleic safflower or sunflower oil, soybean oil and sunflower or canola lecithin. ARA-DHA blend and fat soluble vitamin premix are added. Mineral and trace minerals as well as vitamins and nutrients are added. The mix is held at 140-145° F at high agitation during mixing, then homogenized at 2000-3500 PSI and cooled at 40° F.
- OPO Sn2 palmitate fat
- coconut oil high oleic safflower or sunflower oil
- soybean oil and sunflower or canola lecithin soybean oil and sunflower or canola lecithin.
- ARA-DHA blend and fat soluble vitamin premix are added. Mineral and trace minerals as well as vitamins and nutrients are added. The mix is held at 140-145°
- Nucleotide premix is added to the cold mix and agitated before pasteurization at 170-180° F for 60 seconds followed by spray-drying to a resulting moisture content of 1.5-3.5 %.
- Probiotics and human lactoferrin are added to the base formulation via dry -blending.
- a batch of prenatal formula powder (with DHA and choline) is prepared according to the formulation in Table 21.
- Proteins milk protein concentrate and soy protein isolate
- the oils high oleic safflower oil and canola oil
- lecithin low oleic safflower oil and canola oil
- DHA oil low oleic safflower oil and canola oil
- lecithin high oleic safflower oil and canola oil
- DHA oil and fat soluble vitamin premix are added followed by the maltodextrin, sugar and fructooligosaccharides.
- Mineral and trace minerals as well as other vitamins and nutrients are added.
- the mix is held at 140-145° F at high agitation during mixing, then homogenized at 2000-3500 PSI and cooled at 40° F.
- Vitamin C in 5% solution with a portion of potassium hydroxide and human lactoferrin in 10% solution (the human lactoferrin can be added at another stage by dry blending) along with N&A flavors are added to the cold mix.
- the mix is pasteurized at 170-180° F for 60 seconds followed by spray-drying to a resulting moisture content of 2.5-4.0 %.
- rhLF Recombinant human lactoferrin produced in P. pastoris (K. phaffii) was tested to ascertain survivability of oral dosing forms through the digestive system. Apo and holo forms were tested to determine effect, if any, of iron loading. Native apo and holo human and bovine lactoferrin served as controls.
- a simulated salivary fluid was prepared. The pH was 7. A sample of lactoferrin was added and the mixture incubated with mixing at 37° C for 2 minutes. A sample was taken for SDS gel and Western blot testing for LF presence.
- a simulated gastric chyme and fluid were prepared.
- the pH was 3.
- Porcine pepsin (Sigma) (2000 U/ml) was added.
- the simulated oral cavity sample was introduced into the simulated gastric fluid and the mixture incubated with mixing at 37° C for 2 hours.
- a sample was taken for SDS gel and Western blot testing for LF presence.
- a simulated intestinal fluid was prepared. Bile salts (Sigma) (10 mM), lOOU/ml of porcine trypsin (Sigma) and 25U/m of porcine chymotrypsin (sigma) were added. The pH of the mixture was 7. The simulated gastric sample was introduced to the simulated intestinal fluid and the mixture incubated with mixing at 37° C for 2 hours. A sample was taken for SDS gel and Western blot testing for LF presence
- allergens are pepsin resistant, Almond et al., supra, for example, bovine ⁇ -lactoglobin.
- rhLF was tested for level of susceptibility to pepsin.
- a simulated gastric fluid was prepared with a pH of 1-2 and 1600U/ml porcine pepsin (Sigma). Holo (iron loaded) and apo forms of native bovine and human LF, and rhLF were tested.
- compositions and methods of edible compositions disclosed herein are available commercially as food grade or drug grade compounds or can be made as provided in the art. While compositions and methods of the disclosure have been described in terms of certain embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the disclosure. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for agents described herein while same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the present disclosure.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Disclosed are recombinant human secretory proteins, along with compositions comprising such proteins and methods for using such compositions. Aspects of the disclosure include microbially generated human secretory proteins and edible and potable compositions containing same, such as, an infant formula comprising such proteins. Also disclosed are methods for use of the disclosed edible and potable compositions to provide nutrition and other benefits.
Description
EDIBLE COMPOSITION COMPRISING
RECOMBINANT HUMAN SECRETORY PROTEIN
SEQUENCE LISTING
[1] The instant application contains a Sequence Listing submitted in xml format and hereby is incorporated by reference in entirety. Said xml copy, created on 04 August 2023, is named 080201-80180201. ml and is 7,577 bytes in size.
BACKGROUND
I. Technical Field
[2] Embodiments relate to human secretory proteins, compositions comprising such proteins, and use thereof in specific edible compositions, such as, food, beverage and supplement compositions, including an infant formula.
II. Background
[3] Secretory proteins have important roles in a body, including nutrition, protection, lubrication and so on. Dedicated cell machinery is needed to modify an incipient secreted protein, for example, glycosylation, and to traffic that nascent secretory protein to a membrane or out of a cell.
[4] Although from a phylogenetic perspective, secretory proteins may be similar across taxa, the range, amount and structure of a secretory protein is a species-specific characteristic or feature. For example, in mammal milk, type of secretory protein, amount of a secretory protein and structure of a secretory protein, for example, nature of glycosylation and structure of carbohydrates, vary, and can vary considerably from species to species. Thus, for example, the secretory protein or glycosylation profile, pattern or fingerprint of bovine milk varies from that of human milk.
[5] (Secretions, serous fluid and the like containing secretory proteins also contain a range of lipids and carbohydrates, which can be unique to an organ, a stage of life and so on. Hence, for example, human milk contains fat globules encased in a milk fat globule membrane (MFGM), a complex assemblage of lipids and proteins. Composition of MFGM can vary as an
infant ages. Oligosaccharides (human milk oligosaccharides, HMO), also vary in content and amount amongst species. HMO’s of breast milk are not necessarily an energy source for an infant, instead, may serve to provide a conducive environment and food source of microbes in the gut of an infant.)
[6] Because of variability of secretory molecules among species, the goal of isolating and using secretory molecules for therapeutic or nutritional value in human is elusive and currently unattained as obtaining commercial amounts of collected human secretory molecules is not feasible; and species differences translate to use of non-human secretory molecules resulting in product imperfectly matched for human use. If a current commercial product lacking a molecule normally found in human milk were to contain an excess of a compensatory non-human ingredient, that can be a burden to a subject and so on.
[7] For example, many current infant formulae are produced with food ingredients derived from conventional agricultural and manufacturing practices. In recent years, manufacturers have attempted to create formulations with components that more closely resemble human secretory protein, and for example, breast milk. Microbially-expressed HMO’s are added to some branded infant formulae. Such technologies have proven to be useful in making high-value and densely nutritious food ingredients that are unattainable from conventional agricultural practices or from natural sources.
[8] Infant formula commonly is based on bovine milk proteins, which differ from human breast milk proteins, for example, in total amino acid composition. To address amino acid needs of a human infant, bovine protein level in infant formula generally is raised. That provides a much higher total intake of protein by formula-fed infants, which can precipitate metabolic stress on infants.
[9] Increased protein intake resulting from high protein content of formulae on the market leads to higher insulin levels in formula-fed infants. Formula-fed infants get about 70% more protein than do breastfed infants between 3-6 months of age (for example, Heinig et al., Am J Clin Nutr, 1993; 58: 152-156; and Koletzko et al., Adv Exp Med Biol, 2005; 569:69-79).
[10] Morbidity differences between breastfed and formula-fed infants have been observed, breastfed infants have fewer respiratory infection, ear infection and gastroenteritis than do formula-fed infants. (Wright et al., BMJ, 299, 946-949, 1989; Duncan et al., Pediatrics, 2003,
91(5)867-873; Aniansson et al., Pediatr Infect Dis J, 1994, 13(3)182-188; and Dewey et al., J Pediatr, 1992, 126(5)part 1 :695-702). A possible explanation is greater level of immune modulating substances in human as compared to bovine milk.
[11] For example, approximately 70% of protein found in human milk is whey protein. Primary whey proteins are α-lactalbumin, lactoferrin (LF) and secretory IgA. Those proteins are bioactive and possess unique properties, such as, antimicrobial activities, anti-inflammatory activity and anti -oxi dative properties. Those proteins also may aid in absorption of key vitamins and minerals.
[12] Human milk whey proteins for human consumption currently are unavailable for commercial use. Current infant formulae rely solely on protein sources from bovine, goat or soy. There are no commercially available human milk whey proteins available for use in edible or potable compositions. Human neonates who do not have access to human milk will be unable to reap the health benefits of human secretory molecules. Adults also will not benefit from the virtues of human secretory molecules.
[13] Because of the numerous health and nutrition benefits of human secretory molecules, there is interest in including human secretory molecules in a range of edible or potable compositions, such as, drinks, infant formulae, bars, dairy products, beverages and so on.
SUMMARY
[14] The present disclosure addresses needs in the art by providing microbially expressed human secretory proteins, such as, human milk proteins, as well as unique edible or potable compositions (hereinafter, “edible compositions,”) comprising such proteins and methods of use for providing nutrition to a subject. Such compositions achieve immunomodulatory and other benefits of native human secretory proteins, previously only available using non-human sources. Aspects of the disclosure include combinations of individual ingredients to maximize immunomodulatory impact of a formulation. In aspects, compositions of the disclosure include, in addition to one or more human secretory proteins, one or more human secretory oligosaccharides (for example, 2'-fucosyllactose), a probiotic bacterium (for example, Bifidobacterium, such as, Bifidobacterium infantis), a lipid source, such as, MFGM, and so on.
[15] Accordingly, disclosed herein, in aspects, is an edible composition comprising lactose, one or more lipids, protein, a human secretory oligosaccharide, such as, a human milk
oligosaccharide (HMO), one or more minerals, one or more vitamins, a probiotic organism and a human secretory protein. In embodiments, an HMO is 2'-fucosyllactose, lacto-N-neotetraose, 3-fucosyllactose, 6'-sialyllactose, difucosyllactose or lacto-N-tetraose. In embodiments, an HMO is 2'-fucosyllactose. In embodiments, an HMO is lacto-N-neotetraose. In embodiments, an edible composition comprises one or more of high oleic sunflower oil, mid-oleic sunflower oil, canola oil, safflower oil, coconut oil, low erucic rapeseed oil, sunflower oil, ascorbyl palmitate, mixed tocopherol concentrate, Mortierella alpina oil, alga oil, soybean oil or palm oil. In embodiments, an edible composition comprises high oleic sunflower oil, coconut oil, low erucic rapeseed oil, canola oil, sunflower oil, ascorbyl palmitate, mixed tocopherol concentrate, Mortierella alpina oil and alga oil. In embodiments, one or more minerals comprise one or more of calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium or selenium. In embodiments, an edible composition comprises calcium phosphate, calcium citrate, magnesium chloride, potassium citrate, potassium chloride, sodium chloride, copper sulfate, ferrous sulfate, manganese sulfate, zinc sulfate, sodium selenite or potassium iodide. In embodiments, one or more vitamins comprise one or more of vitamin A, vitamin D, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, niacinamide, calcium pantothenate, folic acid, pantothenic acid, vitamin Bl 2, vitamin C, biotin, choline, inositol, and salts thereof. In embodiments, an edible composition comprises vitamin A palmitate, vitamin D3, D-a tocopherol, vitamin KI, thiamine hydrochloride, riboflavin, niacinamide, calcium pantothenate, pyridoxine hydrochloride, biotin, folic acid, cyanocobalamin, choline bitartrate, inositol and ascorbic acid.
[16] In embodiments, an edible composition comprises one or more nucleotides. In embodiments, one or more nucleotides comprise one or more of cytidine 5 ’-monophosphate, uridine 5 ’-monophosphate, adenosine 5 ’ -monophosphate or guanosine 5 ’-monophosphate. In embodiments, an edible composition comprises cytidine 5 ’-monophosphate, disodium uridine 5 ’-monophosphate, adenosine 5 ’-monophosphate and disodium guanosine 5 ’-monophosphate.
[17] In embodiments, an edible composition comprises a whey protein-lipid concentrate, for example, an edible composition comprises from about 3.0% to about 5.0% by weight whey protein-lipid concentrate.
[18] In embodiments, an edible composition comprises milk fat globule membrane (MFGM)
[19] In embodiments, an edible composition comprises casein, such as, a micellar casein. In embodiments, an edible composition comprises from about 5% to about 8% by weight micellar casein.
[20] In embodiments, an edible composition comprises from about 50% to about 55% by weight of lactose powder. In embodiments, an edible composition comprises a whole milk powder. In embodiments, an edible composition comprises from about 13% to about 18% by weight whole milk powder.
[21] In embodiments, a probiotic organism is a Bifidobacterium. In embodiments, a Bifidobacterium is Bifidobacterium infantis.
[22] In embodiments, an edible composition comprises from about 43% to about 70% by weight of lactose, from about 0.5% to about 6% by weight of milk fat, from about 9% to about 13% by weight of protein, from about 1.5% to about 3.0% by weight of minerals, from about 0.5% to about 2.0% by weight of vitamins, from about 0.5% to about 2.0% by weight of 2'-fucosyllactose, from about 5x108 cfu/lOOg to about IxlO11 cfu/100g of probiotic microbe and from about 0.02% to about 0.3% by weight of a human secretory protein.
[23] In embodiments, an edible composition comprises from about 0.01% to about 0.06% by weight of nucleotides.
[24] In embodiments, an edible composition comprises from about 0.06% to about 0.4% by weight of arachidonic acid (ARA).
[25] In embodiments, an edible composition comprises from about 0.03% to about 0.3% by weight of docosahexaenoic acid (DHA).
[26] In embodiments, an edible composition comprises from about 0.00002% to about 0.00009% by weight of lutein.
[27] In embodiments, an edible composition comprises from about 0.025% to about 0.07% by weight of taurine.
[28] In embodiments, an edible composition comprises from about 0.002% to about 0.015% by weight of L-carnitine.
[29] Also disclosed, in embodiments, is an edible composition comprising lactose, one or more lipids, protein, a human milk oligosaccharide (HMO), one or more minerals, one or more vitamins, a probiotic microbe and recombinant human lactoferrin (rhLF), which can comprise one or more human-like glycans, N-glycan found in human protein. Further described, in
embodiments, is an edible composition comprising a recombinant human secretory protein from a non-mammal cell, a recombinant human secretory protein comprising one or more human-like glycans, N-glycans found on human glycoproteins.
[30] In embodiments, a human secretory protein is a recombinant protein. In embodiments, a human secretory protein is from a mammal cell. In embodiments, a human secretory protein is from a non-mammal cell. In embodiments, a human secretory protein is from a bacterium. In embodiments, a human secretory protein is from a fungus cell. In embodiments, a human secretory protein is from a yeast cell. In embodiments, a yeast cell is of a genus, Arxula, Aspergillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tr erne Ila, Trichosporon, Wicker hamomyces or Yarrowia. In embodiments, a human secretory protein is secretory IgA (slgA), human serum albumin, xanthine dehydrogenase, lactoferrin, lactoperoxidase, butyrophilin, lactadherin, adiponectin, β-casein, κ-casein, leptin, lysozyme or α-lactalbumin. In embodiments, a human secretory protein is human lactoferrin. In embodiments, a human secretory protein is a human whey protein.
[31] In embodiments, a human secretory protein comprises a human-like glycan, that is, an N-glycan found in human glycoprotein. In embodiments, a human secretory protein comprises a hybrid N-glycan. In embodiments, a human secretory protein comprises a complex N-glycan. In embodiments, a human secretory protein comprises a bi-antennary, a tri-antennary or a tetra-antennary N-glycan. In embodiments, the human secretory protein comprises a glycan comprising sialic acid, galactose, N-acetylgalactosamine or fucose. In embodiments, a human secretory protein comprises a high-mannose N-glycan. In embodiments, a human secretory protein comprises a glycan having less than ten mannose residues. In embodiments, a human secretory protein comprises a glycan having less than four mannose residues. In embodiments, a human secretory protein comprises a glycan having four or more mannose residues.
[32] In embodiments, a method for providing nutrition to a subject comprising feeding said subject an edible composition of interest as described herein.
[33] Also described is a method for producing an edible composition comprising generating a mixture disclosed herein, for example, a mixture comprising a protein and a human
secretory protein (for example, a recombinant human milk protein, such as, a recombinant human lactoferrin, which can have human-like glycans), and optionally including one or more of, a lactose, one or more lipids, protein, a human secretory oligosaccharide, such as, a human milk oligosaccharide (HMO), one or more minerals, one or more vitamins and a probiotic microbe.
[34] In embodiments, an edible composition comprises a food, such as, a bar, a dairy product, such as, a yogurt or an ice cream, a nutritional powder, an infant formula powder, a candy, such as, a gummy, and so on. An edible composition of interest also comprises a potable composition, such as, a beverage, a smoothie, a shake, a ready to use infant formula, a liquid nutraceutical, a drinkable nutritional composition and so on.
[35] In a first embodiment, the invention relates to an infant formula comprising lactose, one or more lipids, protein, a human milk oligosaccharide (HMO), one or more minerals, one or more vitamins, a probiotic microbe and a human secretory protein.
[36] In a second embodiment, the infant formula of the first embodiment comprises secretory IgA (slgA), human serum albumin, xanthine dehydrogenase, lactoferrin (LF), such as, human LF (hLF), lactoperoxidase, butyrophilin, lactadherin, adiponectin, β-casein, κ-casein, leptin, lysozyme or α-lactalbumin.
[37] In a third embodiment, the human secretory protein of the second embodiment is human lactoferrin.
[38] In a fourth embodiment, in the infant formula of the first embodiment, the human secretory protein is a human whey protein.
[39] In a fifth embodiment, the human secretory protein of any of the formula of embodiments 1-4 comprises a hybrid N-glycan.
[40] In a sixth embodiment, the human secretory protein of any of the formula of embodiments 1-4 comprises a complex N-glycan.
[41] In a seventh embodiment, the human secretory protein of the 6th embodiment comprising a bi-antennary, tri-antennary or tetra-antennary N-glycan.
[42] In an eighth embodiment, the human secretory protein of any of the formula of embodiments 1-4 comprises a high-mannose N-glycan.
[43] In a ninth embodiment, the human secretory protein of any of the formula of embodiments 1-4 comprises sialic acid, galactose, N-acetylgalactosamine, or fucose.
[44] In a tenth embodiment, the human secretory protein of any of the formula of embodiments 1-4 comprises a glycan having less than ten mannose residues.
[45] In an eleventh embodiment, the human secretory protein of any of the formula of embodiments 1-4 comprises a glycan having less than four mannose residues.
[46] In a twelvth embodiment, the human secretory protein of any of the formula of embodiments 1-4 comprises a glycan having four or more mannose residues.
[47] In a thirteenth embodiment, the formula of any of the previous embodiments wherein the HMO is 2'-fucosyllactose, lacto-N-neotetraose, 3 -fucosy llactose, 6'-sialyllactose, difucosyllactose or lacto-N-tetraose.
[48] In a fourteenth embodiment, the formula of embodiment 13 comprises 2'-fucosyllactose.
[49] In a fifteenth embodiment, the formula of embodiment 13 comprises
1 acto-N -neotetraose .
[50] In a sixteenth embodiment, the formula of any of the previous embodiments comprises one or more of high oleic sunflower oil, mid-oleic sunflower oil, safflower oil, coconut oil, canola oil, low erucic rapeseed oil, sunflower oil, ascorbyl palmitate, mixed tocopherol concentrate, Mortierella alpina oil, alga oil, soybean oil and palm oil.
[51] In a seventeenth embodiment, the formula of the 16th embodiment comprises high oleic sunflower oil, coconut oil, canola oil, low erucic rapeseed oil, sunflower oil, ascorbyl palmitate, mixed tocopherol concentrate, Mortierella alpina oil and alga oil.
[52] In an eighteenth embodiment, the formula of any of the previous embodiments comprises one or more of calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium and selenium.
[53] In a nineteenth embodiment, the formula of the 18th embodiment comprises calcium phosphate, calcium citrate, magnesium chloride, potassium citrate, potassium chloride, sodium chloride, copper sulfate, ferrous sulfate, manganese sulfate, zinc sulfate, sodium selenite and potassium iodide.
[54] In an twentieth embodiment, the formula of any of the previous embodiments comprises one or more of vitamin A, vitamin D, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, niacinamide, calcium pantothenate, folic acid, pantothenic acid, vitamin B 12, vitamin C, biotin, choline, inositol, and salts thereof.
[55] In a twenty-first embodiment, the formula of the 20th embodiment comprises vitamin A palmitate, vitamin D3, D-a-tocopherol, vitamin KI, thiamine hydrochloride, riboflavin, niacinamide, calcium pantothenate, pyridoxine hydrochloride, biotin, folic acid, cyanocobalamin, choline bitartrate, inositol and ascorbic acid.
[56] In a twenty-second embodiment, the formula of any of the previous embodiments comprising one or more nucleotides.
[57] In a twenty-third embodiment, the formula of the 22nd embodiment where one or more nucleotides comprise cytidine 5 ’ -monophosphate, uridine 5 ’-monophosphate, adenosine 5 ’-monophosphate and guanosine 5 ’-monophosphate.
[58] In a twenty-fourth embodiment, the formula of the 23rd embodiment comprises cytidine 5 ’-monophosphate, disodium uridine 5 ’-monophosphate, adenosine 5 ’-monophosphate and di sodium guanosine 5 ’-monophosphate.
[59] In a twenty-fifth embodiment, the formula of any of the previous embodiments comprising whey protein-lipid concentrate.
[60] In a twenty-sixth embodiment, the formula of the 25th embodiment comprising from about 3.0% to about 5.0% whey protein-lipid concentrate.
[61] In a twenty-seventh embodiment, the formula of any of the previous embodiments comprising milk fat globule membrane (MFGM).
[62] In a twenty-eighth embodiment, the formula of any of the previous embodiments comprising casein.
[63] In a twenty-ninth embodiment, the formula of the 28th embodiment comprising from about 5% to about 8% micellar casein.
[64] In a thirtieth embodiment, the formula of the 25th to 29th embodiments comprises from about 50% to about 55% by weight of lactose powder.
[65] In a thirty-first embodiment, the formula of the 1st to 24th embodiments comprises whole milk powder.
[66] In a thirty-second embodiment, the formula of any of the prior embodiments comprising from about 13% to about 18% whole milk powder.
[67] In a thirty -third embodiment, the formula of any of the previous embodiments comprising Bifidobacterium .
[68] In a thirty-fourth embodiment, the formula of the 33rd embodiment comprising Bifidobacterium infantis.
[69] In a thirty-fifth embodiment, the human secretory protein of any of the formula of the previous embodiments which is a recombinant protein.
[70] In a thirty-sixth embodiment, the human secretory protein of the formula of the 35th embodiment which is from a mammal cell.
[71] In a thirty-seventh embodiment, the human secretory protein of the formula of the 35th embodiment which is from a non-mammal cell.
[72] In a thirty-eighth embodiment, the human secretory protein of the formula of the 35th embodiment which is from a bacterium.
[73] In a thirty-ninth embodiment, the human secretory protein of the formula of the 35th embodiment which is from a fungus cell.
[74] In a fortieth embodiment, the human secretory protein of the formula of the 35th embodiment which is from a yeast cell.
[75] In a forty-first embodiment, the human secretory protein of the formula of the 40th embodiment which is from a yeast cell of an Arxula, Aspergillus, Aurantiochy trium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon, Wicker hamomyces or Yarrow ia.
[76] In a forty-second embodiment, the formula of any the prior embodiments comprises from about 43% to about 70% by weight of lactose, from about 0.5% to about 6% by weight of milk fat, from about 9% to about 13% by weight of protein, from about 1.5% to about 3.0% by weight of minerals, from about 0.5% to about 2.0% by weight of vitamins, from about 0.5% to about 2.0% by weight of 2'-fucosyllactose, from about 5xl08 cfu/lOOg to about IxlO11 cfu/lOOg of the probiotic organism and from about 0.02% to about 0.3% by weight of the human milk protein.
[77] In a forty-third embodiment, the formula of any of the previous embodiments comprising from about 0.01% to about 0.06% by weight of nucleotides.
[78] In a forty-fourth embodiment, the formula of any of the previous embodiments comprising from about 0.06% to about 0.4% by weight of arachidonic acid
[79] In a forty-fifth embodiment, the formula of any of the previous embodiments comprising from about 0.03% to about 0.3% by weight of docosahexaenoic acid.
[80] In a forty-sixth embodiment, the formula of any of the previous embodiments comprising from about 0.00002% to about 0.00009% by weight of lutein.
[81] In a forty-seventh embodiment, the formula of any of the previous embodiments comprising from about 0.025% to about 0.07% by weight of taurine.
[82] In a forty-eighth embodiment, the formula of any of the previous embodiments comprising from about 0.002% to about 0.015% by weight of L-camitine.
[83] The forty-ninth embodiment relates to an infant formula comprising lactose, one or more lipids, protein, a human milk oligosaccharide (HMO), one or more minerals, one or more vitamins, a probiotic microbe, and a recombinant human lactoferrin protein comprising one or more human-like glycans.
[84] In a fiftieth embodiment, the formula of the 49th embodiment wherein the recombinant human lactoferrin protein is from a non-mammal cell.
[85] In a fifty-first embodiment, the formula of the 49th or 50th embodiment wherein the recombinant human lactoferrin protein is from a yeast cell.
[86] The fifty-second embodiment relates to a method for providing nutrition to an infant comprising feeding to an infant the infant formula of any of the prior embodiments.
[87] The fifth-third embodiment relates to an infant formula comprising a recombinant human secretory protein from a non-mammal cell, comprising one or more human-like glycans.
[88] In a fifty-fourth embodiment, in the infant formula of the 53rd embodiment, the human secretory protein is secretory IgA (slgA), human serum albumin, xanthine dehydrogenase, lactoferrin, lactoperoxidase, butyrophilin, lactadherin, adiponectin, β-casein, κ- casein, leptin, lysozyme, or α-lactalbumin.
[89] In a fifty-fifth embodiment, in the infant formula of the 53rd embodiment, the human secretory protein is human lactoferrin (hLF).
[90] In a fifty-sixth embodiment, in the infant formula of the 53rd embodiment, the human secretory protein is a human whey protein.
[91] In a fifty-seventh embodiment, the human secretory protein of embodiments 53-56 comprising a glycan comprising sialic acid, galactose, N-acetylgalactosamine, or fucose.
[92] In a fifty-eighth embodiment, the human secretory protein of embodiments 53-56 comprises a complex N-glycan.
[93] In a fifth-ninth embodiment, the human secretory protein of embodiment 58 comprises a bi-antennary, tri-antennary or tetra-antennary N-glycan.
[94] In a sixtieth embodiment, the human secretory protein of embodiments 53-56 comprising a hybrid N-glycan.
[95] In a sixty-first embodiment, the human secretory protein of the 53rd embodiment is from a bacterium.
[96] In a sixty-second embodiment, the human secretory protein of the 53rd embodiment is from a fungus cell.
[97] In a sixty-third embodiment, the human secretory protein of the 53rd embodiment is from a yeast cell
[98] In a sixty-fourth embodiment, the yeast cell of the 63rd embodiment is of a genus Arxiila, Aspergillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon, Wickerhamomyces or Yarrowia.
[99] The sixty-fifth embodiment relates to a method for providing nutrition to an infant comprising feeding to an infant the infant formula of any of embodiments 53-64.
[100] The sixty-sixth embodiment relates to a method for producing an infant formula comprising generating a mixture comprising lactose, one or more lipids, bovine protein, a human milk oligosaccharide (HMO), one or more minerals, one or more vitamins, a probiotic microbe, and a human secretory protein.
[101] In a sixty-seventh embodiment, in the method of the 66th embodiment, the human secretory protein is from a mammal cell.
[102] In a sixty-eighth embodiment, in the method of the 66th embodiment, the human secretory protein is from a non-mammal cell.
[103] In a sixty-ninth embodiment, in the method of the 68th embodiment, the cell is a yeast cell.
[104] In a seventieth embodiment, in the method of the 69th embodiment, the yeast cell is of a genus of Arxula, Aspergillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus,
Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon, Wickerhamomyces or Yarrowia.
[105] In a seventy-first embodiment, in the method of embodiments 66-70, the human secretory protein is secretory IgA (slgA), human serum albumin, xanthine dehydrogenase, lactoferrin, lactoperoxidase, butyrophilin, lactadherin, adiponectin, β-casein, κ-casein, leptin, lysozyme or u-lactalbumin.
[106] In a seventy-second embodiment, in the method of the 71st embodiment, the human secretory protein is human lactoferrin.
[107] In a seventy-third embodiment, in the method of the 66th-70th embodiments, the human secretory protein is human whey protein.
[108] In a seventy-fourth embodiment, in the method of the 66th-73rd embodiments, the human secretory protein comprises a glycan comprising sialic acid, fucose, galactose or N-acetylgalactosamine.
[109] In a seventy -fifth embodiment, in the method of the 74th embodiment, the human secretory protein comprises a complex N-glycan.
[HO] In a seventy-sixth embodiment, in the method of the 75th embodiment, the human secretory protein comprises a bi-antennary, tri-antennary or tetra-antennary N-glycan.
[Hl] In a seventy-seventh embodiment, in the method of the 66th-73rd embodiments, the human secretory protein comprises a hybrid N-glycan.
[112] In a seventy-eighth embodiment, in the method of the 66th-73rd embodiments, the human secretory protein comprises a high-mannose N-glycan.
[113] It is contemplated that any embodiment discussed herein can be implemented with respect to any method or edible composition of embodiments of the disclosure, and vice versa. Furthermore, compositions of certain embodiments can be used to achieve methods of certain embodiments.
[114] Other objects, features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the disclosure,
are given by way of illustration only, since various changes and modifications will become apparent to those skilled in the art from the instant detailed description.
DETAILED DESCRIPTION
[115] Aspects of the present disclosure address the lack or scarcity of human secretory proteins in the commercial market by including a source of recombinant human secretory proteins (for example, lactoferrin) for use as a food ingredient or foodstuff in edible compositions, such as, an infant formula. That will bring the antimicrobial, anti-inflammatory and anti -oxi dative properties of those proteins to consumers who previously, realistically, could only access those proteins in non-human milk, despite interspecies differences in milk of different mammals, or from human milk. Edible compositions comprise, in addition to one or more human secretory protein, custom combinations of other individual ingredients of similar biologic activity to maximize immunomodulatory and nutritional impact of a formulation of interest. Also disclosed is an edible composition comprising one or more human secretory proteins together with one or more human oligosaccharides, such as, human milk oligosaccharides (HMO) with probiotic microbes (for example, a Bifidobacterium, such as, Bifidobacterium infantis).
I. Definitions
[116] An, “infant formula,” is any composition comprising components which serve as a simulation of human milk or as a complete or partial substitute for human milk. In aspects, an, “infant formula,” is a composition as defined in 21 U.S.C. § 321. An infant formula of the present disclosure may be a solid composition (for example, a powder). An infant formula of the disclosure may be a liquid composition. A liquid composition can be a concentrate or ready to use.
[117] A, “nutritional composition,” or an, “edible composition,” according to the instant invention is, for example, an, “infant formula,” and relates to a foodstuff intended for nutritional use by infants from birth and during the first 6-12 months of life and satisfying nutritional requirements of infants and babies. An infant formula can be intended for use as the only source
of nutrients from birth to about 6 months of age. A formula used in the first six months of life can be termed a, “starter formula.”
[118] The term, “preterm infant formula,” means an infant formula intended for a preterm infant.
[119] A, “milk fortifier,” refers to liquid or solid edible and nutritional compositions suitable for mixing with breast milk (which is human milk for a human milk fortifier) or infant formula. A milk fortifier can be used to increase calories, protein content, mineral amount and vitamins in breast milk fed to preterm infants or infants with a low birth weight. “Breast milk,” is not only milk but also relates to colostrum of a mother, or a donor milk or a colostrum of a donor.
[120] Further, an edible composition according to the invention may be intended as a, “follow-on formula,” a complement or as a part of a progressively diversified diet wherein formula feeding starts, for example, when an infant is about 4 months of age and feeding of formula is part of an infant diet up to the first year birthday of a baby. An infant may start to include a formula according to the invention between 4-6 months, which is when most infants start with solids, or at least when breastfed infants nutrient intake is complemented with solids from 6 months up to 12 months. A follow-on formula is a formula intended to be used from about 6 months onwards during a weaning period, as a complement to solids which are introduced at about 6 months.
[121] An infant formula can be mixed with a cereal to form an, “infant cereal composition,” a foodstuff intended for particular nutritional use by infants or children, such as, young children, during first years of life.
[122] An edible composition can be a powder concentrate or a liquid concentrate intended to be mixed with water before use, or a liquid ready-to-use product.
[123] The term, “ready-to-use product,” or synonymous equivalent terms, such as, ready to feed, ready to drink or ready to consume, as used herein, unless otherwise specified, refers to liquid formulae suitable for direct oral administration out of a packaging to an infant, wherein a formula is a ready to-feed liquid, a reconstituted powder or a diluted liquid concentrate.
[124] As used herein, an, “infant,” is a child under the age of 12 months.
[125] ‘Isolated,” is used to describe a biologic moiety that is removed from a normal environment thereof. Isolating is a form of, “purifying,” as extraneous material is removed from
a target of interest. Thus, a gene can be excised from a chromosome away from upstream and downstream elements normally associated with an open reading frame. Similarly, a protein can be removed from the soup of the intracellular milieu or can be dissociated from an intracellular structure or from a membrane, for example. An external intervention removes an entity from normal surroundings thereof to isolate that entity.
[126] ‘Recombinant,” in biotechnology or molecular biology means pieces of biologic molecules not normally found together are joined to form a new, artificial, synthetic composite molecule. Hence, pieces of nucleic acids of different origin are joined to make a new, unnatural unitary nucleic acid that otherwise, would not be found in nature. Similarly, as to proteins, polypeptides or domains thereof can be joined to form a new molecular entity with composite or new functions, that otherwise would not be found in nature. A recombinant is artificial. A synonymous term in the art is, “engineered,” or grammatic forms thereof.
[127] An, “N-glycan,” is an N-linked oligosaccharide, that is, a sugar attached by an asparagine-N-acetylglucosamine linkage to nitrogen of an asparagine residue of a polypeptide.
[128] A, “hybrid,” N-glycan is a glycan (also termed a polysaccharide) having both substituted (GlcNAc linkage) and unsubstituted mannose residues.
[129] A, “complex,” N-glycan is a glycan having at least one GlcNAc attached to a 1,3-mannose arm and at least one GlcNAc attached to a 1,6-mannose arm of a trimannose core. In cases, a complex N-glycan has at least one branch that terminates in an oligosaccharide such as, for example, NeuNAc-, NeuAca2-6GalNAcal-, NeuAca2-3Galbl-3GalNAcal- orNeuAca2- 3/6Galbl-4GlcNAcbl-. Complex N-glycans also can have intrachain substitutions comprising, “bisecting,” GlcNAc and core fucose (“Fuc”).
[130] A, “high-mannose,” glycan is a glycan having at least 4 mannose residues. In aspects, a high-mannose glycan has 4, 5, 6, 7, 8, 9 or more mannose (Man) residues.
[131] ‘Milk fat globule membrane,” (MFGM) comprises about 120 different proteins in a phospholipid double layer surrounding fat droplets in milk. Sphingomyelin, phosphatidyl choline, phosphatidyl serine and phosphatidyl ethanolamine are dominating phospholipids of MFGM. Butyrophilin, MUC1, PAS6/7 (lactadherin), CD14, TLR1 and TLR4 are examples of MFGM proteins, those with antimicrobial effect (Spitsberg, J Dairy Sci, 2005, 88:2289-2294; Reinhardt & Lippolis, J Dairy Res, 2006,. 73(4)406-416; Brink & Lonnerdahl, J Nutr Biochem,
86: 108465, 2020; Wang et al., Fron Nutr 8:807284, 2022; and Chai et al., Food Sci Anim Res 42(3)351-371, 2022).
[1321 Lacprodan MFGM-10 (Aria Foods, Viby J, Denmark) or similar raw materials from other suppliers are enriched in MF GM and may be used as enriched phospholipid whey protein concentrate solids or a lipid source in an edible composition of interest.
[133] "Recombinant," as introduced above, refers to a cell, nucleic acid, protein or vector, which has been modified due to introduction of an exogenous nucleic acid or alteration of a native nucleic acid by human manipulation or intervention. Resulting cells, nucleic acids, proteins or vectors are considered recombinant, as are progeny, offspring, duplications or replications thereof, which also are considered recombinant. Thus, for example, recombinant cells can express genes not found within a native (non-recombinant) form of the cell or express native genes differently than those same genes are expressed by a non-recombinant cell. Recombinant cells can, without limitation, include recombinant nucleic acids that encode for a gene product or for suppression elements, such as mutations, knockouts, antisense, interfering RNA (RNAi) or dsRNA and so on that reduce level of an active gene product in a cell. A, "recombinant nucleic acid," is derived from nucleic acid originally formed in vitro, in general, by exogenous, human-originated or human-mediated manipulation of nucleic acid, for example, using polymerases, ligases, exonucleases and endonucleases, or otherwise to form an artificial form not normally found in nature. Once a recombinant nucleic acid is made and introduced into a host cell or organism, that artificial, synthetically created nucleic acid may replicate using the in vivo cellular machinery of a host cell; however, such nucleic acids, once produced recombinantly, although subsequently replicated intracellularly, are still considered recombinant for purposes of the instant disclosure. Additionally, a recombinant nucleic acid refers to nucleotide sequences that comprise an endogenous nucleotide sequence and an exogenous nucleotide sequence; thus, an endogenous gene that has undergone recombination with an exogenous promoter is a recombinant nucleic acid. A, "recombinant protein," is a protein made using recombinant techniques, for example, through expression of a recombinant nucleic acid.
[134] From perspective of a consumer of an edible composition of interest, aside from age, “individual," “infant,” “subject,” and, “patient,” are used interchangeably herein, and can refer to a human or a non-human.
[135] Throughout the instant application, “about,” is used to indicate a value includes inherent variation of error of a measurement or quantification method. Such variation can be up to 10% above and below a value, that is, (0.9 x q) to q to (1.1 x q).
[136] Use of, “a,” or, “an.” may mean “one,” but also is consistent with, “one or more,” “at least one,” and, “one or more than one.”
[137] “And/or,” means, “and,” or, “or.” To illustrate, A, B, and/or C includes: A alone, B alone, C alone, a combination of A and B, a combination of A and C, a combination of B and C, or a combination of A, B, and C. In other words, “and/or,” operates as an inclusive or.
[138] “Comprising,” (and any grammatic form of comprising, such as, “comprise,” and, “comprises,”) “having,” (and any grammatic form of having, such as, “have,” and, “has,”) “including” (and any grammatic form of including, such as, “includes,” and, “include,”) or “containing” (and any grammatic form of containing, such as, “contains,” and, “contain,”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
[139] Compositions and methods for use thereof can, “comprise,” “consist essentially of,” or, “consist of,” any of ingredients or steps disclosed throughout the specification. Compositions and methods, “consisting essentially of,” ingredients or steps disclosed defines scope of a claim to specified materials or steps which materially impact the basic and novel characteristic of the claimed embodiment.
[140] ‘Foodstuff,” a focus of the instant invention, relates to a composition that is consumed. Consumable foodstuffs include compositions that are edible or are used to produce foodstuffs, that is, food-grade ingredients that are edible.
[141] ‘Food grade,” relates to material used to make a foodstuff or is permitted to come into direct contact with a foodstuff intended for human consumption. Food grade generally means a material that is FDA compliant and meets FDA guidelines and rules for foodstuffs.
Such FDA guidelines and rules define when a foodstuff is generally regarded as safe (GRAS) for consumption.
[142] Foodstuffs can be manufactured and handled under local and federal guidelines and regulations, such as, compliance with ISO 9001 or 22000 (International Organization of Standardization, Geneva, CH) and GMP guidelines provided by the FDA, such as, 21 CFR, various parts, such as, 117, to provide foodstuffs safe for human consumption.
[143] As used herein, “edible,” relates to a composition that can be consumed by a subject. An edible composition can be a solid or a liquid. As known, a solid has definite volume and definite shape, such as, a powder, a bar, a gummy, a pasta and so on. A liquid, a potable, has volume but no shape, such as, a beverage, a syrup, a lotion, a tonic and so on.
[144] Edible food products can be consumer packaged good (CPG), loose or bulk items and so on, consumable items and packages thereof found in, for example, groceries, stores, supermarkets, convenience stores, service stations, markets, vending machines and so on that vend, sell or distribute edible compositions.
[145] As used herein, a, “flavorant,” is any ingredient in an edible composition that imparts a flavor, taste on or to that composition. A flavorant can include compounds and compositions in the food and pharmaceutic arts for imparting a taste or flavor, such as, an essence, a compound, for example, butyric acid, and so on, with no apparent or necessary nutritional value, but as used herein, flavorant also includes any ingredient, compound or composition used in an edible composition of interest to impart a flavor or taste on or to an edible composition, such as, a juice, milk, milk solids, ascorbic acid, corn syrup, lactose, sugar, nuts, which may be ground, fruit, which may be dried, macerated and so on, roots, vegetables and so on.
[146] " ichia pastoris,” is a yeast commonly used for commercial production of recombinant protein. Recently, the genus, Pichia, was renamed, “Komagataella,” and the species as, “Komagataella pastoris ” Other studies revealed many strains, cultures, lines and the like used in laboratories around the world identified as P. pastoris, comprise at least two species, K. pastoris and K. phaffii. For purposes herein, because the genetic differences between K. pastoris and K. phaffii are minimal and de minimis; phenotypically, the strains may not be readily distinguishable; and for all intents and purposes are substantially equivalent, despite the nomenclature, P. pastoris, K. pastoris and K. phaffii are considered equivalent, and unless specifically noted herein as specific for just one species, one name can be used for another, and use of one name includes the other two names as well. One name is substitutable for both of the other of the two names.
[147] ‘Probiotic,” describes microbial cells or components of microbial cells with a beneficial effect on health or well-being of a host. A probiotic bacterium can be of the genera, Lactobacillus, Bifidobacterium and Bacillus, known to possess probiotic activity. A probiotic composition can comprise a fungus or a yeast.
[148] Probiotic microbes may be present in a compositions of any aspect or embodiment of the instant invention, for example, in an amount: >5 million, >10 million, >15 million, >20 million, >25 million, >30 million, >35 million, >45 million, >50 million, >75 million, >100 million, >250 million, >500 million, >750 million, >1 billion or >2 billion bacteria per serving. For example, a probiotic may be present in amounts of: 5 million to 2500 million, 10 million to 2500 million, 30 million to 2500 million, 50 million to 2500 million, 50 million to 1000 million, 75 million to 2500 million, 75 million to 1000 million, 100 million to 2500 million, 100 million to 1000 million, 250 million to 2500 million, 250 million to 1000 million, 500 million to 2500 million, 500 million to 1000 million, 750 million to 2500 million or 750 million to 1000 million, 1 billion to 2.5 billion, 1.5 to 2.5 billion or more microbes per serving.
[149] Compositions of the instant invention may be formulated to provide a daily dose of a probiotic microbe of, for example, from 103 to 1014, 104 to 1012, 105 to 1012, 106 to 1012, 107 to 1011, from about 107 to about 1010 or more colony forming units (cfu), microbes or other unit of measurement.
[150] A probiotic microbe may be cultured according to any suitable method and prepared for addition to an edible composition by known techniques, such as, for example, freeze-drying or spray-drying. Probiotic microbe preparations can be purchased, for example, from Morinaga Milk, Institut Rosell, Christian Hansen and so on.
[151] A, “prebiotic,” molecule or moiety is a compound that fosters, encourages, supports, enhances and so on growth of beneficial microbes in vivo, such as, in the gut, providing a conducive microbiota. Generally, a prebiotic moiety is indigestible in stomach, is fermented by microbes and stimulates growth of microbes. Compounds considered prebiotic include fiber, β-glucan, inulin, oligosaccharides, pectin, HMO’s, fructans, xylans and so on.
[152] Ingredients for making an edible composition of interest are known, are available commercially as food grade or pharmaceutical grade ingredients, or can be made or obtained as taught in the art. For example, some ingredients taught herein can be purchased from Hilmar Cheese, Hilmar, CA (lactose, whey protein isolate, whey protein hydrosylate, whey protein concentrate and milk protein isolate), Foremost Farms, Middleton, WI (lactose), Adams Group, Arbuckle, CA (vegetable oil blend and lecithin), AAK USA Inc., Edison, NJ (Sn2 palmitate and vegetable oil blend), Fonterra, Chicago, IL (whole milk powder and milk protein isolate), Leprino Nutrition, Denver, CO (whey protein concentrate), Aria Foods, Basking Ridge, NJ
(MFGM and α-lactalbumin enriched whey protein), DSM Foods USA, Germantown, WI (mineral mix, 2’-fucosyllactose, lutein, DHA oil and ARA-DHA blend), Balchem, Montvale, NJ (choline bitartrate), Univar, Baltimore, MD (potassium bicarbonate), Chr. Hansen, New Berlin, WI (2’-fucosyllacrose and probiotics), Morinaga Milk, Irvine, CA (probiotics), Ingredion, Westchester, IL (com syrup, resistant starch, pea protein concentrate and maltodextrin), ADM, Decatur, IL (soy protein isolate, flavorants, fructose and sodium citrate), DuPont, Wilmington, DE (carrageenan and cellulose), Idaho Milk Products, Jerome, ID (casein and milk protein concentrate), Sensus, Rye Brook, NJ (fructooligosaccharides), Beneo, Troy, NJ (fructooligosaccharides), ICL Food Specialties, Creve Coeur, ID (tricalcium phosphate), Lipotech, S.A., Lewisville, TX (magnesium chloride), Cargill, Minneapolis, MN (lecithin, canola oil, prebiotics, citric acid, caramel and potassium chloride), Jungbunzlauer, Des Plaines, IL (sodium citrate, zinc citrate and potassium citrate), Belle Chemical, Belle, WV (sodium hydroxide), Spectrum Chemical, Brunswick, NJ (magnesium phosphate, high oleic safflower oil and potassium phosphate), Prinova, Hanover Park, IL (flavorants), CellMark Ingredients, Naugatuck, RI (choline chloride, vitamin A, taurine and carnitine), CP Kelco, Atlanta, GA (gellan gum), Univar, Baltimore, MD (potassium iodide), Milkfood Ltd, Punjab, India (milk acid casein), Farbest, Park Ridge, NJ (fructose and vitamin D), Penta Mfg. Co., Livingston, NJ (m-inositol, tapioca starch, casein and maltitol), Foodchem Inti Coop, City of Industry, CA (maltitol, carnitine, sucralose, cocoa powder and m-inositol), Northwest Naturals, Bothell, WA (juices), Saputo, Montreal, Canada (skim milk powder), Virginia Date, Brooklyn, NY (flavorants), Firmenich, Plainsboro, NJ (flavorants), Exberry, Mierlo, Netherlands (colorants), United Sugars, Edina, MN (sugar), Graham Chem Corp, Barrington, IL (sucralose and sugar alcohol), Vyse, Schiller Park, IL (gelatin), Wilmar, Pearland TX (glucose syrup), Georg Lemke, Berlin, Germany (almond), Royal Ridge Fruits, Royal City, WA (dried fruits), Orient Resources Co, Hong Kong (pumpkin seeds), Golden Barrel, Honey Brook, PA (inverted sugar), AG Commodities, Oxford, PA (brown rice syrup and glycerin), Martin Bauer, Secaucus, NJ (fava bean protein concentrate), Puratos, Pennsauken, NJ (chocolate liquor) and so on.
II. Proteins
[153] “Protein,” or, “polypeptide,” refers to a molecule comprising at least five amino acid residues. “Wild-type,” refers to an endogenous version of a molecule that occurs naturally in an
organism in the wild. A wild type form generally is the more prevalent from in a panmictic population. A common form may be, for example, a gene, a protein, a trait and so on.
[1541 In embodiments, a wild-type version of a protein or polypeptide is employed, however, in embodiments of the disclosure, a modified protein or polypeptide can be employed. The terms described above may be used interchangeably. A, “modified protein,” or, “modified polypeptide,” “mutant,” “altered,” or a, “variant,” refers to a protein or polypeptide where the chemical structure thereof, particularly the amino acid sequence thereof, is altered relative to the wild-type protein or polypeptide; or a variant carries one or more other elements attached to a wild type polypeptide. In embodiments, a modified/variant protein or polypeptide has at least one modified activity or function (recognizing that proteins or polypeptides may have multiple activities or functions). A modified/variant protein or polypeptide may be altered with respect to one activity or function yet retain a wild-type activity or function in other respects
[155] Where a protein specifically is mentioned herein, that reference is to a native (wild-type) or a recombinant (modified) protein, such as, an incipient secreted protein in which any signal sequence attached thereto is removed. A protein may be isolated directly from an organism of which it is native, produced by a recombinant DNA/exogenous expression method, produced by solid-phase peptide synthesis (SPPS) or other in vitro method. In embodiments, there are isolated nucleic acid segments and recombinant vectors incorporating nucleic acid sequences that encode a polypeptide.
[156] In embodiments, size of a protein or polypeptide (wild-type or modified) may comprise, but is not limited to, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1100, 1200, 1300, 1400, 1500, 1750, 2000, 2250, 2500 amino acid residues or greater, and any range derivable therein, or derivative of a corresponding amino sequence described or referenced herein. It is contemplated that polypeptides may be mutated by truncation, rendering a polypeptide shorter than a corresponding wild-type or modified form. Also, a polypeptide might be altered by fusing or conjugating a heterologous
protein or polypeptide sequence with a particular function (for example, for targeting or localization, for purification etc.) thereto or therewith.
[157] As used herein, “domain,” as known in the art, refers to a distinct functional or structural unit or portion of a protein or polypeptide, and generally refers to a sequence of amino acids with one of a structure or function recognizable by one skilled in the art associated with a protein with that one or multiple structures or functions.
[158] “Polynucleotide,” refers to a nucleic acid molecule that either is recombinant or has been isolated from total genomic nucleic acid. Included within the term, “polynucleotide,” are oligonucleotides (nucleic acids 100 residues or less in length), recombinant vectors, including, for example, plasmids, cosmids, phage, viruses and the like. Polynucleotides include regulatory sequences, isolated substantially away from associated or related naturally occurring genes or protein encoding sequences, such as, control sequences. Polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be RNA, DNA (genomic, cDNA, synthetic and so on), analogs thereof or a combination thereof. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide. A polynucleotide may be modified as known in the art for a desired purpose, such as, codon optimization, stability and so on.
[159] Gene,” “polynucleotide,” or, “nucleic acid,” is used to refer to a nucleic acid that encodes a protein, polypeptide or peptide (including any sequences, such as control sequences, required for proper transcription, post-translational modification or localization). As will be understood by those in the art, the term encompasses genomic sequences, expression cassettes, cDNA sequences and smaller engineered nucleic acid segments that express, or may be adapted to express, proteins, polypeptides, domains, peptides, fusion proteins and mutants. A nucleic acid encoding all or part of a polypeptide may contain a contiguous nucleic acid sequence encoding all or a portion of such a polypeptide. It also is contemplated that a particular polypeptide may be encoded by nucleic acids containing variations, having slightly different nucleic acid sequences but, nonetheless, encode the same or substantially similar protein, and so, herein, which can be identified as modified polynucleotides.
[160] In embodiments, there are polynucleotide variants having substantial identity to sequences disclosed herein; those comprising at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher sequence identity, including all values and ranges there between,
compared to a polynucleotide sequence provided herein using methods described herein (for example, BLAST analysis using standard parameters). In aspects, an isolated polynucleotide will comprise a nucleotide sequence encoding a polypeptide that has at least 90%, and in some cases, 95% or more identity to an amino acid sequence described herein, over the entire length of the sequence; or a nucleotide sequence complementary to said isolated polynucleotide.
[161] Nucleic acid segments, regardless of length of the coding sequence, an open reading frame, may be combined with other nucleic acid sequences, such as, promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments other control and expression regions and the like, such that overall length may vary considerably. Nucleic acids can be any length. A nucleic acid of interest can be, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 175, 200, 250, 300, 350, 400, 450, 500, 750, 1000, 1500, 3000, 5000 or more nucleotides in length, and/or can comprise one or more additional sequences, for example, regulatory sequences, and/or be a part of a larger nucleic acid, for example, a vector. It therefore is contemplated that a nucleic acid fragment of almost any length may be employed, with total length preferably being limited by ease of preparation and manipulation, and use in an intended recombinant nucleic acid protocol. In cases, a nucleic acid sequence may encode a polypeptide sequence with additional heterologous coding sequences, for example, to allow for purification of a polypeptide, transport, secretion, post-translational modification, or for therapeutic benefit, such as, targeting or efficacy. As discussed above, a tag or other heterologous polypeptide may be added to a modified polypeptide-encoding sequence, wherein, “heterologous,” refers to a polypeptide that is not the same as the modified polypeptide.
[162] Polypeptides, proteins or polynucleotides encoding such polypeptides or proteins of the disclosure may include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (or any derivable range therein) or more variant amino acids, or nucleic acid substitutions; or be at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any derivable range therein) similar, identical to or homologous with at least, or at most 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62,
63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129,
130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148,
149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167,
168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,
187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205,
206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224,
225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243,
244, 245, 246, 247, 248, 249, 250, 300, 400, 500, 550, 1000 or more contiguous amino acids or nucleic acids, or any range derivable therein, for example, of SEQ ID NOs:l-4.
[163] Nucleotide as well as a protein, polypeptide and peptide sequences for various genes have been previously disclosed, and may be found in recognized computerized databases. Two commonly used databases are Genbank and Genpept of the National Center for Biotechnology Information (ncbi.nlm.nih.gov) and The Universal Protein Resource (UniProt at uniprot.org). Coding regions for genes may be amplified and/or expressed using techniques disclosed herein or as would be known to those of ordinary skill in the art.
[164] It is contemplated that in compositions of the disclosure, there is between about 0.001 mg and about 10 mg of total polypeptide, peptide and/or protein per ml. Concentration of protein in a composition can be about, at least about or at most about 0.001, 0.010, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0 mg/ml or more (or any range derivable therein).
A. Human Milk Proteins
[165] Aspects of the present disclosure include human milk proteins, as well as compositions comprising such proteins and methods of use thereof. As used herein, a, “human milk protein,” describes any protein present in human breast milk. A human milk protein includes a protein derived from (for example, isolated from) human breast milk, as well as any protein produced by other means (for example, recombinant expression, chemical synthesis etc.) having an amino acid sequence of a protein present in human breast milk, the wild type form. Various human milk proteins are recognized in the art and are contemplated herein, including,
but not limited to, secretory IgA (slgA), human serum albumin, xanthine dehydrogenase, lactoferrin (LF), lactoperoxidase, butyrophilin, lactadherin, adiponectin, β-casein, κ-casein, leptin, lysozyme and α-lactalbumin. In embodiments, a human milk protein of the disclosure is a human whey protein. In embodiments, a human milk protein of the disclosure is a recombinant human milk protein (for example, produced by a non-mammal cell, such as, a yeast cell).
[166] Certain aspects of the disclosure are directed to human milk proteins having, “human-like,” glycans. Human-like glycans (also, “human-like glycan structures,”) are glycans having structures present in human glycoprotein. Such glycans include, for example, hybrid N-glycans, complex N-glycans, bi-antennary, tri-antennary and tetra-antennary N-glycans, high-mannose glycans and glycans comprising sialic acid, galactose, N-acetylgalactosamine or fucose. Human-like glycans include those having a Man3GlcNAc2 core structure. Accordingly, human milk proteins of the disclosure include those having one or more human-like glycans, for example, hybrid N-glycans, complex N-glycans, high-mannose glycans, bi-antennary N-glycans, tri-antennary N-glycans, tetra-antennary N-glycans and combinations thereof.
[167] Accordingly, in embodiments, disclosed are recombinant (r) human (rh) milk proteins (for example, recombinant human lactoferrin, rhLF) comprising one or more human-like glycans. Such recombinant protein includes, for example, those produced by engineered mammal, fungus, yeast, bacterium or other cells, including engineered cells described herein. In aspects, such recombinant proteins can have a glycan pattern different from a glycan pattern of a corresponding natural or naturally occurring wild type human milk protein. For example, in embodiments, disclosed is a recombinant human lactoferrin comprising one or more human-like glycans, where the lactoferrin has a glycan pattern that can be different from a glycan pattern of any naturally occurring human lactoferrin (for example, human lactoferrin in human breast milk). Also disclosed is a composition comprising a plurality of recombinant human lactoferrin proteins, where glycan pattern across all of the recombinant human lactoferrin proteins can be different than a glycan pattern across all naturally occurring human lactoferrin in a human secretion (for example, breast milk).
[168] Recombinant glycoproteins often have glycosylation profiles, patterns or fingerprint different from that found on, in or of the corresponding wild-type or naturally occurring glycoprotein. Nevertheless, the varying carbohydrates may not negatively impact glycoprotein function, such as, observed with the instant rhLF of interest, for example, binding iron. Also,
carbohydrate on recombinant glycoprotein may not be as allergenic or immunogenic; or immunogenic or allergenic as wild type might be or is (Almond et al., Toxicology 301:50-57, 2012).
B. Lactoferrin
[169] Aspects of the present disclosure are directed to lactoferrin (LF), as well as compositions comprising lactoferrin, including edible compositions, such as, infant formula compositions. Lactoferrin (also, “lactotransferrin,”) is a whey protein found in exocrine fluids, such as, breast milk and is encoded by the LTF gene. LF binds iron (the holo form), and the apo form is free of iron. Without wishing to be bound by theory, lactoferrin is understood to have antimicrobial and anti-inflammatory properties. Aspects of the disclosure are directed to human lactoferrin (hLF) (UniProtKB/Swiss-Prot accession number P02788), including isoforms thereof. Full sequence of human lactoferrin, including signal peptide, is provided as SEQ ID NO: 1. Sequence of mature human lactoferrin following cleavage of the signal peptide is provided as SEQ ID NO:2.
[170] In aspects, a human lactoferrin of the present disclosure is a recombinant human lactoferrin (rhlactoferrin). In aspects, a recombinant human lactoferrin of the disclosure is obtained from a mammal, fungus, yeast, bacterium or other cell. In aspects, a recombinant human lactoferrin of the disclosure is not obtained from a mammal cell. In aspects, a recombinant human lactoferrin of the disclosure is obtained from a yeast cell. The yeast cell may be, for example, from an Arxula, Aspergillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella,
Trichosporon, Wicker hamomyces or Yarrowia. In aspects, the yeast cell is a Komagataella cell (for example, Komagataella phaffii, Pichia pastoris, Komagataella pastoris, Komagataella pseudopastoris). Additional yeast species suitable for recombinant protein production are recognized in the art and contemplated herein. In aspects, a recombinant human lactoferrin of the disclosure is obtained from a bacterium. In aspects, a human lactoferrin of the disclosure is isolated from a natural source.
[171] Aspects of the present disclosure are directed to human lactoferrin having at least one hybrid or complex N-glycan. In aspects, a human lactoferrin comprises a glycan comprising one or more of sialic acid, galactose, N-acetylgalactosamine or fucose. In aspects, a human lactoferrin comprises a bi-antennary, tri-antennary or tetra-antennary N-glycan. As disclosed herein, human lactoferrin having one or more hybrid, complex, bi-antennary, tri-antennary or tetra-antennary N-glycan may be useful in, for example, infant formula or other edible or nutritional compositions, or supplements.
[172] Recombinant technology provides a virtually unlimited supply of a human secretory protein, amounts unattainable from natural sources because human tissue or secretions is needed and low amounts of human secretory protein in fluids and so on. Moreover, human tissue sources command rigorous testing and extraordinary purification methods to produce secure and safe, yet limiting amounts of naturally occurring secretory protein.
[173] On the other hand, recombinant human secretory proteins of interest have at least three advantages over naturally occurring secretory protein. Because the instant method relates to a sole non-human source of secretory protein, the transformed microbe, once FDA approval of the manufacturing process of interest is obtained, that will make available unlimited amounts of recombinant secretory protein, such as, rhLF, which is less immunogenic and less allergenic than wild-type. The instant invention enables commercial development of edible compositions comprising human secretory proteins, allowing all to profit from benefits of human secretory proteins.
C. Alpha-lactalbumin (a-lactalbumin)
[174] Aspects of the present disclosure are directed to α-lactalbumin (alpha-lac, a-lac and so on), as well as compositions comprising α-lactalbumin, including an infant formula composition. a-Lactalbumin is a whey protein found in breast milk and is encoded by the
LALBA gene. Aspects of the disclosure are directed to human α-lactalbumin (UniProtKB/Swiss-Prot accession number P00709), including isoforms thereof. Full sequence of human α-lactalbumin, including signal peptide, is provided as SEQ ID NO:3. Sequence of mature human α-lactalbumin following cleavage of the signal peptide is provided as SEQ ID NO:4.
[175] In aspects, a human α-lactalbumin of the present disclosure is a recombinant human α-lactalbumin. In aspects, a recombinant human α-lactalbumin of the disclosure is obtained from a mammal, fungus, yeast, bacterium or other cell. In aspects, a recombinant human α-lactalbumin of the disclosure is not obtained from a mammal cell. In aspects, a recombinant human α-lactalbumin of the disclosure is obtained from a yeast cell. A yeast cell may be, for example, of a genus, Arxula, Aspergillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon, Wicker hamomyces or Yarrowia. In aspects, a yeast cell is a Komagataella cell (for example, Komagataella phaffii, Pichia pastor is, Komagataella pastoris, Komagataella pseudopastoris). Additional yeasts suitable for recombinant protein production are recognized in the art and contemplated herein. In aspects, a recombinant human α-lactalbumin of the disclosure is obtained from a bacterium. In aspects, a human α-lactalbumin of the disclosure is isolated from a natural source.
[176] Particular aspects of the present disclosure are directed to human α-lactalbumin having at least one hybrid or complex N-glycan. In aspects, a human α-lactalbumin comprises a glycan comprising one or more of sialic acid, galactose, N-acetylgalactosamine or fucose. In aspects, a human lactoferrin comprises a bi-antennary, tri-antennary or tetra-antennary N-glycan. As disclosed herein, human α-lactalbumin having one or more hybrid, complex, bi-antennary, tri-antennary, or tetra-antennary N-glycan may be useful in, for example, an infant formula or other nutritional or edible compositions, or supplements.
D. Additional human milk proteins
[177] Additional human milk proteins contemplated in compositions (for example, edible compositions) and methods of the disclosure include, but are not limited to, as taught hereinabove for rhLF and rhaLac, and are applicable to secretory IgA (slgA), human serum albumin, xanthine dehydrogenase, lactoperoxidase, butyrophilin, lactadherin, adiponectin, 0- casein, κ-casein, leptin, osteopontin, bile salt stimulated lipase (BSSL) and lysozyme. Any one or more of those human milk proteins, the coding sequences of which are available in the art, may be included in edible compositions (for example, edible or potable compositions) of the present disclosure. Any one or more of those human milk proteins may be excluded in embodiments.
III. Edible Composition and Infant Formula
[178] Aspects of the present disclosure are directed to edible compositions for consumption by a human, for example, an infant formula, as well as methods of use for providing nutrition to a subject, such as, an infant. The following description and that hereinabove relate also to making an edible composition of interest including nutritional compositions, such as, candy, bars, yogurt, ice cream, beverages and so on. Hence, a composition comprising lactose and a recombinant secretory protein of interest can comprise a dairy product, such as, ice cream, a milk-based nutritional beverage and so on. Any discussion herein relating to an infant formula applies also to any edible composition.
[179] An infant formula disclosed herein may be in any form capable of consumption, or capable of dissolving, combining or diluting for consumption. In embodiments, an infant formula can be in a ready-to-consume form. In embodiments, an infant formula is in a solid
concentrated form (for example, as a powder). In embodiments, an infant formula is in liquid concentrate form. An infant formula of the present disclosure may comprise one or more components useful in providing nutrition to an infant. Such components may include, but are not limited to, lactose (for example, lactose from a lactose powder), lipids (for example, lipids from one or more oils, such as, sunflower oil, safflower oil, coconut oil, canola oil, low rapeseed erucic oil etc ), protein (for example, α-lactalbumin, whey protein concentrate etc.), casein, a human milk oligosaccharide (HMO) (for example, 2'-fucosyllactose, lacto-N-neotetraose, 3-fucosyllactose, 6'-sialyllactose, difucosyllactose, lacto-N-tetraose), minerals (for example, calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium, selenium, and salts thereof), vitamins (for example, vitamin A, vitamin D, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, niacinamide, calcium pantothenate, vitamin B6, biotin, folic acid, pantothenic acid, vitamin B 12, vitamin C, choline, inositol, L-carnitine, taurine, and salts thereof), a probiotic, nucleotides (for example, cytidine 5 ’-monophosphate, uridine 5 ’-monophosphate, adenosine 5 ’-monophosphate, guanosine 5 ’-monophosphate), arachidonic acid (ARA), docosahexaenoic acid (DHA), milk fat globule membrane (MF GM) and a human milk protein (for example, secretory IgA, human serum albumin, xanthine dehydrogenase, lactoferrin, lactoperoxidase, butyrophilin, lactadherin, adiponectin, p-casein, κ-casein, leptin, lysozyme or α-lactalbumin). Any one or more, or all, of the preceding components may be included in an edible composition of the present disclosure. Any one or more of those components may be excluded from embodiments.
[180] As described herein, an infant formula comprising a human milk protein addresses various needs by providing a formula having particular benefits previously associated with breast milk alone, including anti-inflammatory and anti-bacterial benefits. Accordingly, aspects of the present disclosure are directed to infant formula compositions comprising a human secretory protein, in cases, a human milk protein, comprising one or more human-like glycans, and methods of use thereof in providing nutrition to an infant.
[181] In embodiments, an infant formula comprises lactose. In embodiments, an infant formula comprises at least, at most, about, or exactly 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70% or more lactose by weight of a dry composition, including any range or value derivable therein. In embodiments, an infant formula comprises at least 45% lactose by dry weight. In embodiments, an infant formula comprises at
least 70% lactose by dry weight. An infant formula may comprise lactose from any source, including, for example, edible lactose powder. In aspects, an infant formula comprises less than 5, 4, 3, 2, 1, 0.5, 0.1, 0.01 % lactose by dry weight, or less. In aspects, an infant formula does not comprise lactose.
[182] In embodiments, an infant formula comprises one or more lipids. An infant formula may comprise one or more lipids from any source, including, for example, one or more of high oleic sunflower oil, mid-oleic sunflower oil, safflower oil, coconut oil, canola oil, low erucic rapeseed oil, sunflower oil, Mortierella alpina oil, alga oil (for example, from a Schizochytrium) soybean oil and palm oil. Any one or more, or all, of the preceding components may be included in an infant formula of the present disclosure. Any one or more of those components may be excluded from embodiments. In embodiments, an infant formula comprises at least, at most, about, or exactly 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8,
2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1,
5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4,
7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7,
9.8, 9.9, 10, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11, 11.1, 11.2,11.3, 11.4, 11.5,
11.6, 11.7, 11.8, 11.9, or 12% of any one or more of oils by weight, including any range or value derivable therein.
[183] In embodiments, an infant formula comprises protein. An infant formula may comprise a protein from any one or more sources including, for example, whey protein lipid concentrate, whole milk powder, whey protein concentrate, non-fat dry milk, milk protein concentrate or isolate, whey protein hydrolysate, isolated protein (for example, isolated α-lactalbumin) or any other source of protein. Any one or more, or all, of the preceding components may be included in an infant formula of the present disclosure. Any one or more of those components may be excluded from embodiments. In embodiments, an infant formula comprises at least, at most, about, or exactly 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2,
2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5,
4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8,
6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1,
9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11,
11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9, or 12, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7, 12.8, 12.9, or 13% protein by dry weight, including any range or value derivable therein.
[184] In embodiments, an infant formula comprises one or more human milk oligosaccharides (HMO). An HMO may be, for example, 2'-fucosyllactose or lacto-N-neotetraose. Various additional HMO’s are recognized in the art and are contemplated herein. In embodiments, an infant formula comprises at least, at most, about, or exactly 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3% of an HMO by dry weight, including any range or value derivable therein.
[185] In embodiments, an infant formula comprises one or more minerals. Various minerals are recognized in the art and are contemplated herein. In embodiments, an infant formula comprises one or more of calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium, selenium, including any salt thereof. For example, an infant formula may comprise one or more (or all) of calcium phosphate, calcium citrate, magnesium chloride, potassium citrate, potassium chloride, sodium chloride, copper sulfate, ferrous sulfate, manganese sulfate, zinc sulfate, sodium selenite, calcium chloride, magnesium phosphate, sodium citrate, potassium phosphate and potassium iodide. Any one or more, or all, the preceding components may be included in an infant formula of the present disclosure. Any one or more of those components may be excluded from embodiments. In embodiments, an infant formula comprises at least, at most, about, or exactly 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3% of any one or more minerals by dry weight, including any range or value derivable therein. In embodiments, an infant formula comprises at least 0.1% of any one or more minerals by dry weight. In embodiments, an infant formula comprises at most, 3% of any one or more minerals by dry weight.
[186] In embodiments, an infant formula comprises one or more vitamins. Various vitamins are recognized in the art and contemplated herein. In embodiments, an infant formula comprises one or more of vitamin A, vitamin D, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, niacinamide, calcium pantothenate, pyridoxine hydrochloride, biotin, folic acid, pantothenic acid, cyanocobalamin, vitamin C, choline, inositol, L-carnitine, inositol, and taurine, including any salt thereof. For example, in embodiments, an infant formula comprises one or more (or all) of vitamin A palmitate, vitamin D3, D-α tocopherol, vitamin KI, thiamine
hydrochloride, riboflavin, niacinamide, calcium pantothenate, pyridoxine hydrochloride, biotin, folic acid, cyanocobalamin, choline bitartrate, inositol and ascorbic acid. Any one or more, or all, of the preceding components may be included in an infant formula of the present disclosure. Any one or more of those components may be excluded from embodiments. In embodiments, an infant formula comprises at least, at most, about, or exactly 0.000001, 0.00001, 0.0001, 0.001, 0.01, 0.1, or 1 % of any one or more vitamins by weight, including any range or value derivable therein. In embodiments, an infant formula comprises at least 0.000001 % of any one or more vitamins by weight, and at times, for liquid reagents, by volume. In embodiments, an infant formula comprises at most 1% of any one or more vitamins by weight.
[187] In embodiments, an infant formula disclosed herein comprises one or more probiotic microbes. As used herein, a, “probiotic,” microbe as described above, comprises a microbe, such as, a bacterium or other microorganism known or suspected to have a beneficial effect on health or well-being of an individual. Various probiotics microbes are recognized in the art and are contemplated herein. Probiotic microbes which may be used in the disclosed compositions and methods include, for example, probiotic Lactobacillus and probiotic Bifidobacterium organisms. In embodiments, a probiotic microbe is Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus fermentum, Lactobacillus paracasei, Lactobacillus johnsonii, Lactobacillus helveticus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium adolescentis or Bifidobacterium infantis.
[188] An infant formula of the disclosure may comprise at least, at most, or exactly 1, 2, 3, 4 or 5 different probiotic species of microbe. In embodiments, an infant formula does not comprise a probiotic organism. In embodiments, an infant formula comprises Bifidobacterium infantis, for example, Bifidobacterium infantis M-63. Additional beneficial probiotic microbes are disclosed in, for example, U.S. Pat. No, 9,226,521, incorporated herein by reference in entirety. An infant formula of the disclosure may comprise at least, at most, about, or exactly 103, 104, 105, 106, 107, 108, 109, 1010, 1011, 1012, 1013, 1014, 1015 or more colony forming units (cfu), particles or other metric of probiotic microbe (for example, Bifidobacterium infantis) per 100 grams, including any range or value derivable therein.
[189] In embodiments, an infant formula comprises one or more nucleotides. Various nucleotides, including nucleotides useful as supplements for infant formula or other food compositions, are recognized in the art and are contemplated herein In embodiments, an infant
formula comprises one or more (or all) of cytidine 5 ’-monophosphate, uridine
5 ’-monophosphate, adenosine 5 ’-monophosphateor guanosine 5 ’-monophosphate. Any one or more, or all, of the preceding components may be included in an infant formula of the present disclosure. Any one or more of those components may be excluded from embodiments.
[190] In embodiments, an infant formula comprises one or more additional components, including, but not limited to, arachidonic acid, docosahexaenoic acid, a prebiotic, casein, such as, micellar casein, and MFGM.
[191] In embodiments, disclosed is an infant formula comprising, in addition to one or more additional components described herein, a human secretory protein. An infant formula may comprise any human secretory protein, including human milk proteins disclosed herein, for example recombinant human milk proteins, human milk proteins comprising hybrid, complex or other human-like glycans, human whey proteins, as well as any one or more particular human milk protein, such as, lactoferrin (for example, recombinant lactoferrin). In embodiments, an infant formula comprises a naturally derived human secretory protein. In embodiments, an infant formula comprises a recombinant human secretory protein. In embodiments, an infant formula comprises a recombinant human secretory protein having a glycan pattern that is different from a glycan pattern of a corresponding natural human secretory protein.
[192] An infant formula of the present disclosure may comprise at least, at most, about, or exactly 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49, 0.5,
0.51, 0.52, 0.53, 0.54, 0.55, 0.56, 0.57, 0.58, 0.59, 0.6, 0.61, 0.62, 0.63, 0.64, 0.65, 0.66, 0.67,
0.68, 0.69, 0.7, 0.71, 0.72, 0.73, 0.74, 0.75, 0.76, 0.77, 0.78, 0.79, 0.8, 0.81, 0.82, 0.83, 0.84, 0.85, 0.86, 0.87, 0.88, 0.89, 0.9, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, 0.99, 1.00, 1.01,
1.02, 1.03, 1.04, 1.05, 1.06, 1.07, 1.08, 1.09, 1.1, 1.11, 1.12, 1.13, 1.14, 1.15, 1.16, 1.17, 1.18,
1.19, 1.2, 1.21, 1.22, 1.23, 1.24, 1.25, 1.26, 1.27, 1.28, 1.29, 1.3, 1.31, 1.32, 1.33, 1.34, 1.35,
1.36, 1.37, 1.38, 1.39, 1.4, 1.41, 1.42, 1.43, 1.44, 1.45, 1.46, 1.47, 1.48, 1.49, 1.5, 1.51, 1.52,
1.53, 1.54, 1.55, 1.56, 1.57, 1.58, 1.59, 1.6, 1.61, 1.62, 1.63, 1.64, 1.65, 1.66, 1.67, 1.68, 1.69,
1.7, 1.71, 1.72, 1.73, 1.74, 1.75, 1.76, 1.77, 1.78, 1.79, 1.8, 1.81, 1.82, 1.83, 1.84, 1.85, 1.86,
1.87, 1.88, 1.89, 1.9, 1.91, 1.92, 1.93, 1.94, 1.95, 1.96, 1.97, 1.98, 1.99, 2.00 % or more of one or more human secretory protein (for example, slgA, human serum albumin, xanthine
dehydrogenase, lactoferrin, lactoperoxidase, butyrophilin, lactadherin, adiponectin, β-casein, κ-casein, leptin, lysozyme, or α-lactalbumin) by dry weight, including any range or value derivable thereof.
[193] In embodiments, an infant formula comprises about or exactly 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49, 0.5% or more human lactoferrin (for example, recombinant human lactoferrin) by dry weight, or any range or value derivable therein.
[194] In embodiments, an infant formula comprises about or exactly 0.01, 0.02, 0.03, 0.04,
0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21,
0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38,
0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49, 0.5, 0.51, 0.52, 0.53, 0.54, 0.55, 0.56, 0.57, 0.58, 0.59, 0.6, 0.61, 0.62, 0.63, 0.64, 0.65, 0.66, 0.67, 0.68, 0.69, 0.7, 0.71, 0.72,
0.73, 0.74, 0.75, 0.76, 0.77, 0.78, 0.79, 0.8, 0.81, 0.82, 0.83, 0.84, 0.85, 0.86, 0.87, 0.88, 0.89,
0.9, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, 0.99, 1.00, 1.01, 1.02, 1.03, 1.04, 1.05, 1.06, 1.07, 1.08, 1.09, 1.1, 1.11, 1.12, 1.13, 1.14, 1.15, 1.16, 1.17, 1.18, 1.19, 1.2, 1.21, 1.22, 1.23,
1.24, 1.25, 1.26, 1.27, 1.28, 1.29, 1.3, 1.31, 1.32, 1.33, 1.34, 1.35, 1.36, 1.37, 1.38, 1.39, 1.4,
1.41, 1.42, 1.43, 1.44, 1.45, 1.46, 1.47, 1.48, 1.49, 1.5, 1.51, 1.52, 1.53, 1.54, 1.55, 1.56, 1.57,
1.58, 1.59, 1.6, 1.61, 1.62, 1.63, 1.64, 1.65, 1.66, 1.67, 1.68, 1.69, 1.7, 1.71, 1.72, 1.73, 1.74,
1.75, 1.76, 1.77, 1.78, 1.79, 1.8, 1.81, 1.82, 1.83, 1.84, 1.85, 1.86, 1.87, 1.88, 1.89, 1.9, 1.91,
1.92, 1.93, 1.94, 1.95, 1.96, 1.97, 1.98, 1.99, 2.00% or more dry weight of human α-lactalbumin, or any range or value derivable therein.
IV. Genetic Engineering
[195] Aspects of the present disclosure include recombinant protein products (for example, human secretory proteins) generated by engineered microorganisms. In aspects, disclosed are recombinant human secretory proteins (for example, recombinant lactoferrin) produced and secreted by an engineered microorganism, for example, an engineered eukaryote cell, fungus cell, yeast cell, bacterium or other cell. Vectors for transforming microorganisms in accordance with the present disclosure can be prepared by known techniques familiar to those skilled in the art in view of the disclosure herein. A vector typically contains one or more genes, in which
each gene codes for expression of a desired product (a gene product) and is operably linked to one or more control sequences that regulate gene expression or target a gene product to a particular location in a recombinant cell.
[196] Exogenous nucleic acid sequences, including, for example, nucleic acid sequences encoding fusion proteins, nucleic acid sequences encoding wild-type or mutant protein and so on, may be introduced into different host cells. Nucleic acid sequences configured to facilitate a genetic mutation in a gene also may be introduced into various host cells, as described further herein. Suitable host cells are microbial hosts that can be found broadly within fungus families. Examples of suitable host strains include but are not limited to fungus or yeast species, such as, of genera, Arxula, Aspegillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Hansenula, Kluyveromyces, Komagataella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon and Yarrowia. Various fungus organisms are recognized in the art and contemplated herein. In embodiments, a host cell of the present disclosure is a Komagataella cell. In embodiments, a host cell of the present disclosure is Komagataella phaffii. In embodiments, a host cell of the present disclosure is Komagataella pastoris or Pichia pastoris. In embodiments, a host cell of the present disclosure is Komagataella pseudopastoris . Additional host cells include a non-fungus eukaryote cell and a bacterium.
[197] Microbial expression systems and expression vectors are known to those skilled in the art. Any such expression vector could be used to introduce instant genes and nucleic acid sequences into an organism. Nucleic acid sequences may be introduced into appropriate microorganisms via transformation techniques. For example, a nucleic acid sequence can be cloned in a suitable plasmid, and a parent cell can be transformed with a resulting plasmid. A plasmid is not particularly limited so long as said plasmid renders a desired nucleic acid sequence inheritable to progeny of that microorganism.
[198] Vectors or cassettes useful for transformation of suitable host cells are recognized in the art. Typically, a vector or cassette contains a gene, sequences directing transcription and translation of a relevant gene including a promoter, a selectable marker and sequences allowing autonomous replication or chromosome integration. Suitable vectors comprise a region 5' of a
gene harboring a promoter and other transcriptional initiation controls (5’ untranslated region, 5’ UTR) and a region 3' of a DNA fragment that controls transcriptional termination (3’ UTR). [1991 Promoters, cDNA’s and 3' UTR’s, as well as other elements of vectors, can be generated through cloning techniques using fragments isolated from native sources (Green & Sambrook, “Molecular Cloning: A Laboratory Manual,” (4th ed., 2012); and U.S. Pat. No. 4,683,202; both references incorporated herein by reference in entirety). Alternatively, elements can be generated synthetically using known methods (Gene 164:49-53, 1995).
A. Vectors and Vector Components
[200] Vectors for transforming microorganisms in accordance with the present disclosure can be prepared by known techniques familiar to those skilled in the art in view of the disclosure herein. A vector typically contains one or more genes, in which each gene codes for expression of a desired product (the gene product) and is operably linked to one or more control sequences that regulate gene expression or target a gene product to a particular location in a recombinant cell.
1. Control Sequences
[201] Control sequences are nucleic acid sequences that regulate expression of a coding sequence or direct a gene product to a particular location in or outside a cell. Control sequences that regulate expression include, for example, promoters that regulate transcription of a coding sequence and terminators that terminate transcription of a coding sequence. Another control sequence is a 3' untranslated sequence located downstream of a coding sequence that encodes a polyadenylation signal. Control sequences that direct gene products to particular locations, for example, those that encode signal peptides, which direct a protein attached thereto to a particular location inside a cell.
[202] Thus, an exemplary vector design for expression of a gene in a microbe contains a coding sequence for a desired gene product (for example, a selectable marker, an enzyme, a fusion protein etc.) in operable linkage with a promoter active in host yeast cells. Alternatively, if a vector does not contain a promoter in operable linkage with a coding sequence of interest, a coding sequence can be transformed into cells such that an open reading frame becomes operably linked to an endogenous promoter at vector integration. Examples of promoters contemplated
herein include, but are not limited to, known and publicly available AOX1, GAP, TEF1, TPI1, DAS1, DAS2, CAT1 and FMD promoters.
[2031 A- promoter used to express a gene can be a promoter naturally linked to that gene or a different promoter of a different gene.
[204] A promoter generally can be characterized as constitutive or inducible. Constitutive promoters generally are active or function to drive expression at all times (or at certain times in cell life cycle) at the same level. Inducible promoters are active (or rendered inactive) or are significantly up-regulated or down-regulated only in response to a stimulus. Both types of promoters find application herein. Useful inducible promoters include those that mediate transcription of an operably linked gene in response to a stimulus, such as, an exogenously provided small molecule, such as, methanol, temperature (heat or cold), lack of nitrogen in culture media etc. Suitable promoters can activate transcription of an essentially silent gene or upregulate transcription of an operably linked gene that is transcribed at a low level.
[205] Inclusion of a termination region control sequence is optional. A termination region may be native to a transcriptional initiation region (a promoter), may be native to a DNA sequence of interest or may be obtainable from another source (see, for example, Chen & Orozco, Nucleic Acids Research 16:8411, 1988).
[206] In cases, a full nucleotide sequence of a promoter is not necessary to drive transcription, and sequences shorter than full length nucleotide sequence of a promoter can drive transcription of an operably-linked gene. A minimal portion of a promoter, termed a core promoter, include a transcription start site, a binding site for a RNA polymerase and a binding site for a transcription factor.
[207] A promoter may be linked to a target by introducing a promoter and a target into a nucleic acid molecule, for example, a vector. A vector may be introduced into a cell, thereby expressing promoter and target. In an embodiment, a promoter is linked to a target by introducing a promoter into DNA of a cell, for example, via homologous recombination, thereby integrating a promoter into a genome of a cell.
B. Genes and Codon Optimization
[208] Typically, a gene includes a promoter, a coding sequence and termination control sequence. When assembled by recombinant DNA technology, a gene may be termed an
expression cassette and may be flanked by restriction sites for convenient insertion into a vector that is used to introduce that recombinant gene into a host cell. An expression cassette can be flanked by DNA sequences from a genome or other nucleic acid target to facilitate stable integration of an expression cassette into a genome by homologous recombination.
Alternatively, a vector and expression cassette may remain unintegrated (for example, an episome), in which case, a vector typically includes an origin of replication, which is capable of providing for replication of a vector DNA.
[209] A common gene present on a vector is a gene encoding a protein, expression of which allows a recombinant cell containing a protein to be differentiated from cells that do not express that protein. Such a gene, and corresponding gene product, is called a selectable marker or selection marker. Any of a wide variety of selectable markers can be employed in a transgene (foreign gene, recombinant gene or gene of interest) construct useful for transforming organisms covered in the disclosed embodiments.
[210] For optimal expression of a recombinant protein, it may be beneficial to employ coding sequences that produce mRNA with codons optimally used by a host cell to be transformed. Thus, proper or maximal expression of transgenes can require codon usage of a transgene to match specific codon bias of an organism in which a transgene is being expressed. Precise mechanisms underlying such effect are many, but include proper balancing of available aminoacylated tRNA pools with proteins being synthesized in a cell, coupled with more efficient translation of transgene messenger RNA (mRNA) when the need is met. When codon usage in a transgene is not optimized, available tRNA pools may not be sufficient to allow for efficient translation of a transgene mRNA resulting in ribosomal stalling and termination, and possible instability of a transgene mRNA.
[211] A coding sequence of the present disclosure can be codon optimized for a particular host cell by replacing one or more rare codons with one or more codons more frequently found in a host cell. A rare codon in a host cell is a codon found in less than 5%, less than 10% or less than 20% of coding sequences in a host cell. Rare codons can be identified using methods known to those of skill in the art.
[212] Aspects of the disclosure comprise transformation of a microorganism with a nucleic acid sequence comprising a gene that encodes a protein. A gene may be native to a cell or from a different species. A gene may be derived from a different species yet modified (for example,
codon optimized) for optimal expression in a microorganism. In embodiments, a gene is inheritable in progeny of a transformed cell. In embodiments, a gene is inheritable by residing on a plasmid. In embodiments, a gene is inheritable by integrating into a genome of a transformed cell.
[213] Further aspects of the disclosure may comprise transformation of a microorganism with a nucleic acid sequence configured to generate a mutation in a gene of a microorganism. For example, aspects of the disclosure may comprise transformation of a microorganism with a nucleic acid sequence comprising sequences upstream and downstream of a gene (for example, an 0CH1 gene encoding a 1,6-mannosyl transferase of yeast), thereby facilitating reduced expression or deletion of a gene via homologous recombination. Various methods for generating mutations (including deletions or knockout mutations, as well as mutations which reduce expression of a gene) in genes of a microorganism are recognized in the art and envisioned herein. A microorganism having a deletion or knockout mutation of a gene does not produce a functional copy of a protein. For example, a recombinant yeast cell of the disclosure may comprise a deletion of an endogenous 0CH1 gene, such that a recombinant yeast cell does not express an endogenous, functional 0CH1 protein. A microorganism having reduced expression of a gene or protein can produce a functional copy of a protein, but at a reduced level as compared to wild-type (that is, a non-recombinant or non-genetically modified) microorganism of the same species. Methods for reducing expression of a protein are recognized in the art and include, for example, replacement of an endogenous promoter and/or modification of one or more regulatory elements.
C. Transformation
[214] Cells can be transformed by any suitable technique including, for example, use of biolistic devices, electroporation, glass bead transformation, silicon carbide whisker transformation and so on. Any convenient technique for introducing a transgene into a microorganism can be employed in embodiments disclosed herein.
[215] Vectors for transformation of microorganisms can be prepared by known techniques familiar to those skilled in the art. In an embodiment, an exemplary vector design for expression of a gene in a microorganism contains a gene encoding an enzyme in operable linkage with a promoter active in a microorganism. Alternatively, if a vector does not contain a promoter in
operable linkage with a gene of interest, a gene can be transformed into cells to be operably linked to a native promoter at vector integration. A vector also can contain a second gene that encodes a protein. Optionally, one or both gene(s) is/are followed by a 3' untranslated sequence containing a polyadenylation signal. Expression cassettes encoding those two genes can be physically linked in a vector or reside on separate vectors. Co-transformation of microbes also can be used, in which distinct vector molecules are simultaneously used to transform cells (Protist 155:381-93, 2004). Transformed cells optionally can be selected based on ability to grow in presence of an antibiotic or other selectable marker under conditions in which cells lacking a resistance cassette would not grow or flourish.
D. Genetically Engineered Cells
[216] Aspects of the disclosure comprise genetically engineered cells (also, “engineered cells,” and, “recombinant cells,”) and methods for making and using such cells. In embodiments, disclosed do recombinant cells comprise one or more exogenous nucleic acid sequences. Also disclosed are methods for generating such recombinant cells comprising introducing one or more exogenous nucleic acid sequences into a host cell. Further described are methods for collecting one or more products (for example, a mammal glycoprotein) from such recombinant cells comprising culturing cells and collecting product.
[217] In embodiments, a recombinant cell is a prokaryote cell, such as, a bacterium. Tn embodiments, a recombinant cell is a eukaryote cell, such as, a mammal cell, a yeast cell, a filamentous fungus cell, a protist cell, an alga cell, a bird cell, a plant cell, an insect cell and so on. In embodiments, a recombinant cell is not a mammal cell. In embodiments, a host cell is a yeast cell. Those with skill in the art will recognize that many forms of fdamentous fungus produce yeast-like growth, and definition of yeast herein encompasses such cells. A recombinant cell of the disclosure may be selected from the group consisting of alga, bacterium, mold, fungus, plant and yeast. In embodiments, a recombinant cell of the disclosure is a bacterium (for example, E. coli), a fungus cell or a yeast cell, such as, Saccharomyces cerevisiae.
[218] In embodiments, a recombinant cell of the disclosure is a recombinant yeast cell. A recombinant yeast cell may be any suitable yeast cell recognized in the art. In aspects, the yeast cell is an Arxula, Aspergillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagataella,
Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon, Wicker hamomyces or Yarrowia cell. In embodiments, a yeast cell is Arxula adeninivorans, Aspergillus niger, Aspergillus orzyae, Aspergillus terreus, Aur anti ochy trium limacinum, Candida utilis, Claviceps purpurea, Cryptococcus albidus, Cryptococcus curvatus, Cryptococcus ramirezgomezianus, Cryptococcus terreus, Cryptococcus wieringae, Cunninghamella echinulata, Cunninghamella japonica, Geotrichum fermentans, Hansenula polymorpha, Kluyveromyces lact is, Komagalaella phaffii, Komagalaella pas tor is, Komagalaella pseudopastoris, Kluyveromyces marxianus, Kodamaea ohmeri, Leucosporidiella creatinivora, Lipomyces lipofer, Lipomyces starkeyi, Lipomyces tetrasporus, Mortierella isabellina, Mortierella alpina, Ogataea polymorpha, Pichia ciferrii, Pichia guilliermondii, Pichia pastoris, Pichia stipit.es, Prototheca zopfii, Rhizopus arrhizus, Rhodosporidium babjevae, Rhodosporidium toruloides, Rhodosporidium paludigenum, Rhodotorula glutinis, Rhodotorula mucilaginosa, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Tremella enchepala, Trichosporon cutaneum, Trichosporon fermentans, Wickerhamomyces ciferrii or Yarrowia lipolytica.
[219] In embodiments, a yeast cell is a Komagataella cell. In embodiments, a yeast cell is Kluyveromyces phaffii, Pichia pastoris, Komagataella pastoris or Komagataella pseudopastoris. In embodiments, a yeast cell is Kluyveromyces phaffii cell.
V. Manufacturing
[220] Edible compositions according to the present invention may be prepared by any known or otherwise suitable manner. For example, an infant formula may be obtained by blending a protein with a human secretory protein, and optionally, a carbohydrate source and a lipid source, in appropriate proportions. Emulsifiers may be included. Vitamins and minerals may be added, but also may be added later during manufacture to avoid thermal degradation. Water, such as, water subjected to purification, such as, reverse osmosis or deionized water, then may be added and mixed to form a liquid mixture. Temperature of mixing can be room temperature, but also may be higher to facilitate suspension and mixing, though below temperatures that might damage an ingredient.
[221] If desired, a liquid mixture is dried in a suitable drying apparatus, such as, a spray drier or freeze drier, and can be converted into or to a powder.
[2221 Powdered infant formula may be produced using various processes, such as, dry blending dehydrated ingredients to constitute a uniform mixture or hydrating and wet-mixing a mixture of ingredients, such as, fat, protein and carbohydrate ingredients and then evaporating or spray drying the resultant mixture. A combination of processes may be used where a base powder is first produced by wet-mixing and spray drying all or some of the macro-ingredients and then dry blending the remaining ingredients, including carbohydrate, minerals and vitamins and other micronutrients, to create a final composition. Liquid formulae are available in a ready -to-feed format or as a concentrated liquid, which requires dilution, such as, 1 : 1, with water.
[223] To produce a liquid infant formula, a homogenized mixture is filled into suitable containers, preferably aseptically. However, a liquid composition may be retorted in a suitable container, using suitable apparatus for filling and retorting using commercially available machinery.
[224] As mentioned above, the invention relates to ready -to-drink formulations and processes for preparing ready -to-drink formulations. A liquid food may be a beverage, such as, a nutraceutical drink, an energy drink, a milkshake, a performance or nutrition product, such as, a protein shake, and so on.
[225] Steps that eliminate or restrict microbial growth are practiced during production. In general, for example, preservation of an oil-in-water (o/w) emulsion by dehydration for powder products or sterilization in the case of ready-to-feed or concentrated liquid products. A liquid mixture then may be thermally treated or sterilized by another method to reduce risk of spoilage. A mixture then may be homogenized.
[226] A manufacture of the invention can involve high-temperature-processing at about 110° C. or above.
[227] During high-temperature-processing (UHT), an edible composition is heated sufficiently to sterilize a liquid composition, which may lengthen shelf-life of a composition or formulation.
[228] High-temperature-processing may be carried out at about 110° C. to about 150° C. For example, high-temperature-processing may be carried out at about 110° C. to about 145° C ,
about 110° C. to about 140° C., about 110° C. to about 135° C., about 110° C. to about 130° C., about 110° C. to about 125° C., about 110° C. to about 120° C., about 110° C. to about 115° C., about 115° C. to about 150° C., about 115° C. to about 145° C., about 115° C. to about 140° C., about 115° C. to about 135° C., about 115° C. to about 130° C., about 115° C. to about 125° C., about 115° C. to about 120° C., about 120° C. to about 150° C., about 120° C. to about 145° C., about 120° C. to about 140° C., about 120° C. to about 135° C., about 120° C. to about 130° C., about 120° C. to about 125° C., about 125° C. to about 150° C., about 125° C. to about 145° C., about 125° C. to about 140° C., about 125° C. to about 135° C., about 125° C. to about 130° C., about 130° C. to about 150° C., about 130° C. to about 145° C., about 130° C. to about 140° C., about 130° C. to about 135° C., about 135° C. to about 150° C., about 135° C. to about 145° C., about 135° C. to about 140° C., about 140° C. to about 150° C., about 140° C. to about 145° C., or about 145° C to about 150° C
[229] High-temperature-processing may be carried out for about 5 seconds to about
60 minutes, for about 5 seconds to about 45 minutes, about 5 seconds to about 30 minutes, about 5 seconds to about 15 minutes, about 5 seconds to about 5 minutes, about 5 seconds to about 120 seconds, about 5 seconds to about 60 seconds, about 5 seconds to about 30 seconds, about 30 seconds to about 60 minutes, about 30 seconds to 45 minutes, about 30 seconds to about 30 minutes, about 30 seconds to about 15 minutes, about 30 seconds to about 5 minutes, about 30 seconds to about 120 seconds, about 30 seconds to about 60 seconds, about 60 seconds to about minutes, about 60 seconds to about 45 minutes, about 60 seconds to about 30 minutes, about 60 seconds to about 15 minutes, about 60 seconds to about 5 minutes, about 60 seconds to about 120 seconds, about 120 seconds to about 60 minutes, about 120 seconds to about 45 minutes, about 120 seconds to about 30 minutes, about 120 seconds to about 15 minutes, about 120 seconds to about 5 minutes, about 5 minutes to about 60 minutes, about 5 minutes to about 45 minutes, about 5 minutes to about 30 minutes, about 5 minutes to about 15 minutes, about 15 minutes to about 60 minutes, about 15 minutes to about 45 minutes, about 15 minutes to about 30 minutes, about 30 minutes to about 60 minutes, about 30 minutes to about 45 minutes, or about 45 minutes to about 60 minutes.
[230] High-temperature-processing may be carried out by direct or indirect heating. For example, high-temperature-processing may be carried out by steam injection, heat exchange or using a retort.
[231] An edible composition can be treated with high pressure prior to packaging and sale, with high pressure enhancing safety and prolonging shelf life. High pressure processing (HPP) is known and requires pressures of about 6000 bar or more. Pressure of 50 MPa to about 1000 MPa can be used at room temperature or lower, see, for example, US Pat Nos 5,213,029, 5,316,745; 5,683,735; and 6,033,717; and US Pub No 20080050507.
[232] An edible composition of interest is sterile filled into a suitable packaging, such as, a lined can, a pouch, a package wrapping, a powder container, a bottle and so on, which is sealed, optionally treated for quality control and shelf stability, and distributed for sale.
[233] All references cited herein, are incorporated herein by reference in entirety.
[234] The instant disclosure now will be exemplified in the following non-limiting examples. It should be understood that the Examples, while indicating embodiments of the invention, are given by way of illustration only. From the above discussion and the Examples, one skilled in the art can ascertain essential characteristics of the instant invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt same to various uses and conditions.
[235] Herein, percentages of dry ingredients are on a weight basis. For liquid compositions, percentages can be on a weight basis as water generally is the predominant medium with a density of 1 g/cc, or on a weight per volume basis. Percentages of liquid ingredients in a dry formulation can be on a weight basis. Ratios of ingredients in a dry formulation can be used to determine percentages of reagents in an analogous liquid formulation based on the targeted solids level in the analogous liquid formulation.
EXAMPLES
Example 1
[236] A batch of a milk-based infant formula was prepared according to the formulation in the table below. Lactose was hydrated at 45-55% solids in 150-160° F water, then proteins were added. The vegetable oil blend, ARA-DHA blend and fat soluble vitamin premix were mixed into lactose. Mineral and trace minerals, as well as other minerals, vitamins and nutrients were added. The mix was held at 140-145° F with high agitation during mixing, then the mixture was homogenized at 2000-3500 PSI and cooled at 40° F. Nucleotide premix was added to the cold mix and agitated before pasteurization at 170-180° F for 60 seconds followed by spray-drying to
a resulting moisture content of 1.5-3.5 %. Probiotic microorganisms and human lactoferrin were added to the base formulation via dry -blending.
[237] The powder was mixed with water at a rate of 1 tablespoon to 2 ounces of water to yield a drinkable infant formula.
Example 2
[238] A batch of milk-based infant formula containing lower amount of lactose is prepared as provided in Example 1 using the formulation provided in the table below.
Table 2
Example 3
[239] A batch of soy-based infant formula is prepared as provided in Example 1 and using the formulation provided in the table below.
Example 4
[240] A batch of milk-based infant formula containing partially hydrolyzed whey is prepared as provided in Example 1 using the formulation noted in the table below.
Example 5
[241] A batch of milk-based infant formula ready-to-feed is prepared as follows, using the formulation provided in Table 5.
[242] A quantity of reverse osmosis (RO) water representing 50% of the total quantity is heated to 150-160° F. Proteins and carrageenan are hydrated using high shear agitation. While maintaining high agitation, the vegetable oil blend, ARA-DHA blend and fat soluble vitamin premix are added followed by the lactose. Mineral and trace minerals as well as other minerals, vitamins and nutrients are added. The mix is held at 140-145° F at high agitation during mixing, then pasteurized at 185-190° F for 30 seconds, homogenized at 2000-3500 PSI and cooled at 40° F. Nucleotide premix and human lactoferrin are added to the cold mix along with the residual RO water to bring the total solids to 12.8-13.2% w/w. The mix is UHT -treated and filled aseptically in 8 oz plastic bottles.
Example 6
[243] A batch of ready to use liquid nutritional beverage is prepared according to the formulation in Table 6. A quantity of reverse osmosis (RO) water representing 50% of the total quantity is heated to 150-160° F. Proteins (milk protein concentrate and soy protein isolate), cellulose gel & gum and carrageenan are hydrated using high shear agitation. While maintaining high agitation, the oils (high oleic safflower oil and canola oil), lecithin and fat soluble vitamin premix are added, followed by the maltodextrin, sugar and fructooligosaccharides. Individual minerals, the trace mineral premix, the water soluble vitamin premix and other nutrients are added. The mix is held at 140-145° F at high agitation during mixing, then the mixture is pasteurized at 185-190° F for 30 seconds, homogenized at 2000-3500 PSI and then is cooled at 40° F. Vitamin C in 5% solution with a portion of potassium hydroxide and human lactoferrin in 10% solution along with flavors are added to the cold mix along with the residual RO water to bring the total solids to 22.8-24.2% w/w The mix is UHT -treated and filled aseptically in 8 oz plastic bottles.
Example 7
[244] A batch of ready to use liquid nutritional low glycemic index beverage is prepared as provided in Example 6 using the formulation of Table 7.
Table 7
Example 8
[245] A batch of nutritional beverage powder is prepared using the formulation of Table 8. Proteins (milk protein concentrate and soy protein isolate) are hydrated at 45-55% solids in 145-150° F water, then the oils (high oleic safflower oil and canola oil), lecithin and fat soluble vitamin premix are added followed by the maltodextrin, sugar and fructooligosaccharides. Mineral and trace minerals as well vitamins and nutrients are added. The mix is held at 140-145° F at high agitation during mixing, then homogenized at 2000-3500 PSI and cooled at 40° F. Vitamin C in 5% solution with a portion of potassium hydroxide and human lactoferrin in 10% solution along with N&A flavors are added to the cold mix. The mix is pasteurized at 170-180° F for 60 seconds followed by spray-drying to a resulting moisture content of 2.5 - 4.0 %.
[246] Optionally, the human lactoferrin is added to the base formulation via dry-blending.
Example 9
[247] Stable juice-based protein beverages are prepared by mixing a fruit juice with 0.1-10.0% of protein (for example, casein, lactalbumin, serum albumin, glycomacropeptide, soy protein, rice protein, pea protein, whey protein, canola protein, wheat protein, hemp protein, zein, flax protein, egg white protein, ovalbumin, gelatin protein and combinations thereof) using the formulation of Table 9. pH of the admixture is adjusted to between 2 and 3.4. Optionally, one or more of an anti-foaming agent, a nutrient, calcium, an herbal supplement, a flavoring agent, a sweetener, a coloring agent, a preservative and an energy-generating additive selected from caffeine, magnesium and citrulline malate) are added to the mixture. Microbes are inactivated by high pressure processing (EIPP). The protein beverage is packaged in a container which may be stored without refrigeration for more than one year before use by a consumer of the protein beverage.
Table 9
Example 10
[248] A carbonated milk beverage with enhanced shelf stability is prepared based on the formulation provided in Table 10. First, skim milk powder solution is heated at least 85-138° C for 5 seconds. The milk liquid dairy product is ultra-heat treated at least at 150° C and at a pressure of 700 kPa. In the blending tank, other ingredients are added and homogenized at 2,000-5,000 psi for 5 min. The liquid dairy product is cooled to a temperature of less than 10° C. The cooled liquid dairy product is subject to pressurized carbon dioxide so that at least 3-8 vols. of carbon dioxide are dissolved in the liquid dairy product. The carbonated liquid dairy product is packaged in shelf-stable closed containers that do not require refrigeration.
Example 11
[249] A protein-fortified frozen dessert formulation is prepared using the formulation described in Table 11. The ingredients are blended at 5,000-7,000 rpm to prepare a sweet mix. The sweet mix is preheated at 30-60° C. The preheated sweet mix is pasteurized by heating at 69° C for 30 minutes (batch) or at 80° C for 25 seconds (continuous). The sweet mix is homogenized at 2000-3000 psi (one-stage homogenization) or at 2000-2500 psi, followed by 500 psi (two-stage homogenization). Homogenized sweet mix is cooled to 3-5° C for 4-6 hours to produce an aged sweet mix and the aged mix is frozen to prepare a protein-fortified frozen dessert.
Example 12
[250] A protein-fortified spreadable yogurt product is prepared according to the formulation provided in Table 12 by combining a casein-containing ingredient with milk to make yogurt milk. Yogurt culture is added to the yogurt milk and allowed to ferment. The resulting yogurt mixture is separated into a yogurt retentate and a yogurt permeate. Yogurt retentate is used as a spreadable protein-fortified yogurt. The spreadable yogurt can be flavored and then packaged.
Table 12
Example 13
[251] A gummy snack with high protein is produced using the formulation in the following table. A mixture is formed by mixing water, glucose syrup, first sugar alcohol and second sugar alcohol. The mixture is cooked at 230-285° F for 10-60 minutes to form a sugar mixture, which then is cooled to 60-80° F. An acid solution (malic acid) is added to form a sugar-acid mixture of pH 2-4. The sugar-acid mixture is mixed with a gelatin for 4-12 minutes to form a sugar-gelatin mixture. The sugar-gelatin mixture is mixed with protein to form a gel mixture. The gel mixture then is processed by machinery for forming shapes.
Example 14
[252] A high protein snack food is produced using the formulation provided in Table 14.
Any of a variety of protein particles (for example, chicken powder, pea protein powder etc.) are extruded to form protein pieces. The pieces or crisp and the remaining ingredients are combined
and the mixture is used to form a bar, which is treated at 160° F until an internal temperature of 140° F is reached.
Example 15
[253] A batch of nutritional plant-based beverage powder is prepared according to the formulation in Table 15. Proteins (pea protein concentrate and fava bean protein isolate) are hydrated at 45-55% solids in 145-150° F water. Then, the oils (high oleic safflower oil and canola oil), lecithin and fat soluble vitamin premix are added followed by the maltodextrin, sugar and fructooligosaccharides. Mineral and trace minerals as well as vitamins and nutrients are added. The mix is held at 140-145° F at high agitation during mixing, then homogenized at 2000-3500 PSI and cooled to 40° F. Vitamin C in 5% solution with a portion of potassium hydroxide and human lactoferrin in 10% solution along with N&A flavors are added to the cold mix. The mix is pasteurized at 170-180° F for 60 seconds followed by spray-drying to a resulting moisture content of 2.5-4.0 %.
[255] An immunity shot beverage with human lactoferrin was prepared using the formulation of Table 16. Human lactoferrin was mixed with water and stirred for 10 minutes. A high protein content fruit juice is selected, for example, guava, orange, blackberry, banana, peach, kiwi and so on. Alternatively, a protein source, such as, whey protein, can be included. An elderberry juice-based matrix was blended with the human lactoferrin solution for a few minutes and transferred to a plastic bottle (~60 mL). Blended samples were cooled to ~4 °C and high pressure process (HPP) treated at ~87,000 psi.
[256] The bottles were tested for shelf stability.
Example 17
[257] A batch of liquid nutritional (ready -to-feed) composition is prepared using the formulation in Table 17. Reverse osmosis (RO) water is heated to 150-160° F. Pea protein isolate, cellulose gel & gum, and tapioca starch are hydrated using high shear agitation. While maintaining high agitation, the oils (high oleic safflower oil and canola oil), lecithin, and fat soluble vitamin premix are added followed by the maltodextrin and sucralose. Individual minerals, the trace mineral premix, the water soluble vitamin premix and other nutrients are added. The mix is held at 140-145° F at high agitation during mixing, then pasteurized at 185-190° F for 30 seconds, homogenized at 2000-3500 PSI and cooled at 40° F. Vitamin C in 5% solution with a portion of potassium hydroxide and human lactoferrin in 10% solution along with N&A flavors are added to the cold mix along with the residual RO water to bring the total solids to 20-30% w/w. The mix is UHT-treated and filled aseptically in 8 oz plastic bottle.
[258] The composition is suitable for FODMAP (fermentable oligosaccharides, di saccharides, monosaccharides and polyols) diets.
Table 17
Example 18
[259] A batch of milk-based infant formula was prepared according to the formulation in Table 18. Lactose was hydrated at 45-55% solids in 140-145° F water, then proteins were added followed by the vegetable oil blend, ARA-DHA blend and fat soluble vitamin premix. Mineral and trace minerals as well as vitamins and nutrients were added to the mixture. The mix was held at 117-127° F at high agitation during mixing, then homogenized at 2000-3500 PSI and pasteurized at 170-180° F for 60 seconds. The mixture was cooled to 122-131° F before spray-drying to a resulting moisture content of 1.5-3.5 %. Probiotics and human lactoferrin were added to the base formulation via dry -blending.
[260] The resulting infant formula powder was packaged. The powder was added to water to form a drinkable infant formula.
Example 19
[261] A nutrition bar fortified with human milk oligosaccharides (HMO’s) and human lactoferrin is prepared using the formulation in Table 19. Powder ingredients including HMO’s powder, human lactoferrin and vitamin premix are mixed. Liquid components of binder syrup (maltitol syrup, chocolate liquor) are blended and heated to 150° F. Dry components of the binder, such as, cocoa powder are mixed together and heated to 180° F. Binder materials are added to blended powder ingredients and stirred using a spatula. Approximately 160 g of mixed sample is placed into a bar press mold and chilled in the freezer for 5-10 minutes.
Example 20
[262] A batch of milk-based infant formula with OPO is prepared according to the formulation in Table 20. Lactose is hydrated at 45-55% solids in 150-160° F water, then proteins are added followed by the vegetable oil blend consisting of Sn2 palmitate fat (OPO), coconut oil, high oleic safflower or sunflower oil, soybean oil and sunflower or canola lecithin. ARA-DHA blend and fat soluble vitamin premix are added. Mineral and trace minerals as well as vitamins and nutrients are added. The mix is held at 140-145° F at high agitation during mixing, then homogenized at 2000-3500 PSI and cooled at 40° F. Nucleotide premix is added to the cold mix and agitated before pasteurization at 170-180° F for 60 seconds followed by spray-drying to a resulting moisture content of 1.5-3.5 %. Probiotics and human lactoferrin are added to the base formulation via dry -blending.
Example 21
[263] A batch of prenatal formula powder (with DHA and choline) is prepared according to the formulation in Table 21. Proteins (milk protein concentrate and soy protein isolate) are hydrated at 45-55% solids in 145-150° F water then the oils (high oleic safflower oil and canola oil), lecithin, DHA oil and fat soluble vitamin premix are added followed by the maltodextrin, sugar and fructooligosaccharides. Mineral and trace minerals as well as other vitamins and nutrients are added. The mix is held at 140-145° F at high agitation during mixing, then homogenized at 2000-3500 PSI and cooled at 40° F. Vitamin C in 5% solution with a portion of potassium hydroxide and human lactoferrin in 10% solution (the human lactoferrin can be added at another stage by dry blending) along with N&A flavors are added to the cold mix. The mix is pasteurized at 170-180° F for 60 seconds followed by spray-drying to a resulting moisture content of 2.5-4.0 %.
Example 22
[264] Recombinant human lactoferrin (rhLF) produced in P. pastoris (K. phaffii) was tested to ascertain survivability of oral dosing forms through the digestive system. Apo and holo forms were tested to determine effect, if any, of iron loading. Native apo and holo human and bovine lactoferrin served as controls.
[265] A simulated salivary fluid was prepared. The pH was 7. A sample of lactoferrin was added and the mixture incubated with mixing at 37° C for 2 minutes. A sample was taken for SDS gel and Western blot testing for LF presence.
[266] A simulated gastric chyme and fluid were prepared. The pH was 3. Porcine pepsin (Sigma) (2000 U/ml) was added. The simulated oral cavity sample was introduced into the simulated gastric fluid and the mixture incubated with mixing at 37° C for 2 hours. A sample was taken for SDS gel and Western blot testing for LF presence.
[267] A simulated intestinal fluid was prepared. Bile salts (Sigma) (10 mM), lOOU/ml of porcine trypsin (Sigma) and 25U/m of porcine chymotrypsin (sigma) were added. The pH of the mixture was 7. The simulated gastric sample was introduced to the simulated intestinal fluid and the mixture incubated with mixing at 37° C for 2 hours. A sample was taken for SDS gel and Western blot testing for LF presence
[268] Testing revealed intact protein and LF peptides for apo and holo forms of the enzymes after the gastric phase. LF peptides were detected following intestinal digestion. The holo forms yielded slightly greater amounts of peptides.
[269] Recombinant human lactoferrin behaved similarly to human and bovine apo and holo forms of lactoferrin.
Example 23
[270] It was suggested allergens are pepsin resistant, Almond et al., supra, for example, bovine β-lactoglobin. Thus, rhLF was tested for level of susceptibility to pepsin.
[271] A simulated gastric fluid (SGF) was prepared with a pH of 1-2 and 1600U/ml porcine pepsin (Sigma). Holo (iron loaded) and apo forms of native bovine and human LF, and rhLF were tested.
[272] After LF was added to the SGF, the mixture was incubated at 37° C. for 60 minutes, with samples taken at 0, 0.5, 2, 5, 10, 30 and 60 minutes to monitor course of digestion, if any, by SDS gel electrophoresis and Western blot.
[273] Over the 60 minute period, pepsin was present in all samples indicating there was no auto or self-digestion.
[274] All LF samples were digested totally by 2 minutes.
Example 24
[275] Immunogenicity of rhLF produced in P. pastoris (K. phaffii) was tested. Cord blood mononuclear cells (StemCell) from a female infant were exposed to rhLF and to native bovine LF (Sigma) and human LF obtained from human breast milk. Samples were tested with or without LPS (Sigma) stimulation. Levels of IL-6, IL-1β, IL-8, TNF-α, IL-10, IL12p70, MCP1/CCL-2, MIP-la/CCL-3 and MIP-ip/CCL-4 were determined. None of the samples contained endotoxin.
[276] Neither native human LF nor rhLF stimulated cytokine production, with or without LPS. On the other hand, the human immune cells reacted to the bovine protein.
[277] All materials and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure Ingredients or reagents of edible compositions disclosed herein are available commercially as food grade or drug grade compounds or can be made as provided in the art. While compositions and methods of the disclosure have been described in terms of certain embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the disclosure. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for agents described herein while same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the present disclosure.
Claims
1. An edible or potable composition comprising a protein and a recombinant human secretory protein.
2. The edible or potable composition of claim 1, wherein said secretory protein comprises a human milk protein.
3. The edible or potable composition of claim 1, wherein said recombinant human secretory protein comprises secretory IgA (slgA), serum albumin, xanthine dehydrogenase, lactoferrin, lactoperoxidase, butyrophilin, lactadherin, adiponectin, β-casein, κ-casein, leptin, lysozyme or α-lactalbumin.
4. The edible or potable composition of claim 1, wherein said recombinant human secretory protein comprises lactoferrin.
5. The edible or potable composition of claim 1, wherein said secretory protein comprises one or more fucose, hybrid N-glycan, complex N-glycan, N-acetylgalactosamine, mannose or sialic acid,.
6. The edible or potable composition of claim 1, further comprising 2'-fucosyllactose, lacto-N-neotetraose, 3-fucosyllactose, 6'-sialyllactose, difucosyllactose or lacto-N-tetraose.
7. The edible or potable composition of claim 1, further comprising one or more lipids.
8. The edible or potable composition of claim 1, further comprising one or more minerals.
9. The edible or potable composition of claim 1, further comprising one or more vitamins.
10. The edible or potable composition of claim 1, further comprising one or more nucleotides.
11. The edible or potable composition of claim 1, further comprising whey protein lipid concentrate, whole milk powder, whey protein concentrate, non-fat dry milk, milk protein concentrate or isolate, whey protein hydrolysate or an isolated protein.
12 The edible or potable composition of claim 1, further comprising high oleic sunflower oil, mid-oleic sunflower oil, safflower oil, coconut oil, low erucic rapeseed oil, sunflower oil, ascorbyl palmitate, mixed tocopherol concentrate, Mortierella alpina oil, alga oil, soybean oil or palm oil.
13. The edible or potable composition of claim 1, further comprising one or more of calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium or selenium.
14. The edible or potable composition of claim 1, further comprising one or more of vitamin A, vitamin D, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, niacinamide, calcium pantothenate, vitamin B6, biotin, folic acid, pantothenic acid, vitamin B 12, vitamin C, choline, inositol, and salts thereof.
15. The edible or potable composition of claim 1, further comprising a probiotic or a prebiotic.
16. The edible or potable composition of claim 1, wherein said recombinant human secretory protein is from a mammal cell, a bacterium or a fungus cell.
17. The edible or potable composition of claim 1, wherein said recombinant human secretory protein is from a yeast cell.
18. The edible or potable composition of claim 1, wherein said recombinant human secretory protein is from a cell of genus, Arxula, Aspergillus, Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Komagalaella, Leucosporidiella, Lipomyces, Mortierella, Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon, Wickerhamomyces or Yarrowia.
1 . The edible or potable composition of claim 1, wherein said recombinant human secretory protein comprises one or more N-glycans found on a human protein.
20. The edible or potable composition of claim 1, comprising from about .01% to about 2% by weight of said recombinant human secretory protein.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263371174P | 2022-08-11 | 2022-08-11 | |
US63/371,174 | 2022-08-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024036227A2 true WO2024036227A2 (en) | 2024-02-15 |
WO2024036227A3 WO2024036227A3 (en) | 2024-06-06 |
Family
ID=89852520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/071955 WO2024036227A2 (en) | 2022-08-11 | 2023-08-09 | Edible composition comprising recombinant human secretory protein |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024036227A2 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200412942A (en) * | 2002-08-06 | 2004-08-01 | Abbott Lab | Appetite control method |
KR20080049330A (en) * | 2006-11-30 | 2008-06-04 | (주)아모레퍼시픽 | Food composition for increasing the satiety and satiation |
WO2021067641A1 (en) * | 2019-10-03 | 2021-04-08 | Turtletree Labs Pte. Ltd. | Nutrient compositions and methods, kits, and cell compositions for producing the same |
EP4137511A4 (en) * | 2020-04-16 | 2024-01-10 | Dermopartners, S.L. | New composition for use to treat and prevent infections by covid-19 and other coronaviruses |
-
2023
- 2023-08-09 WO PCT/US2023/071955 patent/WO2024036227A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024036227A3 (en) | 2024-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Soukoulis et al. | Ice cream as a vehicle for incorporating health‐promoting ingredients: Conceptualization and overview of quality and storage stability | |
Nehir El et al. | Food technological applications for optimal nutrition: an overview of opportunities for the food industry | |
US20220395466A1 (en) | Microcapsule, preparation method and application thereof | |
DK202300014Y3 (en) | Protein compositions and consumable products thereof | |
WO2016046294A1 (en) | INFANT FORMULA SYSTEM WITH ADAPTIVE LEVELS OF HUMAN MILK OLIGOSACCHARIDES (HMOs) | |
US11974592B1 (en) | Protein compositions and consumable products thereof | |
WO2006039768A1 (en) | Fermented functional food on the basis of soy containing probiotics and prebiotics and process of production thereof | |
WO2016109509A1 (en) | Formulation and process for making fermented probiotic food and beverage products | |
CN108713756A (en) | Alimentation composition based on fortified milk | |
EP2217081B1 (en) | Fermented soy-based beverage | |
JP2022526283A (en) | Field Bean Protein Composition | |
CN110312440A (en) | Protolysate and preparation method thereof | |
CN116634889A (en) | Protein digestion and amino acid bioavailability by probiotic strains | |
WO2024036227A2 (en) | Edible composition comprising recombinant human secretory protein | |
CN105007760A (en) | Nutritional compositions containing peptide component and uses thereof | |
CN114946989B (en) | Gel candy rich in milk fat globule membrane component and preparation method thereof | |
US11638726B2 (en) | Methods for producing probiotics fortified avian eggs and egg products and formulations thereof | |
KR20180038184A (en) | Compositions of dietary supplements for improvement of hyperlipidemia | |
Madureira et al. | Functional dairy ingredients | |
TW201325460A (en) | Compositions comprising maltotriose and methods of using same to inhibit damage caused by dehydration processes | |
WO2024185888A1 (en) | Nutrition-adjusted food and production method for same | |
TWI786090B (en) | Liquid nutritional composition containing protein derived from lacto-fermented ingredients | |
El-Said et al. | Research Article Functional Properties and in vitro Bio-Accessibility Attributes of Light Ice Cream Incorporated with Purple Rice Bran | |
KR20240059178A (en) | Cheese analog manufactured by using lactobacillus culture filtrate and method of manufacturing the same | |
Poonia | Fermented Foods: Recent Advances and Trends |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23853516 Country of ref document: EP Kind code of ref document: A2 |